aspirin has been researched along with Acute Coronary Syndrome in 939 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to explore the sex differences in clinical outcomes among patients with acute coronary syndrome treated with ticagrelor monotherapy after ticagrelor-based 3-month versus 12-month dual-antiplatelet therapy." | 9.69 | Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, B; Lee, SJ; Lee, YJ, 2023) |
| " prasugrel in patients with acute coronary syndromes (ACSs) are influenced by pre-admission treatment with aspirin and/or clopidogrel." | 9.51 | Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. ( Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E, 2022) |
| " We randomized 200 patients on long-term aspirin monotherapy with prior acute coronary syndrome in a 1:1 fashion to receive ticagrelor 60 mg BD (n=100) or aspirin 100 mg OD (n=100)." | 9.51 | Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome. ( Chan, YH; Ganguly, A; Hwa, K; Li, Z; Ling, XB; Su, KJ; Tam, CF; Tse, HF; Wong, YK; Zhu, X, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 9.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 9.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 9.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| "We sought to compare the biological efficacy of aspirin given once a day versus aspirin divided twice per day in a population of diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test." | 9.41 | ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. ( Addad, F; Baccouche, H; Bennour, E; Boussofara, A; Halima, AB; Kachboura, S; Kammoun, I; Kasbaoui, S; Laroussi, L; Marrakchi, S; Romdhane, NB; Triki, H; Zied, EH, 2021) |
| "A significant number of patients with acute coronary syndrome (ACS) are nonadherent to aspirin after hospital discharge, with an associated increased risk of subsequent cardiovascular events." | 9.34 | A behavioral economics-based telehealth intervention to improve aspirin adherence following hospitalization for acute coronary syndrome. ( Daus, M; Jaskowiak-Barr, A; Kimmel, SE; Riegel, B; Stephens-Shields, A, 2020) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 9.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 9.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES)." | 9.34 | Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. ( Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavik, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, S; Moliterno, D; Nicolas, J; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS)." | 9.34 | Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. ( Calabrò, P; Cesaro, A; Cirillo, PL; Concilio, C; Crisci, M; Di Maio, D; Di Maio, M; Diana, V; Fimiani, F; Gragnano, F; Moscarella, E; Pariggiano, I; Taglialatela, V, 2020) |
| "Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events." | 9.30 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. ( Angiolillo, DJ; Bhatt, DL; Chang, CC; Chichareon, P; Dangas, GD; Deliargyris, EN; Hamm, C; Kogame, N; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Steg, PG; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S, 2019) |
| " Comparative pharmacodynamic analyses for different adenosine diphosphate (ADP) receptor inhibitors in percutaneous coronary intervention-treated acute coronary syndrome (ACS) patients are lacking and this pre-specified analysis from the randomized Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syndromes (TROPICAL-ACS) trial aimed for the first time at investigating diurnal variability of on-treatment platelet reactivity in clopidogrel versus prasugrel treated patients." | 9.30 | Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. ( Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 9.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 9.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models." | 9.27 | Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. ( Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 9.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| "We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR)." | 9.27 | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. ( Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 9.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 9.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "P2Y12 inhibitors, including aspirin, are key components of dual-antiplatelet therapy (DAPT), which is the optimal therapeutic strategy for preventing arterial thrombosis in patients with acute coronary syndromes (ACS) who underwent stent implantation." | 9.22 | A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. ( Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y, 2022) |
| "Trials investigating aspirin omission in patients taking oral anticoagulation (OAC) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) were not powered to assess rates of major bleeding or ischemic events." | 9.22 | Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. ( Alvarez-Covarrubias, HA; Byrne, RA; Cassese, S; Colleran, R; Kastrati, A; Kuna, C; Mayer, K; Ndrepepa, G; Rai, H, 2022) |
| "Aspirin is promptly administered to patients presenting with acute coronary syndromes." | 9.22 | Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. ( Ayele, GM; Brener, SJ; Lansky, AJ; Mehran, R; Stone, GW, 2016) |
| "This randomized prospective clinical trial aimed to evaluate safety and efficacy of preoperative use of eptifibatide in high risk patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), requiring urgent coronary artery bypass graft surgery (CABG)." | 9.22 | Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial. ( Bochenek, A; Buldak, Ł; Buszman, P; Kondys, M; Milewski, K; Sanak, M; Wilczynski, M; Wita, K; Wybraniec, MT, 2016) |
| "Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy." | 9.22 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. ( Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "This study suggests that impaired response to both intravenous and oral aspirin is frequent in comatose patients resuscitated from OHCA." | 9.22 | Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. ( Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "There are a number of economic evaluation studies of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) published from the perspective of multiple countries in recent years." | 9.22 | A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. ( Chen, C; Chen, EZ; Cui, M; Tan, SC; Tu, CC; Wang, XL, 2016) |
| "To evaluate the safety of preoperative use of ticagrelor with or without aspirin in patients with acute coronary syndromes (ACS) undergoing isolated coronary artery bypass grafting (CABG) compared with aspirin alone." | 9.22 | Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting. ( Bancone, C; Biancari, F; Chocron, S; Dalén, M; De Feo, M; Dominici, C; Faggian, G; Fischlein, T; Gatti, G; Gherli, R; Gherli, T; Gulbins, H; Kinnunen, EM; Mariscalco, G; Maschietto, L; Maselli, D; Mignosa, C; Musumeci, F; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Svenarud, P; Verhoye, JP; Zanobini, M, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "This study describes the implications of the pharmacokinetics of low-dose chewable aspirin for acute coronary syndromes." | 9.20 | Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ( Ebner, J; Hobl, EL; Jilma, B; Schmid, RW; Stimpfl, T, 2015) |
| "Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary intervention with stenting remains uncertain." | 9.20 | Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. ( Bach, RG; Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Zettler, ME, 2015) |
| "Prior aspirin treatment is considered a risk factor for adverse outcomes in acute coronary syndrome (ACS) patients." | 9.20 | Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study. ( Brener, SJ; de Bruyne, B; Maehara, A; Mintz, GS; Serruys, PW; Stone, GW; Weisz, G, 2015) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 9.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial compared vorapaxar and placebo in 12,944 high-risk patients with non-ST-segment elevation acute coronary syndrome." | 9.19 | Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). ( Armstrong, PW; Aylward, PE; Chen, E; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Leonardi, S; Mahaffey, KW; Moliterno, DJ; Rorick, T; Storey, RF; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial." | 9.17 | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. ( Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 9.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective." | 9.17 | Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. ( Gasche, D; Greiner, RA; Meier, B; Ulle, T, 2013) |
| " Clopidogrel in the patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) by measuring inhibition of platelet aggregation after loading and maintenance dose of both the drugs." | 9.17 | A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK, 2013) |
| " The aim of the study was to assess the antiplatelet activity and safety of a combined antiplatelet treatment with indobufen and clopidogrel in acute coronary syndrome (ACS) patients with hypersensitivity to aspirin, undergoing coronary stenting." | 9.17 | Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. ( Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Paravati, V; Pellicano, M; Pulcinelli, FM; Tanzilli, G; Torromeo, C, 2013) |
| "The aim of this study was to test the hypothesis that aspirin would reduce the risk for acute coronary syndromes (ACSs) in patients with pneumonia." | 9.17 | Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. ( Abakay, O; Akkoyun, CD; Bulut, I; Cetinkaya, E; Elitok, A; Ersin, G; Gibson, MC; Gul, S; Kaya, MG; Oflaz, H; Oncul, A; Oz, F; Yazici, M, 2013) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 9.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 9.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Large randomized clinical trials have shown the efficacy of aspirin, ACE (angiotensin converting enzyme) inhibitors and statins as secondary prevention measures in patients after an acute coronary syndrome with and without ST elevations." | 9.15 | Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Senges, J; Zahn, R; Zeymer, U, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 9.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI)." | 9.15 | [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]. ( Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH, 2011) |
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 9.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 9.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 9.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 9.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "Prasugrel led to a significant reduction in ischemic cardiovascular events among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation compared to clopidogrel." | 9.14 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio ( Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C, 2009) |
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 9.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| "Currently 162-325 mg aspirin is recommended for the treatment of acute coronary syndrome." | 9.14 | Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. ( Derhaschnig, U; Frossard, M; Fuchs, I; Jilma, B; Riedmüller, E; Spiel, AO, 2010) |
| "To observe the impact of various application time of aspirin and clopidogrel on the circadian rhythm changes of platelet aggregation in patients with acute coronary syndrome." | 9.14 | [Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome]. ( Cui, W; Li, Z; Liu, F; Liu, J; Lu, JC; Ren, XJ; Xie, RQ; Yang, XC; Zheng, HM, 2010) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 9.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 9.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "In data we published earlier, there is a correlation between platelet aggregation in patients with acute coronary syndrome (ACS) who are receiving aspirin and elevated hsCRP-level." | 9.13 | The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. ( Kasyanova, O; Shpektor, A; Vasilieva, E, 2008) |
| "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS)." | 9.13 | Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. ( Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 9.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "To investigate the effects of aspirin-omitted dual antithrombotic therapy (DAT) on myocardial infarction and stent thrombosis in non-valvular atrial fibrillation (NVAF) patients presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)." | 9.12 | Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. ( Li, GQ; Liu, SM; Luo, CF; Mo, P, 2021) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 9.12 | Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. ( Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B, 2021) |
| "Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS)." | 9.12 | Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis. ( Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X, 2021) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 9.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 9.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| "Recently, three randomized trials reported that dual antithrombotic treatments (DATs) including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor without aspirin were associated with significantly less bleeding than vitamin K antagonist (VKA)-based triple antithrombotic therapy (TAT) in atrial fibrillation (AF) patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)." | 9.05 | Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr ( Collet, JP; Dagres, N; Heidbuchel, H; Hindricks, G; Lip, GYH; Mujovic, N; Potpara, TS; Proietti, M; Valgimigli, M, 2020) |
| "The use of aspirin, as part of a dual antiplatelet therapy regimen, is an established standard following coronary stenting in patients suffering from acute coronary syndrome (ACS)." | 8.95 | Aspirin safety in glucose-6-phosphate dehydrogenase deficiency patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Al Hout, AR; Feghaly, J; Mercieca Balbi, M, 2017) |
| "Aspirin allergy in a patient with acute coronary syndrome represents one of the more urgent challenges an allergist may face." | 8.93 | Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. ( Cook, KA; White, AA, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "A short cut review was carried out to establish whether, in patients with suspected acute coronary syndromes presenting to the emergency department, what form of aspirin has the most rapid onset of action." | 8.91 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction? ( Hogg, K; Morris, N; Rigg, K, 2015) |
| "The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS)." | 8.90 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. ( Storey, RF; Thomas, MR, 2014) |
| "PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors." | 8.90 | Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF, 2014) |
| "Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary syndromes (ACS)." | 8.89 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. ( Dinicolantonio, JJ; Norgard, NB, 2013) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 8.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| "Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 8.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
| "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor." | 8.89 | A critical overview on ticagrelor in acute coronary syndromes. ( Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A, 2013) |
| " In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome." | 8.87 | [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. ( Hinneburg, I, 2011) |
| "To update the previous systematic review of the use of clopidogrel in combination with aspirin for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), investigating the optimal duration of treatment and effects of withdrawal from treatment." | 8.85 | The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. ( Burch, J; Craigs, C; Golder, S; Palmer, S; Rogowski, W; Woolacott, N, 2009) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 8.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| "This study evaluated the association among the plasma concentration of ticagrelor, ARC124910XX, aspirin, and salicylic acid with the risk of recent bleeding in patients with the acute coronary syndrome." | 8.31 | The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023) |
| "To explore the effects of ticagrelor and clopidogrel dual antiplatelet therapy on the mean platelet volume-to-lymphocyte ratio (MPVLR), maximum amplitude of adenosine diphosphate-induced platelet-fibrin clots (MAADP), and arachidonic acid (AA) inhibition rates in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI)." | 8.31 | Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention. ( Gao, ST; Ma, L; Wang, Y, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 8.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Patients diagnosed with acute coronary syndrome and receiving dual antiplatelet therapy (aspirin and ticagrelor) were enrolled and followed up for 12 months." | 8.12 | Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. ( Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X, 2022) |
| "The patient developed acute profound thrombocytopenia following eptifibatide administration." | 8.12 | Eptifibatide-induced acute profound thrombocytopenia: A case report. ( Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F, 2022) |
| "AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and similar ischemic events than regimens including a vitamin K antagonist (VKA), aspirin, or both." | 8.02 | Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. ( Dhanda, D; Di Fusco, M; Kang, A; Kongnakorn, T; Polanco, C; Rivolo, S; Savone, M; Skandamis, A; Soto, J, 2021) |
| "Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event." | 8.02 | Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021) |
| "Recent clinical trials showed that short aspirin duration (1 or 3 months) in dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy reduced the risk of bleeding and did not increase the ischemic risk compared to 12-month DAPT in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)." | 8.02 | Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. ( Chen, CP; Chen, PW; Cheng, CW; Fang, CC; Feng, WH; Ho, MY; Hsieh, IC; Huang, SW; Huang, WC; Li, YH; Lin, HW; Lin, SH; Su, CH; Yeh, HI, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "A total of 351 patients with ACS were treated with clopidogrel and aspirin for at least 12 months; we recorded major adverse cardiovascular events (MACE) or bleeding within 1 year." | 8.02 | Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. ( Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W, 2021) |
| " Nevertheless, external validation of these RSs it has not yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor in a real- world scenario." | 7.96 | Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. ( Alexopoulos, D; Ariza-Solé, A; Assi, EA; Autelli, M; Bernardi, A; Bianco, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; D'ascenzo, F; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Giustetto, C; Gravinese, C; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lopez-Cuenca, Á; Luciano, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Peyracchia, M; Pousa, IM; Pozzi, R; Quadri, G; Queija, BC; Raposeiras Roubin, S; Rinaldi, M; Rognoni, A; Rossini, R; Srdanovic, I; Taha, S; Templin, C; Valgimigli, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 7.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "The aim of this study was to investigate the effect of ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT) or conventional DAPT in patients with or without acute coronary syndrome (ACS) in the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)." | 7.96 | Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. ( Branca, M; Franzone, A; Hamm, C; Heg, D; Jüni, P; Leonardi, S; McFadden, EP; Piccolo, R; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S, 2020) |
| "In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone." | 7.96 | Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020) |
| "In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI)." | 7.96 | Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. ( Aksoy, F; Altınbaş, A; Bağcı, A; Baş, HA; Varol, E, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 7.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "The objective of this study is to explore the relationships of the effects of CYP2C19 and PON1 Q192R polymorphism on the activity of clopidogrel and the risk of high platelet responsiveness (HPR) by thrombelastography in patients with acute coronary syndrome (ACS)." | 7.91 | Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. ( Lin, Y; Peng, W; Shi, X; Xu, X, 2019) |
| "Influence of pre-existing treatment with aspirin and/or statins prior to a first acute coronary syndrome (ACS) on clinical presentation, infarct size and inflammation markers." | 7.91 | Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. ( Denegri, A; Lüscher, TF; Mach, F; Matter, CM; Muller, O; Obeid, S; Räber, L; Shahin, M; Weidmann, L; Yousif, N, 2019) |
| "Despite the known protective cardiovascular effect of aspirin, former studies identified its prior exposure to an acute coronary syndrome (ACS) as an independent risk factor for adverse events." | 7.88 | Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry. ( Belo, A; Correia, J; Morais, J; Ruivo, C; Sá, FM; Santos, LG, 2018) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 7.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 7.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 7.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "Monotherapy with either aspirin or clopidogrel is recommended for long-term use after discontinuation of dual-antiplatelet therapy (DAPT) for acute coronary syndrome (ACS) management after percutaneous coronary intervention (PCI)." | 7.88 | Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective. ( Lin, Z; Liu, J; Xuan, J; Yin, H; Zhang, L, 2018) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 7.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease." | 7.85 | Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 7.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Aspirin hypersensitivity is not a rare condition among patients with acute coronary syndrome." | 7.83 | Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. ( Barrionuevo-Sánchez, MI; Corbí-Pascual, M; Córdoba-Soriano, JG; Fuentes-Manso, R; Gallardo-López, A; Gómez-Pérez, A; Gutiérrez-Díez, A; Hidalgo-Olivares, V; Jiménez-Mazuecos, J; Lafuente-Gormaz, C; López-Neyra, I; Navarro-Cuartero, J; Prieto-Mateos, D, 2016) |
| "Whole blood from 15 patients with acute coronary syndrome who were treated with ticagrelor and aspirin and from eight healthy volunteers was incubated for 1 hour at 28, 33, 37, and 39°C." | 7.81 | Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome. ( Brokopp, J; Erlinge, D; Kander, T; Lood, C; Schött, U, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "National practice guidelines recommend early aspirin administration to reduce mortality in acute coronary syndrome (ACS)." | 7.81 | Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. ( Govindarajan, P; Mercer, MP; Tataris, KL, 2015) |
| "Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI)." | 7.81 | Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. ( Kafkas, NV; Liakos, CI; Mouzarou, AG, 2015) |
| "Current guidelines recommend ticagrelor, in addition to aspirin, for patients with non-ST-segment elevation acute coronary syndromes at moderate to high-risk regardless of initial therapeutic strategy." | 7.81 | Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. ( Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 7.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "To assess the cost-effectiveness relationship of Ticagrelor versus Clopidogrel for the management of acute coronary syndrome in Spain." | 7.80 | [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. ( Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P, 2014) |
| " The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS)." | 7.79 | Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. ( Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 7.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 7.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) commonly receive a loading dose of either clopidogrel or prasugrel, in addition to aspirin." | 7.79 | Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013) |
| " We aimed at assessing the predictors of higher plasma levels of TxB2, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) on previous aspirin (ASA) treatment undergoing coronary angiography." | 7.78 | Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy. ( Biasucci, LM; Burzotta, F; Cataneo, L; Cosentino, N; Crea, F; Fracassi, F; Giubilato, S; Leo, A; Leone, AM; Narducci, ML; Niccoli, G; Porto, I; Pulcinelli, FM; Trani, C, 2012) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 7.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 7.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy with aspirin and clopidogrel (Plavix) or another thienopyridine, plus a parenteral anticoagulant while the patient is hospitalized, followed by antiplatelet therapy alone after discharge." | 7.77 | Rivaroxaban (Xarelto) for acute coronary syndrome. ( , 2011) |
| "We aimed to prospectively evaluate the prevalence of biochemical aspirin resistance in patients on aspirin therapy who were admitted to the emergency clinic with chest pain." | 7.76 | The clinical significance of aspirin resistance in patients with chest pain. ( Acikel, S; Atar, A; Atar, I; Aydinalp, A; Bozbas, H; Ertan, C; Gulmez, O; Muderrisoglu, H; Ozgul, A; Ozin, B, 2010) |
| "The study aimed to determine whether aspirin therapy was differentially administered according to race, sex, or age in patients with undifferentiated chest pain who presented to an urban academic emergency department." | 7.76 | Aspirin administration in ED patients who presented with undifferentiated chest pain: age, race, and sex effects. ( Hollander, JE; Shofer, FS; Takakuwa, KM, 2010) |
| "We used the VerifyNow Aspirin to determine aspirin responsiveness of 314 patients regularly taking aspirin 75-300 mg daily for >or=4 weeks who presented with suspected acute coronary syndrome in Emergency Department." | 7.76 | Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. ( Chambers, J; Chu, JW; Herbison, P; Tang, EW; Wong, CK; Wout, JV, 2010) |
| "Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality." | 7.76 | Prior aspirin use and outcomes in acute coronary syndromes. ( Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Qin, J; Rich, JD, 2010) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 7.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
| "To observe and assess the effect of different dosages of aspirin on inflammatory biomarkers, hemorheology (platelet aggregation rate) and clinical prognosis in patients with acute coronary syndrome (ACS)." | 7.75 | [The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.]. ( Hu, DY; Li, RJ; Liang, YQ; Ren, WL; Song, LF; Xu, YY; Yin, ZN, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 7.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 7.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 7.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 7.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 7.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 6.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| "Vorapaxar is an antagonist of the protease activated receptor-1 (PAR-1), the principal platelet thrombin receptor." | 6.79 | Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. ( Becker, RC; Chen, E; Cornel, JH; Dery, JP; Harrington, RA; Hord, E; Huber, K; Jennings, LK; Judge, HM; Kotha, J; Mahaffey, KW; Moccetti, T; Moliterno, DJ; Rorick, TL; Smyth, SS; Storey, RF; Strony, J; Thomas, GS; Tricoci, P; Valgimigli, M, 2014) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 6.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Bleeding was reported according to Bleeding Academic Research Consortium (BARC) definition." | 6.78 | Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. ( Filipiak, KJ; Grabowski, M; Huczek, Z; Kochman, J; Michalak, M; Opolski, G, 2013) |
| "Aspirin resistance was defined as collagen (1 μg/mL) and adenosine diphosphate (ADP) (5 μmol/L)-induced platelet aggregation of ≥ 40% when compared with control values." | 6.77 | Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. ( ElSafady, LA; Morad, AR; Sabri, NA; Salama, MM; Saleh, MA; Zaki, MM, 2012) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Cilostazol 100 mg b." | 6.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| "Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS)." | 6.74 | Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L, 2009) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 6.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "Fibrin is an important contributor to thrombogenesis and may account for the residual event rates." | 6.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| " A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose." | 6.49 | Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. ( Berger, JS, 2013) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 6.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 6.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| "This study evaluated whether patient support, administered via an electronic device-based app, increased adherence to treatment and lifestyle changes in patients with acute coronary syndrome (ACS) treated with ticagrelor in routine clinical practice." | 5.69 | Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome. ( Appel, KF; Degenhardt, R; Ghanem, A; Jörnten-Karlsson, M; Karlson, BW; Knutsson, M; Köhler, T; Krackhardt, F; Maier, LS; Niklasson, A; Ohlow, MA; Theres, H; Tschöpe, C; Vom Dahl, J; Waliszewski, M, 2023) |
| "gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome." | 5.69 | Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial. ( Alfredsson, J; Erlinge, D; Gudbjartsson, T; Gunn, J; James, S; Jeppsson, A; Malm, CJ; Møller, CH; Nielsen, SJ; Sartipy, U; Tønnessen, T, 2023) |
| "We sought to explore the sex differences in clinical outcomes among patients with acute coronary syndrome treated with ticagrelor monotherapy after ticagrelor-based 3-month versus 12-month dual-antiplatelet therapy." | 5.69 | Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, B; Lee, SJ; Lee, YJ, 2023) |
| "A multicenter randomized controlled trial (OPtimal management of anTIthroMbotic Agents [OPTIMA]-4) is designed to test the hypothesis that, for ACS patients with concomitant nonvalvular atrial fibrillation (NVAF) and having low-to-moderate risk of bleeding, clopidogrel is comparable in efficacy but superior in safety compared to ticagrelor while being used in combination with dabigatran after new-generation drug-eluting stent (DES) implantation." | 5.69 | Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial. ( Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| "Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels." | 5.62 | Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. ( Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y, 2021) |
| " prasugrel in patients with acute coronary syndromes (ACSs) are influenced by pre-admission treatment with aspirin and/or clopidogrel." | 5.51 | Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. ( Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E, 2022) |
| " We randomized 200 patients on long-term aspirin monotherapy with prior acute coronary syndrome in a 1:1 fashion to receive ticagrelor 60 mg BD (n=100) or aspirin 100 mg OD (n=100)." | 5.51 | Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome. ( Chan, YH; Ganguly, A; Hwa, K; Li, Z; Ling, XB; Su, KJ; Tam, CF; Tse, HF; Wong, YK; Zhu, X, 2022) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 5.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "In a real-world population with ACS, DAPT with ticagrelor or prasugrel are associated with increased bleeding compared with DAPT with clopidogrel." | 5.51 | Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe ( Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC, 2022) |
| "In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events." | 5.51 | A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. ( Alexander, JH; Bhatt, DL; Budaj, A; Campo, G; Coppolecchia, R; Eikelboom, J; Ferreiro, JL; Hermanides, RS; James, SK; Jones, WS; Keller, L; Kirsch, B; Merkely, B; Mundl, H; Rao, SV; Shibasaki, T, 2022) |
| "Chest pain recurrence was defined as the first revisit to the emergency room with angina." | 5.48 | Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018) |
| "Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases." | 5.46 | Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome. ( Velázquez de Campos, O, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 5.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 5.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| " We were unable to draw any conclusions regarding acute coronary syndromes, mortality, or length of hospital stay, or for the comparison IVIG versus prednisolone." | 5.41 | Intravenous immunoglobulin for the treatment of Kawasaki disease. ( Broderick, C; Ito, S; Kobayashi, S; Kobayashi, T; Suto, M, 2023) |
| " Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases bleeding, with East Asians (EAs) exhibiting higher bleeding and lower ischemic risk, compared with non-East Asians (nEAs)." | 5.41 | Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. ( Farag, M; Gorog, DA; Jeong, YH; Jeyalan, V; Markides, RIL; Navarese, EP, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 5.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| " Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis." | 5.41 | Personalised antiplatelet therapies for coronary artery disease: what the future holds. ( Angiolillo, DJ; Capodanno, D, 2023) |
| "Myocardial infarction was significantly lower when adding clopidogrel or ticagrelor 90 mg to aspirin than those in the aspirin alone group." | 5.41 | Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. ( Liu, C; Ma, L, 2023) |
| "We sought to compare the biological efficacy of aspirin given once a day versus aspirin divided twice per day in a population of diabetic patients with non-ST elevation acute coronary syndrome (NSTE-ACS) as assessed by the thrombin generation test." | 5.41 | ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial. ( Addad, F; Baccouche, H; Bennour, E; Boussofara, A; Halima, AB; Kachboura, S; Kammoun, I; Kasbaoui, S; Laroussi, L; Marrakchi, S; Romdhane, NB; Triki, H; Zied, EH, 2021) |
| " However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor." | 5.41 | Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice ( Chen, F; Chen, SL; Gao, DS; Gao, XF; Ge, Z; Han, YL; He, YQ; Kan, J; Kong, XQ; Li, F; Lin, S; Liu, ZZ; Qian, XS; Qu, H; Shao, YB; Tao, L; Tian, NL; Wang, Y; Wang, ZZ; Wen, SY; Xia, Y; Xiao, PX; Yang, Q; Yang, S; Ye, F; Zeng, HS; Zhang, JJ; Zuo, GF, 2021) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 5.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| "Aspirin adherence was inversely correlated with the CRP level at 3 months (Spearman's r = -0." | 5.36 | Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. ( Burg, M; Davidson, KW; Kronish, IM; Rieckmann, N; Shimbo, D, 2010) |
| "Aspirin resistants were younger (p-value = 0." | 5.35 | The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes. ( Adamopoulou, EN; Argyrakis, SK; Foussas, SG; Makrygiannis, SS; Mytas, DZ; Patsourakos, NG; Perdiou, AJ; Prekates, AA; Tsirimpis, VG; Tsoukanas, VK; Zairis, MN, 2009) |
| "Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0." | 5.35 | Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. ( Abbas, A; Barth, JH; Cubbon, RM; Das, R; Gale, CP; Grant, PJ; Hall, AS; Kearney, MT; Morrell, C; Rajwani, A, 2008) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 5.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "The present results are similar to those observed in clinical trials where administration of low-dose aspirin plus prasugrel was associated with a low rate of major bleeding and CV events." | 5.34 | Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. ( Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 5.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS)." | 5.34 | Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. ( Calabrò, P; Cesaro, A; Cirillo, PL; Concilio, C; Crisci, M; Di Maio, D; Di Maio, M; Diana, V; Fimiani, F; Gragnano, F; Moscarella, E; Pariggiano, I; Taglialatela, V, 2020) |
| "Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events." | 5.30 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. ( Angiolillo, DJ; Bhatt, DL; Chang, CC; Chichareon, P; Dangas, GD; Deliargyris, EN; Hamm, C; Kogame, N; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Steg, PG; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S, 2019) |
| " Comparative pharmacodynamic analyses for different adenosine diphosphate (ADP) receptor inhibitors in percutaneous coronary intervention-treated acute coronary syndrome (ACS) patients are lacking and this pre-specified analysis from the randomized Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syndromes (TROPICAL-ACS) trial aimed for the first time at investigating diurnal variability of on-treatment platelet reactivity in clopidogrel versus prasugrel treated patients." | 5.30 | Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. ( Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 5.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 5.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models." | 5.27 | Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. ( Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 5.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| "Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome." | 5.27 | 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. ( Bae, JH; Cho, DK; Cho, JH; Choi, JH; Choi, KH; Choi, SH; Choi, WG; Doh, JH; Gwon, HC; Hahn, JY; Jeong, JO; Kim, BO; Kim, DI; Kim, J; Kim, SH; Lee, JB; Lee, JM; Lee, WS; Oh, JH; Park, HK; Park, JS; Park, TK; Song, YB; Suh, IW; Yang, JH, 2018) |
| "Form II clopidogrel bisulfate (Plavix) has been extensively used in patients with acute coronary syndrome." | 5.27 | Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up. ( Chen, J; Fan, Y; Ji, Y; Kong, D; Li, C; Li, J; Meng, H; Xu, K; Ye, S; Zhang, J; Zhu, T, 2018) |
| "We conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR)." | 5.27 | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial. ( Chae, IH; Cho, YS; Lee, W; Park, JJ; Suh, JW; Yoon, CH; Youn, TJ, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 5.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS)." | 5.24 | Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V, 2017) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 5.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "The PLATelet inhibition and patient Outcomes (PLATO) trial showed that treatment with ticagrelor reduced the rate of death due to vascular causes, myocardial infarction and stroke when compared to clopidogrel in patients with ST-elevation or non-ST-elevation acute coronary syndrome (ACS)." | 5.24 | Platelet-related biomarkers and their response to inhibition with aspirin and p2y ( Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L, 2017) |
| " It was designed to test whether low dose rivaroxaban as an antithrombotic agent is as safe as aspirin in patients with acute coronary syndromes (ACS)." | 5.24 | [After the GEMINI-ACS-1 trial]. ( Yılmaz, MB, 2017) |
| "Acute coronary syndrome patients, 1 month after coronary stenting and event free, were randomly assigned to aspirin and clopidogrel (switched DAPT) or continuation of drug regimen (unchanged DAPT)." | 5.24 | Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V, 2017) |
| "Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
| " The use of aspirin in unstable angina in the Canadian Aspirin trial was key to establishing the benefit of aspirin in acute coronary syndrome." | 5.22 | The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey. ( Bainey, KR; Marquis-Gravel, G; Mehta, SR; Robert-Halabi, M; Tanguay, JF, 2022) |
| "P2Y12 inhibitors, including aspirin, are key components of dual-antiplatelet therapy (DAPT), which is the optimal therapeutic strategy for preventing arterial thrombosis in patients with acute coronary syndromes (ACS) who underwent stent implantation." | 5.22 | A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. ( Chen, C; Chen, Z; Gu, X; Liu, W; Mao, X; Ren, S; Tao, L; Zhang, L; Zhao, Y, 2022) |
| "Trials investigating aspirin omission in patients taking oral anticoagulation (OAC) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) were not powered to assess rates of major bleeding or ischemic events." | 5.22 | Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. ( Alvarez-Covarrubias, HA; Byrne, RA; Cassese, S; Colleran, R; Kastrati, A; Kuna, C; Mayer, K; Ndrepepa, G; Rai, H, 2022) |
| "We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post hoc analysis of the PRASugrel compared with clopidogrel For Japanese patIenTs with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (PRASFIT-ACS) study." | 5.22 | Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H, 2016) |
| "Addition of a potent P2Y12 inhibitor to aspirin is the standard therapy for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients undergoing percutaneous coronary intervention (PCI)." | 5.22 | Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial. ( Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB, 2016) |
| "Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month versus DAPT with either ticagrelor (acute coronary syndrome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA ≤100 mg for 24 months." | 5.22 | Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. ( Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S, 2016) |
| "Aspirin is promptly administered to patients presenting with acute coronary syndromes." | 5.22 | Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. ( Ayele, GM; Brener, SJ; Lansky, AJ; Mehran, R; Stone, GW, 2016) |
| "This randomized prospective clinical trial aimed to evaluate safety and efficacy of preoperative use of eptifibatide in high risk patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), requiring urgent coronary artery bypass graft surgery (CABG)." | 5.22 | Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial. ( Bochenek, A; Buldak, Ł; Buszman, P; Kondys, M; Milewski, K; Sanak, M; Wilczynski, M; Wita, K; Wybraniec, MT, 2016) |
| "We analyzed data from the randomized TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes) trial of aspirin plus prasugrel or clopidogrel following ACS." | 5.22 | Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. ( Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy." | 5.22 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. ( Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R, 2016) |
| "This study sought to assess the pharmacodynamic (PD) effects of switching to ticagrelor patients who were treated with prasugrel after undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome." | 5.22 | Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. ( Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " In contrast to overall PLATO results, but similar to PLATO-US cohort, PHILO revealed numerical inferiority of ticagrelor with regard to death, myocardial infarction, stroke, and bleeding over clopidogrel." | 5.22 | Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? ( Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A, 2016) |
| "This study suggests that impaired response to both intravenous and oral aspirin is frequent in comatose patients resuscitated from OHCA." | 5.22 | Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. ( Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate." | 5.22 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016) |
| "There are a number of economic evaluation studies of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) published from the perspective of multiple countries in recent years." | 5.22 | A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. ( Chen, C; Chen, EZ; Cui, M; Tan, SC; Tu, CC; Wang, XL, 2016) |
| "To evaluate the safety of preoperative use of ticagrelor with or without aspirin in patients with acute coronary syndromes (ACS) undergoing isolated coronary artery bypass grafting (CABG) compared with aspirin alone." | 5.22 | Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting. ( Bancone, C; Biancari, F; Chocron, S; Dalén, M; De Feo, M; Dominici, C; Faggian, G; Fischlein, T; Gatti, G; Gherli, R; Gherli, T; Gulbins, H; Kinnunen, EM; Mariscalco, G; Maschietto, L; Maselli, D; Mignosa, C; Musumeci, F; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Svenarud, P; Verhoye, JP; Zanobini, M, 2016) |
| "Simultaneous prescription of clopidogrel and low-dose aspirin is recommended for the treatment of acute coronary syndrome because of improvements in efficacy and patient compliance." | 5.22 | Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men. ( Choi, HK; Choi, YK; Ghim, JL; Jung, JA; Shon, J, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "TWILIGHT is the largest study to date that is specifically designed and powered to demonstrate reductions in bleeding with ticagrelor monotherapy versus ticagrelor plus ASA beyond 3 months post-procedure in a high-risk PCI population treated with DES." | 5.22 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. ( Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU, 2016) |
| "Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI)." | 5.20 | Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. ( Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J, 2015) |
| "Aspirin is the most widely used antiplatelet drug postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary intervention with stenting remains uncertain." | 5.20 | Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. ( Bach, RG; Baker, BA; Effron, MB; Fonarow, GC; Henry, TD; McCoy, LA; Peterson, ED; Wang, TY; Xian, Y; Zettler, ME, 2015) |
| "Prior aspirin treatment is considered a risk factor for adverse outcomes in acute coronary syndrome (ACS) patients." | 5.20 | Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study. ( Brener, SJ; de Bruyne, B; Maehara, A; Mintz, GS; Serruys, PW; Stone, GW; Weisz, G, 2015) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 5.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among patients with acute coronary syndromes (ACS) in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial." | 5.17 | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. ( Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 5.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective." | 5.17 | Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. ( Gasche, D; Greiner, RA; Meier, B; Ulle, T, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| " Clopidogrel in the patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) by measuring inhibition of platelet aggregation after loading and maintenance dose of both the drugs." | 5.17 | A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK, 2013) |
| " The aim of the study was to assess the antiplatelet activity and safety of a combined antiplatelet treatment with indobufen and clopidogrel in acute coronary syndrome (ACS) patients with hypersensitivity to aspirin, undergoing coronary stenting." | 5.17 | Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. ( Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Paravati, V; Pellicano, M; Pulcinelli, FM; Tanzilli, G; Torromeo, C, 2013) |
| "The aim of this study was to test the hypothesis that aspirin would reduce the risk for acute coronary syndromes (ACSs) in patients with pneumonia." | 5.17 | Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. ( Abakay, O; Akkoyun, CD; Bulut, I; Cetinkaya, E; Elitok, A; Ersin, G; Gibson, MC; Gul, S; Kaya, MG; Oflaz, H; Oncul, A; Oz, F; Yazici, M, 2013) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 5.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.16 | The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. ( de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes." | 5.15 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 5.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Large randomized clinical trials have shown the efficacy of aspirin, ACE (angiotensin converting enzyme) inhibitors and statins as secondary prevention measures in patients after an acute coronary syndrome with and without ST elevations." | 5.15 | Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Senges, J; Zahn, R; Zeymer, U, 2011) |
| "Patients with a history of an acute coronary syndrome who had previously received clopidogrel were recruited." | 5.15 | Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ( Bassler, N; Dart, AM; Fernando, H; Habersberger, J; Peter, KH; Sharma, R; Shaw, JA; Sheffield, LJ, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 5.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI)." | 5.15 | [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]. ( Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH, 2011) |
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 5.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 5.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 5.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 5.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "Prasugrel led to a significant reduction in ischemic cardiovascular events among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation compared to clopidogrel." | 5.14 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio ( Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C, 2009) |
| "Thirty-two high risk acute coronary syndrome patients were randomised to bivalirudin and provisional GPIIb/IIIa inhibition (GPIIb/IIIa) or unfractionated heparin (UFH) and mandatory GPIIb/IIIa." | 5.14 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu ( Bett, N; Juneja, M; Ray, MJ; Walters, DL, 2009) |
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 5.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| "Currently 162-325 mg aspirin is recommended for the treatment of acute coronary syndrome." | 5.14 | Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy. ( Derhaschnig, U; Frossard, M; Fuchs, I; Jilma, B; Riedmüller, E; Spiel, AO, 2010) |
| "To observe the impact of various application time of aspirin and clopidogrel on the circadian rhythm changes of platelet aggregation in patients with acute coronary syndrome." | 5.14 | [Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome]. ( Cui, W; Li, Z; Liu, F; Liu, J; Lu, JC; Ren, XJ; Xie, RQ; Yang, XC; Zheng, HM, 2010) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 5.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 5.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "In data we published earlier, there is a correlation between platelet aggregation in patients with acute coronary syndrome (ACS) who are receiving aspirin and elevated hsCRP-level." | 5.13 | The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. ( Kasyanova, O; Shpektor, A; Vasilieva, E, 2008) |
| "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS)." | 5.13 | Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. ( Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 5.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| "To investigate the effects of aspirin-omitted dual antithrombotic therapy (DAT) on myocardial infarction and stent thrombosis in non-valvular atrial fibrillation (NVAF) patients presenting with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)." | 5.12 | Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. ( Li, GQ; Liu, SM; Luo, CF; Mo, P, 2021) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 5.12 | Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. ( Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B, 2021) |
| "Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS)." | 5.12 | Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis. ( Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X, 2021) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 5.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 5.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| "Recently, three randomized trials reported that dual antithrombotic treatments (DATs) including non-vitamin K antagonist oral anticoagulants (NOACs) and a P2Y12 inhibitor without aspirin were associated with significantly less bleeding than vitamin K antagonist (VKA)-based triple antithrombotic therapy (TAT) in atrial fibrillation (AF) patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI)." | 5.05 | Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr ( Collet, JP; Dagres, N; Heidbuchel, H; Hindricks, G; Lip, GYH; Mujovic, N; Potpara, TS; Proietti, M; Valgimigli, M, 2020) |
| "Although having different rationales and purposes, the PEGASUS-TIMI 54 and COMPASS trials present various points of contact and, especially after the first recommended year of dual antiplatelet therapy (DAPT) from an acute coronary syndrome, pose the clinical question of whether DAPT should be prolonged (PEGASUS strategy) or aspirin should be maintained by combining rivaroxaban 2." | 5.05 | [Antithrombotic therapy after acute coronary syndromes: is it possible to identify the PEGASUS and COMPASS patient?] ( De Luca, L, 2020) |
| "The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear." | 5.05 | Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. ( Al-Abdouh, A; Hasan, RK; Khan, MS; Khan, MU; Khan, SU; Mamas, MA; Michos, ED; Osman, M; Savji, N; Zhao, D, 2020) |
| " Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease." | 5.05 | Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020) |
| " In patients with previous myocardial infarction completing at least 1 year of DAPT, continuing DAPT with a reduced dose of ticagrelor 60 mg BID is a regimen to be considered for these patients; in general ACS patients, a reduced dose of 60 mg BID of ticagrelor after the first year of DAPT should be considered; and in the post-percutaneous coronary intervention patients, DAPT beyond 1 year should be considered after careful evaluation of the patient's thrombotic and bleeding risks." | 5.05 | Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. ( Dobesh, PP; Finks, SW; Trujillo, TC, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.01 | De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. ( Han, YL, 2019) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the cornerstone for the treatment of patients with acute coronary syndrome (ACS)." | 4.98 | [Bleeding risk in patients with acute coronary syndromes treated with antiplatelet agents: incidence, prognosis and clinical evaluation. From research to clinical practice]. ( Demarchi, A; Ferlini, M; Mauri, S; Portolan, M; Visconti, LO, 2018) |
| "A cornerstone of medical therapy for patients with acute coronary syndrome (ACS) is dual antiplatelet therapy, which includes aspirin and a P2Y12 inhibitor." | 4.95 | Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. ( Fan, TM; Hwang, I; Khouzam, RN; Rashid, A; Reed, GL; Shah, R, 2017) |
| "The use of aspirin, as part of a dual antiplatelet therapy regimen, is an established standard following coronary stenting in patients suffering from acute coronary syndrome (ACS)." | 4.95 | Aspirin safety in glucose-6-phosphate dehydrogenase deficiency patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Al Hout, AR; Feghaly, J; Mercieca Balbi, M, 2017) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "Aspirin allergy in a patient with acute coronary syndrome represents one of the more urgent challenges an allergist may face." | 4.93 | Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes. ( Cook, KA; White, AA, 2016) |
| " Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes." | 4.93 | The pharmacodynamics of antiplatelet compounds in thrombosis treatment. ( Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "After acute coronary syndromes (ACS), the so-called dual antiplatelet therapy (DAPT), which usually consists of low-dose of aspirin in combination with a thienopyridine (clopidogrel, prasugrel) or with a cyclopentyltriazolopyrimidine (ticagrelor), reduces the risk of ischemic events." | 4.93 | Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. ( Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A, 2016) |
| "Clopidogrel combined with aspirin is routinely prescribed after coronary artery stenting, in patients with acute coronary syndromes, and recently to prevent stroke in patients with acute minor ischemic stroke and TIA." | 4.91 | Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. ( Bakheet, MF; Hart, RG; Pearce, LA, 2015) |
| " We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction." | 4.91 | Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. ( Bainey, KR; Ferguson, C; Sharma, A, 2015) |
| " However, prasugrel and ticagrelor have a more consistent, faster-acting and more potent antiplatelet effect than clopidogrel, which translates into improved clinical outcomes, although at the expense of an increased bleeding risk." | 4.91 | Antiplatelet therapy in acute coronary syndromes. ( Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M, 2015) |
| "A short cut review was carried out to establish whether, in patients with suspected acute coronary syndromes presenting to the emergency department, what form of aspirin has the most rapid onset of action." | 4.91 | Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction? ( Hogg, K; Morris, N; Rigg, K, 2015) |
| "The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS)." | 4.90 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. ( Storey, RF; Thomas, MR, 2014) |
| " Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)." | 4.90 | p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014) |
| "PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors." | 4.90 | Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF, 2014) |
| " Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including clopidogrel in combination with aspirin (dual antiplatelet therapy: DAPT) for the prevention of recurrent ischemic events." | 4.90 | [Antiplatelet drugs]. ( Nishikawa, M, 2014) |
| "Although dual antiplatelet therapy (DAPT) has been a standard treatment in patients with acute coronary syndrome (ACS) for over a decade, only recently have therapeutic options beyond aspirin and clopidogrel become available." | 4.90 | Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes. ( Ardati, AK; Duarte, JD; Ismail, S; Lee, YM; Patel, M, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary syndromes (ACS)." | 4.89 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. ( Dinicolantonio, JJ; Norgard, NB, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 4.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| "Aspirin is still the mainstay of therapy in patients with acute coronary syndromes." | 4.89 | Dual antiplatelet therapy -- management in general practice. ( Adsett, G; Jayasinghe, R; Markham, R, 2013) |
| "Dual antiplatelet therapy with aspirin and an oral ADP P2Y12 receptor antagonist is the standard-of-care for the prevention of ischemic events in patients with acute coronary syndrome or undergoing percutaneous coronary intervention (PCI)." | 4.89 | Cangrelor: a review on pharmacology and clinical trial development. ( Angiolillo, DJ; Cho, JR; Franchi, F; Muñiz-Lozano, A; Rollini, F, 2013) |
| "Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 4.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
| "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor." | 4.89 | A critical overview on ticagrelor in acute coronary syndromes. ( Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "In patients with acute coronary syndromes undergoing percutaneous coronary intervention, the combination of aspirin and clopidogrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist, is the gold standard of antiplatelet therapy." | 4.88 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S, 2012) |
| "P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization." | 4.88 | Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012) |
| "Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI)." | 4.88 | Clopidogrel: the data, the experience, and the controversies. ( Sadanandan, S; Singh, IM, 2012) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events." | 4.87 | Clopidogrel withdrawal: is there a "rebound" phenomenon? ( Curzen, N; Sambu, N; Warner, T, 2011) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| "Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known, estimates about the two most widely used antiplatelet agents - aspirin and clopidogrel - suggest that the resistance rate is high, irrespective of the definition used and parameters measured." | 4.87 | Antiplatelet resistance in stroke. ( Arsava, EM; Ay, H; Topçuoglu, MA, 2011) |
| "The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes." | 4.87 | Triple therapy in hospitalized patients: facts and controversies. ( Smetana, GW; Srour, JF, 2011) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a well-established standard of care for patients with acute coronary syndromes." | 4.87 | Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? ( Moliterno, DJ; Rajan, L, 2011) |
| " In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome." | 4.87 | [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. ( Hinneburg, I, 2011) |
| "Dual oral antiplatelet therapy with aspirin and clopidogrel is the therapy of choice in patients with acute coronary syndromes and in patients undergoing coronary stent placement to lower the risk of thrombotic events." | 4.87 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. ( Bernlochner, I; Byrne, RA; Kastrati, A; Sibbing, D, 2011) |
| "Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y(12) inhibitor, for 6?12 months after percutaneous coronary intervention with drug-eluting stent implantation in all patients and for 1 year in all patients after an acute coronary syndrome (ACS), irrespective of revascularization strategy." | 4.87 | Antiplatelet options for secondary prevention in acute coronary syndromes. ( Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J, 2011) |
| "Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes." | 4.86 | Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes. ( Alagona, P, 2010) |
| "Standard double antiplatelet therapy (aspirin plus clopidogrel) used in patients with coronary artery disease during acute coronary syndromes (ACS) and/or in conjunction with percutaneous coronary interventions (PCI) has some limitations." | 4.86 | [Antiplatelet therapy in coronary heart disease. Some problems and achivements]. ( Gratsianskiĭ, NA, 2010) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| "In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
| "The administration of dual antiplatelet therapy with aspirin and a thienopyridine for the prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention is proven to reduce mortality." | 4.86 | A comparison of the metabolism of clopidogrel and prasugrel. ( Laizure, SC; Parker, RB, 2010) |
| "In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation." | 4.86 | [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review]. ( Husted, SE; Nielsen, HK, 2010) |
| " Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial." | 4.85 | Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. ( Bhatt, DL, 2009) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| " Administration of antiplatelet therapy--a glycoprotein IIb-IIIa inhibitor with or without clopidogrel--before catheterization in patients with high-risk features confers substantially reduced risk of ischemic events while potentially increasing bleeding risk." | 4.85 | Does timing matter? Upstream or downstream administration of antiplatelet therapy. ( Pollack, CV; Slattery, D, 2009) |
| "Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management." | 4.85 | A new generation of antiplatelet agents. ( Harrington, RA; Sellers, MB; Tricoci, P, 2009) |
| "To update the previous systematic review of the use of clopidogrel in combination with aspirin for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), investigating the optimal duration of treatment and effects of withdrawal from treatment." | 4.85 | The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. ( Burch, J; Craigs, C; Golder, S; Palmer, S; Rogowski, W; Woolacott, N, 2009) |
| "A systematic review of published cost-effectiveness analyses was performed for an example drug treatment scenario, dual oral antiplatelet therapy compared with aspirin alone following acute coronary syndromes and/or percutaneous coronary intervention." | 4.85 | Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy. ( Bakhai, A; Birt, J; Boye, KS; Juniper, MD; Mauskopf, JA; McCollam, P; Schmitt, C, 2009) |
| "Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention." | 4.85 | Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009) |
| "The current standard of care for patients with non-ST-elevation acute coronary syndromes--aspirin, clopidogrel, and glycoprotein IIb-IIIa inhibitors for the majority of patients--is being challenged by recent clinical trials (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2, Randomized Evaluation of Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events-2, Acute Catheterization and Urgent Intervention Triage StrategY), raising important questions regarding the value of glycoprotein IIb-IIIa inhibitors as accompaniments of high-dose clopidogrel pretreatment and increased use of the anticoagulant bivalirudin." | 4.84 | Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. ( Jennings, LK; Saucedo, JF, 2008) |
| "The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease." | 4.84 | [Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay regimen for acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI)." | 4.31 | Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention. ( Abramowitz, J; Ben-Dor, I; Bernardo, NL; Case, BC; Deksissa, T; Hashim, H; Rogers, T; Satler, LF; Shea, C; Sutton, JA; Torguson, R; Waksman, R; Zhang, C, 2023) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 4.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| "This study evaluated the association among the plasma concentration of ticagrelor, ARC124910XX, aspirin, and salicylic acid with the risk of recent bleeding in patients with the acute coronary syndrome." | 4.31 | The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023) |
| "Coronary artery bypass grafting and conservatively managed acute coronary syndrome: aspirin (reference) compared with aspirin and clopidogrel." | 4.31 | Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. ( Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S, 2023) |
| "We investigated whether combination of glenzocimab, a GPVI inhibitor, with aspirin and ticagrelor provides additional antithrombotic effects, as GPVI has a critical role in atherothrombosis but minimal involvement in hemostasis." | 4.31 | Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. ( Alenazy, FO; Brady, P; Connolly, DL; Harbi, MH; Hargreaves, O; Harrison, P; Jandrot-Perrus, M; Kalia, N; Kavanagh, DP; Kirchhof, P; Mangin, PH; Nicolson, PLR; Price, J; Slater, A; Thomas, MR; Tiwari, A; Watson, SP, 2023) |
| "To explore the effects of ticagrelor and clopidogrel dual antiplatelet therapy on the mean platelet volume-to-lymphocyte ratio (MPVLR), maximum amplitude of adenosine diphosphate-induced platelet-fibrin clots (MAADP), and arachidonic acid (AA) inhibition rates in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI)." | 4.31 | Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention. ( Gao, ST; Ma, L; Wang, Y, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 4.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Clopidogrel in combination with aspirin after acute coronary syndromes (ACS) reduces recurrent ischaemic events compared to aspirin alone." | 4.12 | Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. ( Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L, 2022) |
| "Patients diagnosed with acute coronary syndrome and receiving dual antiplatelet therapy (aspirin and ticagrelor) were enrolled and followed up for 12 months." | 4.12 | Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. ( Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X, 2022) |
| "Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events." | 4.12 | Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. ( Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R, 2022) |
| "We aimed to investigate the effectiveness and safety of ticagrelor in comparison with clopidogrel on a background of aspirin for elderly Chinese patients with coronary artery disease 12 months after percutaneous coronary intervention." | 4.12 | Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. ( Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022) |
| "The patient developed acute profound thrombocytopenia following eptifibatide administration." | 4.12 | Eptifibatide-induced acute profound thrombocytopenia: A case report. ( Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F, 2022) |
| "AUGUSTUS trial demonstrated that, for patients with atrial fibrillation (AF) having acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), an antithrombotic regimen with apixaban and P2Y12 resulted in less bleeding, fewer hospitalizations, and similar ischemic events than regimens including a vitamin K antagonist (VKA), aspirin, or both." | 4.02 | Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. ( Dhanda, D; Di Fusco, M; Kang, A; Kongnakorn, T; Polanco, C; Rivolo, S; Savone, M; Skandamis, A; Soto, J, 2021) |
| "Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event." | 4.02 | Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "A total of 351 patients with ACS were treated with clopidogrel and aspirin for at least 12 months; we recorded major adverse cardiovascular events (MACE) or bleeding within 1 year." | 4.02 | Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. ( Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W, 2021) |
| "The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction." | 4.02 | Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. ( Guo, L; Man, F; Pan, Q; Wang, W; Wang, X; Zhang, J; Zhang, L, 2021) |
| " Hyperhomocysteinemia is a known determinant of platelet function abnormalities." | 3.96 | Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor. ( De Luca, G; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Tonon, F; Verdoia, M, 2020) |
| " Nevertheless, external validation of these RSs it has not yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor in a real- world scenario." | 3.96 | Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. ( Alexopoulos, D; Ariza-Solé, A; Assi, EA; Autelli, M; Bernardi, A; Bianco, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; D'ascenzo, F; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Giustetto, C; Gravinese, C; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lopez-Cuenca, Á; Luciano, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Peyracchia, M; Pousa, IM; Pozzi, R; Quadri, G; Queija, BC; Raposeiras Roubin, S; Rinaldi, M; Rognoni, A; Rossini, R; Srdanovic, I; Taha, S; Templin, C; Valgimigli, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "Aspirin has been the cornerstone of antiplatelet therapy in patients with acute coronary syndromes and is well accepted and recommended by several major healthcare organizations." | 3.96 | Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome. ( Magrum, BG; Pickworth, KK, 2020) |
| "In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin." | 3.96 | Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 3.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "The aim of this study was to investigate the effect of ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT) or conventional DAPT in patients with or without acute coronary syndrome (ACS) in the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)." | 3.96 | Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. ( Branca, M; Franzone, A; Hamm, C; Heg, D; Jüni, P; Leonardi, S; McFadden, EP; Piccolo, R; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Windecker, S, 2020) |
| "In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone." | 3.96 | Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020) |
| "To investigate the long-term clinical benefit of dual antiplatelet therapy with potent P2Y12 inhibitors compared to clopidogrel in patients with acute coronary syndrome (ACS)." | 3.96 | Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. ( Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP, 2020) |
| "BACKGROUND The purpose of this study was to investigate factors influencing bleeding in patients with acute coronary syndrome (ACS) who are on aspirin and ticagrelor as dual antiplatelet therapy." | 3.96 | Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis. ( Guo, L; Huang, Q; Shi, X; Wang, G; Yang, Y; Yuan, D; Yuan, Y; Zhang, H; Zhao, Y, 2020) |
| "In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI)." | 3.96 | Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. ( Aksoy, F; Altınbaş, A; Bağcı, A; Baş, HA; Varol, E, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 3.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "The objective of this study is to explore the relationships of the effects of CYP2C19 and PON1 Q192R polymorphism on the activity of clopidogrel and the risk of high platelet responsiveness (HPR) by thrombelastography in patients with acute coronary syndrome (ACS)." | 3.91 | Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. ( Lin, Y; Peng, W; Shi, X; Xu, X, 2019) |
| "Influence of pre-existing treatment with aspirin and/or statins prior to a first acute coronary syndrome (ACS) on clinical presentation, infarct size and inflammation markers." | 3.91 | Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. ( Denegri, A; Lüscher, TF; Mach, F; Matter, CM; Muller, O; Obeid, S; Räber, L; Shahin, M; Weidmann, L; Yousif, N, 2019) |
| "Between January 2012 and January 2017, 24 patients undergoing coronary angiography for stable coronary disease (7 cases) or acute coronary syndromes (non-ST-segment myocardial infarction [NSTEMI; 8 cases], STEMI [9 cases]) underwent aspirin desensitization having reported previous reactions to aspirin." | 3.91 | Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience. ( Austin, D; Bolton, S; Callaghan, S; Carter, J; de Belder, MA; Hall, JA; Jackson, M; Muir, DF; Stapleton, J; Sutton, AGC; Swanson, N; Williams, PD; Wright, RA, 2019) |
| "Our study evaluated patients with ACS or stable coronary artery disease undergoing PCI and treated with mono-antiplatelet therapy with P2Y12 inhibitors due to aspirin intolerance shows a 25% incidence of POCE at one year." | 3.91 | Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. ( Bianco, M; Biscaglia, S; Campo, G; Cerrato, E; Corleto, A; Destefanis, P; Giolitto, S; Gravinese, C; Lo Savio, L; Luciano, A; Nuñez-Gil, I; Pozzi, R; Quadri, G; Tizzani, E; Varbella, F, 2019) |
| "For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding." | 3.91 | Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. ( Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D, 2019) |
| "In this prospective cohort study, 2439 Chinese patients with acute coronary syndrome or stable coronary artery disease undergoing coronary stent implantation and receiving clopidogrel and aspirin were consecutively recruited." | 3.91 | Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. ( Chan, NC; Chen, J; Fan, Y; Hu, X; Kong, D; Li, C; Li, J; Wang, F; Xu, K; Xu, L; Yang, L; Yang, M; Ye, S; Ying, L; Zhang, J; Zhang, S; Zhang, X; Zhu, H; Zhu, T, 2019) |
| " In diabetic patients treated with DAPT (ASA + clopidogrel or ticagrelor) platelet reactivity was assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI." | 3.91 | Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. ( Carriero, A; De Luca, G; Kedhi, E; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Tonon, F; Verdoia, M, 2019) |
| "Among diabetic patients receiving dual antiplatelet therapy for an acute coronary syndrome or elective percutaneous coronary intervention, severe vitamin D deficiency is associated with a higher ADP-mediated platelet reactivity and rate of HRPR, and especially for new ADP-antagonists over clopidogrel." | 3.91 | Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. ( Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M, 2019) |
| "Despite the known protective cardiovascular effect of aspirin, former studies identified its prior exposure to an acute coronary syndrome (ACS) as an independent risk factor for adverse events." | 3.88 | Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry. ( Belo, A; Correia, J; Morais, J; Ruivo, C; Sá, FM; Santos, LG, 2018) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 3.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| "Our objective was to measure the risks of acute coronary syndrome (ACS) after dispensing of ibuprofen, versus paracetamol." | 3.88 | Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample. ( Abouelfath, A; Blin, P; Droz, C; Duong, M; Lassalle, R; Moore, N, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents." | 3.88 | [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease]. ( Abrignani, MG; Ambrosetti, M; Aspromonte, N; Barile, G; Caporale, R; Casolo, G; Chiuini, E; Colivicchi, F; De Luca, L; Di Lenarda, A; Faggiano, P; Gabrielli, D; Geraci, G; Gulizia, MM; La Manna, AG; Maggioni, AP; Marchese, A; Massari, FM; Mureddu, GF; Musumeci, G; Nardi, F; Panno, AV; Pedretti, RFE; Piredda, M; Pusineri, E; Riccio, C; Rossini, R; Scotto Di Uccio, F; Urbinati, S; Varbella, F; Zito, GB, 2018) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 3.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS)." | 3.88 | Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians. ( Cavallari, LH; El Wakeel, LL; Fathy, S; Khalil, BM; Langaee, T; Sabry, NA; Saleh, A; Schaalan, MF; Shahin, MH, 2018) |
| "The American College of Cardiology Foundation/American Heart Association guidelines for acute coronary syndrome (ACS) recommend immediate aspirin (ASA) administration, an electrocardiogram (ECG) in less than 10 minutes, and a door-in to door-out (DIDO) time less than 30 minutes for interfacility transfer." | 3.85 | Adult Chest Pain in the Pediatric Emergency Department: Treatment and Timeliness From Door In To Door Out. ( Costello, BE; Flueckiger, PB; Mahle, WT; Sacks, JH; Spandorfer, PR, 2017) |
| " Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel." | 3.85 | Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. ( Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R, 2017) |
| "The initial EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion) demonstrated that patients with acute coronary syndrome caused by plaque erosion might be stabilized with aspirin and ticagrelor without stenting for ≤1 month." | 3.85 | EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. ( Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y, 2017) |
| "Clopidogrel is an antiplatelet drug widely used in patients with acute coronary syndromes or stroke." | 3.85 | The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. ( Bălaşa, R; Bănescu, C; Dobreanu, M; Maier, S; Mărginean, A; Mărginean, M; Moldovan, V; Scridon, A; Ţăruşi, M, 2017) |
| "Acetylsalicylic acid (ASA) and clopidogrel combined therapy has been reported to be beneficial in patients with acute coronary syndrome (ACS)." | 3.85 | ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy. ( Bortolin, RH; Bravo, M; Brion, M; Carracedo, A; Concheiro, M; Cruz, A; Germano, JF; Hirata, MH; Hirata, RD; Iñiguez, A; López-Rivadulla, M; Luchessi, AD; Quintela, O; Silbiger, VN; Sousa, AG, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)." | 3.85 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017) |
| "The effect of prior use of aspirin (ASA) on the onset of acute coronary syndrome (ACS) has not been clarified." | 3.85 | Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography. ( Araki, M; Hada, M; Hamaya, R; Hoshino, M; Ichijo, S; Kakuta, T; Kanaji, Y; Kanno, Y; Lee, T; Matsuda, J; Murai, T; Niida, T; Usui, E; Yonetsu, T, 2017) |
| "There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease." | 3.85 | Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 3.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Aspirin hypersensitivity is not a rare condition among patients with acute coronary syndrome." | 3.83 | Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. ( Barrionuevo-Sánchez, MI; Corbí-Pascual, M; Córdoba-Soriano, JG; Fuentes-Manso, R; Gallardo-López, A; Gómez-Pérez, A; Gutiérrez-Díez, A; Hidalgo-Olivares, V; Jiménez-Mazuecos, J; Lafuente-Gormaz, C; López-Neyra, I; Navarro-Cuartero, J; Prieto-Mateos, D, 2016) |
| "Patients (n=18) with acute coronary syndrome who required urgent CABG and had been treated for up to 2 days before surgery with aspirin plus clopidogrel (n=13) or aspirin plus ticagrelor (n=5) were enrolled." | 3.83 | Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. ( Chava, S; Schneider, DJ, 2016) |
| " We measured prescription rates of evidence-based recommended therapies after ACS including reasons for nonprescription of aspirin, statins, β-blockers, angiotensin converting-enzyme inhibitors (ACEI) / angiotensin II receptor blockers (ARB), along with cardiac rehabilitation attendance and delivery of a smoking cessation intervention." | 3.83 | Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. ( Auer, R; Cornuz, J; Gencer, B; Mach, F; Matter, CM; Muller, O; Nanchen, D; Rodondi, N; Welker, J; Windecker, S, 2016) |
| "To investigate the impact of novel P2Y(12) receptor inhibitors including prasugrel or ticagrelor on platelet reactivity in patients with acute coronary syndrome (ACS) receiving percutaneous coronary intervention (PCI), and provide clinical data for novel oral P2Y(12) receptor inhibitors use among Chinese patients." | 3.83 | [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention]. ( Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX, 2016) |
| " Samter's triad consists of nasal polyps, asthma, and aspirin (or nonsteroidal anti-inflammatory drug) sensitivity." | 3.83 | A Case of Kounis Type I in a Young Woman With Samter's Triad. ( Chou, A; Rayner-Hartley, E; Saw, J; Sedlak, T, 2016) |
| " In patients treated with ASA (100-160 mg) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) platelet reactivity and the reticulated platelets fraction (immature platelets fraction, IPF) were assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI." | 3.83 | Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "In patients receiving dual antiplatelet therapy for coronary artery disease, higher PTH levels are associated with an increased ADP-mediated platelet reactivity and suboptimal response to clopidogrel, especially for values above 96." | 3.83 | Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits." | 3.83 | Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| " In patients with ST-elevation acute coronary syndrome with an indication to primary angioplasty, the administration of unfractionated heparin and aspirin is considered the pre-procedural standard treatment." | 3.83 | [ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization]. ( Borzi, M; Caporale, R; Casolo, G; Colivicchi, F; Di Bartolomeo, R; Formigli, D; Geraci, G; Gerometta, P; Gulizia, MM; Ledda, A; Menozzi, A; Musumeci, G; Romeo, F; Scherillo, M; Tarantini, G, 2016) |
| "The main objective was to investigate if the unit of first contact influenced the frequency and time of aspirin treatment in the Strategy of Registry of Acute Coronary Syndrome (ERICO) study." | 3.83 | Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study. ( Bensenor, IM; Bittencourt, MS; Brandão, RM; Goulart, AC; Kisukuri, AL; Lotufo, PA; Santos, IS; Santos, RC; Sitnik, D; Staniak, HL, 2016) |
| "Dual antiplatelet therapy with aspirin and a P2Y12 antagonist is widely prescribed for the prevention of thrombotic events in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention (PCI)." | 3.81 | Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG; Sheehan, R; Stephens, J; Watkins, S, 2015) |
| "Whole blood from 15 patients with acute coronary syndrome who were treated with ticagrelor and aspirin and from eight healthy volunteers was incubated for 1 hour at 28, 33, 37, and 39°C." | 3.81 | Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome. ( Brokopp, J; Erlinge, D; Kander, T; Lood, C; Schött, U, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "This case reports the sudden development of large burden of thrombi in the left anterior descending coronary artery immediately following distal left main stenting using TAP technique in a middle aged man who presented with non ST-segment elevation acute coronary syndrome despite having been administered 7,500 units of unfractionated heparin and being given 325 mg of aspirin and 60 mg of prasugrel prior to the procedure." | 3.81 | Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome. ( Natarajan, D, 2015) |
| "National practice guidelines recommend early aspirin administration to reduce mortality in acute coronary syndrome (ACS)." | 3.81 | Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. ( Govindarajan, P; Mercer, MP; Tataris, KL, 2015) |
| "Aspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI)." | 3.81 | Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin. ( Kafkas, NV; Liakos, CI; Mouzarou, AG, 2015) |
| "Current guidelines recommend ticagrelor, in addition to aspirin, for patients with non-ST-segment elevation acute coronary syndromes at moderate to high-risk regardless of initial therapeutic strategy." | 3.81 | Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. ( Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015) |
| "We included patients treated with acetylsalycilic acid (ASA) (100-160 mg) and clopidogrel (75 mg) or ticagrelor (90 mg twice a day) for acute coronary syndromes or drug-eluting stent implantation." | 3.81 | Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M, 2015) |
| "Secondary prevention treatment with aspirin/ clopidogrel, beta blockers, inhibitors of the rennin-angiotensin-aldosterone converting system and statins reduces the morbidity and mortality of patients after acute coronary syndrome (ACS)." | 3.81 | [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. ( Elis, A; Lishner, M; Pereg, D; Yahia, DH, 2015) |
| " The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months." | 3.80 | Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 3.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "To investigate the association between adenosine diphosphate (ADP)-induced platelet aggregation measured by single-platelet count testing and postoperative blood loss in clopidogrel-treated patients with acute coronary syndromes undergoing coronary artery bypass grafting (CABG)." | 3.80 | Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting. ( Dalén, M; Holm, M; Ivert, T; Lindvall, G; van der Linden, J, 2014) |
| "To assess the cost-effectiveness relationship of Ticagrelor versus Clopidogrel for the management of acute coronary syndrome in Spain." | 3.80 | [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. ( Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P, 2014) |
| "Good evidence exists to support the use of secondary prevention medications (aspirin, statins, beta-blockers and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)) and smoking cessation in patients after acute coronary syndromes (ACSs)." | 3.80 | Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective. ( Griffiths, B; Lesosky, M; Ntsekhe, M, 2014) |
| " Totally, 202 patients with acute coronary syndrome (ACS) were followed up for 10 months for major clinical events of myocardial infarction, cerebrovascular accident (CVA), and all cause mortality, and RPA after clopidogrel loading was assessed in 30 patients." | 3.80 | Monitoring residual platelet activity among patients with acute coronary syndrome. ( Li, L; Qiao, R; Zhang, J, 2014) |
| " The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS)." | 3.79 | Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. ( Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 3.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 3.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "Current guidelines offer a choice of P2Y12 receptor antagonist among clopidogrel, prasugrel or ticagrelor on top of aspirin (ASA) for dual antiplatelet therapy (DAPT) in patients after acute coronary syndromes (ACS)." | 3.79 | Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. ( Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL, 2013) |
| "It remains unknown whether the time course of the antiplatelet effects of clopidogrel differs according to cytochrome P450 (CYP) 2C19 phenotype in Japanese patients with acute coronary syndromes (ACS)." | 3.79 | Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Nagashima, Z; Sugano, T; Tsukahara, K; Umemura, S, 2013) |
| "We sought to evaluate outcomes, costs of care, quality of life and predictors at 12 months in patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and evaluated use of optimal secondary prevention therapy, defined as use of aspirin and clopidogrel along with ≥ 3 of the following 4 therapies at both hospital discharge and at one-year post-PCI: statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet." | 3.79 | Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). ( Bakhai, A; Belger, M; Berkenboom, G; Coufal, Z; Norrbacka, K; Sartral, M; Zeymer, U, 2013) |
| "The American College of Cardiology and the American Heart Association recommend early aspirin administration to patients with symptoms of acute coronary syndrome (ACS)/acute myocardial infarction (AMI)." | 3.79 | Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin diagnostic and instruction tool. ( Barron, T; Clawson, J; Gummett, J; Olola, CH; Patterson, B; Robinson, D; Scott, G; Shiner, R; Wrigley, F, 2013) |
| "Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) commonly receive a loading dose of either clopidogrel or prasugrel, in addition to aspirin." | 3.79 | Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013) |
| "An economic model estimating the cost-effectiveness of prasugrel plus aspirin relative to clopidogrel plus aspirin for patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) was developed from a managed care organization (MCO) perspective." | 3.78 | Cost-effectiveness of prasugrel in a US managed care population. ( Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ, 2012) |
| " We aimed at assessing the predictors of higher plasma levels of TxB2, the stable metabolite of TxA2, in consecutive patients presenting with non-ST-elevation acute coronary syndrome (NSTE-ACS) on previous aspirin (ASA) treatment undergoing coronary angiography." | 3.78 | Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy. ( Biasucci, LM; Burzotta, F; Cataneo, L; Cosentino, N; Crea, F; Fracassi, F; Giubilato, S; Leo, A; Leone, AM; Narducci, ML; Niccoli, G; Porto, I; Pulcinelli, FM; Trani, C, 2012) |
| "The early administration of the anti-platelet agent clopidogrel in patients with acute coronary syndromes with or without ST-segment elevation has a beneficial effect on mortality and major adverse cardiac events." | 3.78 | Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus. ( Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC, 2012) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 3.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| " In particular, an herbal combination including Tribulus terrestris (TT), Avena sativa (AS), and Panax Ginseng (PG), which may be effective in treatment of atherosclerosis and thrombosis, is used by patients with coronary artery disease." | 3.78 | [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?]. ( Erdoğan, E; Göktekin, Ö; Tasal, A; Vatankulu, MA, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "The aim of this study was to evaluate the prevalence of triple antithrombotic therapy (TT) (warfarin, aspirin and clopidogrel) in patients following an acute coronary syndrome (ACS), the bleeding risk compared to double antiplatelet therapy (DAPT) (aspirin and clopidogrel) and evaluate the accuracy of the HAS-BLED risk score in predicting serious bleeding events in TT patients." | 3.78 | Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. ( Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M, 2012) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 3.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "Pre-hospitalization medication such as aspirin and nitrates has been shown to affect the mode of presentation in acute coronary syndrome (ACS)." | 3.77 | Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry. ( Hoshida, S; Iwasaka, J; Iwasaka, T; Kijima, Y; Lim, YJ; Yuasa, F, 2011) |
| "Current clinical practice guidelines recommend dual antiplatelet therapy with aspirin and clopidogrel or prasugrel for patients with acute coronary syndrome (ACS)." | 3.77 | Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. ( Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The standard antithrombotic therapy for treatment of patients with acute coronary syndrome (ACS) is dual antiplatelet therapy with aspirin and clopidogrel (Plavix) or another thienopyridine, plus a parenteral anticoagulant while the patient is hospitalized, followed by antiplatelet therapy alone after discharge." | 3.77 | Rivaroxaban (Xarelto) for acute coronary syndrome. ( , 2011) |
| "Increased baseline platelet reactivity as well as diabetes mellitus and acute coronary syndrome are associated with low aspirin response in the aged patients." | 3.77 | [Aspirin response and related factors in aged patients]. ( Fan, Y; Feng, XR; Liu, F; Liu, ML; Liu, QZ; Tian, QP, 2011) |
| "We aimed to prospectively evaluate the prevalence of biochemical aspirin resistance in patients on aspirin therapy who were admitted to the emergency clinic with chest pain." | 3.76 | The clinical significance of aspirin resistance in patients with chest pain. ( Acikel, S; Atar, A; Atar, I; Aydinalp, A; Bozbas, H; Ertan, C; Gulmez, O; Muderrisoglu, H; Ozgul, A; Ozin, B, 2010) |
| "The study aimed to determine whether aspirin therapy was differentially administered according to race, sex, or age in patients with undifferentiated chest pain who presented to an urban academic emergency department." | 3.76 | Aspirin administration in ED patients who presented with undifferentiated chest pain: age, race, and sex effects. ( Hollander, JE; Shofer, FS; Takakuwa, KM, 2010) |
| "Feedback reports and quality improvement improved prehospital ECG performance for patients with acute coronary syndrome and ST-elevation myocardial infarction and increased aspirin administration without prehospital transport delays." | 3.76 | Improving use of prehospital 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction. ( Beshansky, JR; Daudelin, DH; Goetz, JD; Kwong, M; Lane, WM; Porcaro, WA; Restuccia, MC; Ruthazer, R; Sayah, AJ; Selker, HP, 2010) |
| "The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation." | 3.76 | Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. ( Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J, 2010) |
| "Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality." | 3.76 | Prior aspirin use and outcomes in acute coronary syndromes. ( Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Qin, J; Rich, JD, 2010) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Premature discontinuation of antiplatelet therapy has been identified as a major risk factor for stent thrombosis and prior aspirin withdrawal has been associated with poor prognosis after acute coronary syndrome." | 3.75 | Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Faille, D; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction." | 3.75 | The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. ( Acikel, S; Aydinalp, A; Bal, U; Kaynar, G; Muderrisoglu, H; Ozin, B; Yildirir, A, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Despite the clinical benefit associated with the combined use of aspirin and clopidogrel in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention, a considerable interindividual variability in response to these drugs have been consistently reported." | 3.75 | Platelet monitoring for PCI: which test is the one to choose? ( Angiolillo, DJ; Capodanno, D, 2009) |
| "The P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin." | 3.75 | P2Y12 inhibitors: thienopyridines and direct oral inhibitors. ( Collet, JP; Montalescot, G, 2009) |
| "Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events." | 3.75 | Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. ( Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T, 2009) |
| "To observe and assess the effect of different dosages of aspirin on inflammatory biomarkers, hemorheology (platelet aggregation rate) and clinical prognosis in patients with acute coronary syndrome (ACS)." | 3.75 | [The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.]. ( Hu, DY; Li, RJ; Liang, YQ; Ren, WL; Song, LF; Xu, YY; Yin, ZN, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 3.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| " Among the key recommendations are the following: for all patients presenting with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), without a clear allergy to aspirin, we recommend immediate aspirin (162 to 325 mg po) and then daily oral aspirin (75 to 100 mg) [Grade 1A]." | 3.74 | Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G, 2008) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 3.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "We analysed data from 800 patients with an acute coronary syndrome who underwent coronary stenting (130 patients received a drug-eluting stent) and were discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet therapy." | 3.74 | Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? ( Agnelli, G; Allegrone, J; Brieger, D; Budaj, A; Goodman, SG; Gulba, DC; Lefkovits, J; Lim, YL; Nguyen, MC; Walton, A, 2007) |
| "To determine the risk of major and minor bleeding associated with the CTT compared with two other regimens using the combination of either ASA and clopidogrel or ASA and warfarin in patients with cardiovascular disease." | 3.74 | Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. ( Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007) |
| "The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment." | 3.74 | Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. ( Abbate, R; Antoniucci, D; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Saracini, C; Sestini, I; Valente, S, 2007) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 3.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS)." | 3.74 | [Efficacy of intravenous aspirin use in patients with acute coronary syndrome]. ( Shen, LH; Yang, M; Zhao, Y, 2007) |
| " Hospital charts review revealed key information for clinical variables, smoking, obesity and use of aspirin at admission." | 3.74 | Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. ( Aguado, J; Castellsague, J; Perez-Gutthann, S; Stang, MR; Tomas, L; Varas-Lorenzo, C, 2008) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 3.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events." | 3.01 | Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. ( Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV, 2023) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 2.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| " A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence." | 2.84 | Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. ( Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, K; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, Y; Tantry, US, 2017) |
| "Ticagrelor is an effective and well-tolerated option to attain a meaningful and clinically relevant reduction in cardiovascular mortality in both acute and chronic settings across a broad range of high-risk patient subpopulations with an acceptable payoff in terms of bleeding risk." | 2.82 | Cardiovascular mortality in patients with acute and chronic coronary syndrome: insights from the clinical evidence on ticagrelor. ( Esposito, G; Gargiulo, G; Serino, F, 2022) |
| "Vorapaxar is an antagonist of the protease activated receptor-1 (PAR-1), the principal platelet thrombin receptor." | 2.79 | Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. ( Becker, RC; Chen, E; Cornel, JH; Dery, JP; Harrington, RA; Hord, E; Huber, K; Jennings, LK; Judge, HM; Kotha, J; Mahaffey, KW; Moccetti, T; Moliterno, DJ; Rorick, TL; Smyth, SS; Storey, RF; Strony, J; Thomas, GS; Tricoci, P; Valgimigli, M, 2014) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 2.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| " The patients in the platelet function monitoring guided group received an antiplated therapy guided by a modified thromboelastography (TEG) platelet mapping: If inhibition of platelet aggregation (IPA) induced by arachidonic acid (AA) was less than 50% the aspirin dosage was raised to 200 mg/d; if IPA induced by adenosine diphosphate (ADP) was less than 30% the clopidogrel dosage was raised to 150 mg/d, for three months." | 2.79 | Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions. ( Li, K; Li, W; Liu, Y; Ni, Z; Sun, H; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014) |
| "Bleeding was reported according to Bleeding Academic Research Consortium (BARC) definition." | 2.78 | Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. ( Filipiak, KJ; Grabowski, M; Huczek, Z; Kochman, J; Michalak, M; Opolski, G, 2013) |
| "Aspirin resistance was defined as collagen (1 μg/mL) and adenosine diphosphate (ADP) (5 μmol/L)-induced platelet aggregation of ≥ 40% when compared with control values." | 2.77 | Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. ( ElSafady, LA; Morad, AR; Sabri, NA; Salama, MM; Saleh, MA; Zaki, MM, 2012) |
| "Major bleeding was strongly associated with 30-day mortality (OR 50." | 2.76 | Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. ( Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Cilostazol 100 mg b." | 2.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| " Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| "The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data." | 2.74 | Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. ( Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG, 2009) |
| "Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS)." | 2.74 | Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L, 2009) |
| " The endpoints were major adverse cardiac events (MACEs), death, stroke, myocardial infarction (MI), stent thrombosis, and bleeding events." | 2.66 | Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. ( Li, D; Li, X; Shen, S; Wu, H; Xiang, X, 2020) |
| "Acute coronary syndrome is a major health problem affecting ~ 1." | 2.66 | Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes. ( Deoker, A; Lehker, A; Mukherjee, D, 2020) |
| "Treatment with ticagrelor appears to yield greater net benefit for patients when the probability of ACS >8%." | 2.61 | Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes. ( Body, R; Jarman, H; Morris, N; Moss, P; Reynard, C, 2019) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 2.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "Aspirin has been the cornerstone of therapy for the secondary prevention treatment of patients with cardiovascular disease since landmark trials were completed in the late 1970s and early 1980s that demonstrated the efficacy of aspirin for reducing the risk of ischemic events." | 2.53 | Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. ( Fanaroff, AC; Roe, MT, 2016) |
| "Aspirin has been in use for prevention and management of cardiovascular diseases for several decades." | 2.52 | Aspirin dosing in cardiovascular disease prevention and management: an update. ( Becker, RC; Ganjehei, L, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "Fibrin is an important contributor to thrombogenesis and may account for the residual event rates." | 2.50 | Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. ( White, H, 2014) |
| "Hypertrophic cardiomyopathy is a well-known clinical entity." | 2.49 | Apical hypertrophic cardiomyopathy--case report and review of the literature. ( Caglar, I; Karakaya, O; Ugurlucan, M; Ungan, I; Vural, A, 2013) |
| " A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose." | 2.49 | Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. ( Berger, JS, 2013) |
| "Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article." | 2.49 | Use of antiplatelet drugs in the treatment of acute coronary syndromes. ( Aronow, WS, 2013) |
| "Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U." | 2.48 | Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 2.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| "Aspirin is a relatively weak anti platelet agent." | 2.47 | Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds. ( Bett, JH; Syed, FA; Walters, DL, 2011) |
| "Tirofiban is safe and effective in patients with ACS." | 2.46 | Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010) |
| "Aspirin alone is a relatively weak antiplatelet agent because it inhibits only one of many paths to platelet activation." | 2.45 | Variability in responsiveness to oral antiplatelet therapy. ( Angiolillo, DJ, 2009) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 2.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| "Aspirin has been the cornerstone of antiplatelet therapy for many decades, but in recent years, adenosine diphosphate (ADP) receptor antagonists, mainly clopidogrel and ticlopidine, and glycoprotein (GP) IIb/IIIa (integrin alpha IIb beta 3) inhibitors have also shown similar effectiveness." | 2.44 | Acute and long-term antiplatelet therapy. ( Goudevenos, JA; Mikhailidis, DP; Papathanasiou, AI; Tselepis, AD, 2008) |
| "Fundamentally, acute coronary syndromes are platelet-centric diseases, resulting from platelet-rich thrombi that develop at the site of vessel wall injury." | 2.44 | The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. ( Gurbel, PA; Tantry, US, 2008) |
| "Aspirin resistance was assessed, using a variety of platelet function assays." | 2.44 | Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. ( Beattie, WS; Brister, SJ; Buchanan, MR; Krasopoulos, G, 2008) |
| " The specific dosing and its clinical usefulness of each medication are considered." | 2.44 | [Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. ( Keltai, M, 2008) |
| "Aspirin was used in 48% of GICU, 96% of CCU, and 79% of CAG-GICU patients (P<0." | 1.91 | Impact of admitting department on the management of acute coronary syndrome after an out of hospital cardiac arrest. ( Jansky, P; Jarkovsky, J; Kafka, P; Knot, J; Kroupa, J; Motovska, Z; Waldauf, P, 2023) |
| "Aspirin was administered to 180 (93." | 1.91 | Acute coronary syndrome in very elderly patients-a real-world experience. ( Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A, 2023) |
| "Cilostazol is a specific and strong inhibitor of phosphodiesterase (PDE) type III which can suppress the platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels." | 1.62 | Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome. ( Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y, 2021) |
| "Patients with higher COPD severity were less likely to receive a beta-blocker than those with lower severity, as were those with no history of previous ACS and/or heart failure." | 1.56 | Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand. ( Barson, D; Dummer, J; Parkin, L; Quon, J; Sharples, K, 2020) |
| "Patients with acute coronary syndrome are treated with dual antiplatelet therapy containing acetylsalicylic acid (ASA) and P2Y12 antagonists." | 1.56 | Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy. ( Choi, YH; Deppe, AC; Gerfer, S; Liakopoulos, O; Schlachtenberger, G; Wahlers, TCW; Zeriouh, M, 2020) |
| "Patients who are at increased risk for MI can be maintained on DAPT up to the time of CABG because surgery is safe when patients are offered PPT." | 1.51 | Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe? ( Charif, F; El Zein, A; Hamdan, R; Issa, M; Jassar, Y; Saab, M; Younes, M; Youness, G, 2019) |
| "Recent studies suggested protruding thrombus and atheroma after stent placement could be a substrate for subsequent adverse ischemic events." | 1.48 | Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. ( Hirata, KI; Kijima, Y; Kozuki, A; Masano, T; Nagoshi, R; Otake, H; Shibata, H; Shinke, T; Shite, J; Takeshige, R; Tsukiyama, Y; Yanaka, KI, 2018) |
| "Chest pain recurrence was defined as the first revisit to the emergency room with angina." | 1.48 | Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018) |
| "Severe thrombocytopenia was identified in 36 patients (36." | 1.48 | Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia. ( Balanescu, DV; Cilingiroglu, M; Donisan, T; Durand, JB; Giza, DE; Iliescu, C; Kim, PY; Lopez-Mattei, JC; Marmagkiolis, K; Mouhayar, EN; Mukerji, SS; Muñoz Gonzalez, ED; Palaskas, N; Song, J, 2018) |
| "Background Obstructive sleep apnea ( OSA ) is a novel risk factor for acute coronary syndrome ( ACS )." | 1.48 | Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy. ( Fan, J; Gong, W; Nie, S; Wang, X; Wei, Y, 2018) |
| "We present a case of reverse takotsubo syndrome (rTS) in a 68-year-old woman who presented with acute chest pain and flu-like symptoms." | 1.48 | Possible association of influenza A infection and reverse takotsubo syndrome. ( Aoi, S; Golfeyz, S; Harrington, M; Kobayashi, T, 2018) |
| "Longitudinal analyses of the STEMI subgroup are reported." | 1.46 | A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. ( Devlin, G; Elliott, JM; Ellis, CJ; French, JK; Gamble, GD; Hamer, A; Mann, S; Matsis, P; Richards, M; Troughton, R; Wang, TK; White, HD; Williams, MJ, 2017) |
| "Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases." | 1.46 | Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome. ( Velázquez de Campos, O, 2017) |
| "Aspirin was effective (defined as light transmission aggregometry induced by arachidonic acid ≤20%) at D1 in 86% of cases (P = 0." | 1.46 | Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. ( Abergel, H; Ajzenberg, N; Alfaiate, T; Chollet-Martin, S; Driss, F; Huisse, MG; Manzo-Silberman, S; Neukirch, C; Nicaise-Roland, P; Steg, PG; Tubach, F, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 1.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "Age above 55 years was associated with recurrence of ACS in C2238/ANP-minor allele carriers (hazard ratio 1." | 1.43 | T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. ( Abbolito, S; Battistoni, A; Bianchi, F; Burocchi, S; Cangianiello, S; Caprinozzi, M; Comito, F; Cotugno, M; De Giusti, M; Di Castro, S; Dito, E; Farcomeni, A; Greco, ES; Marchitti, S; Pagliaro, B; Pierelli, G; Rubattu, S; Sciarretta, S; Stanzione, R; Volpe, M, 2016) |
| "Further, we examined thrombus formation on human atherosclerotic plaque homogenates under arterial shear to address the relevance to human pathology." | 1.43 | Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. ( Brandl, R; Braun, D; Braun, S; Chandraratne, S; Eckart, A; Hoppe, B; Jamasbi, J; Kolb, C; Konrad, I; Lennerz, C; Lorenz, M; Massberg, S; Petzold, T; Regenauer, R; Schubert, I; Schulz, C; Siess, W; Thienel, M, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality." | 1.42 | Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015) |
| "Smoking, alcohol abuse, and obesity were more common in patients with ST elevation myocardial infarction (STEMI) (P < 0." | 1.42 | Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study. ( Bandara, R; De Silva, C; Galgomuwa, MP; Medagama, A, 2015) |
| "Depression is associated with poor adherence to medications and worse prognosis in patients with acute coronary syndrome (ACS)." | 1.40 | The psychosocial context impacts medication adherence after acute coronary syndrome. ( Alcántara, C; Burg, MM; Davidson, KW; Kronish, IM; Rieckmann, N, 2014) |
| "T2DM was associated with increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ(2)/mm, median (IQR), p=0." | 1.40 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG, 2014) |
| "Cangrelor is an intravenous ATP analog that directly, selectively and reversibly inhibits P2Y12 receptors on platelets." | 1.40 | Cangrelor for treatment during percutaneous coronary intervention. ( Dobesh, PP; Oestreich, JH, 2014) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 1.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| " Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction." | 1.40 | Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014) |
| " In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization." | 1.39 | Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013) |
| "In clinical practice, cancer patients are frequently afflicted with MI." | 1.38 | Treatment and outcomes of acute coronary syndrome in the cancer population. ( Abbasi, N; Daher, IN; Daraban, N; Durand, JB; Lei, X; Yusuf, SW, 2012) |
| "Sex disparities in the diagnosis and treatment of chest pain or suspected angina have been demonstrated in multiple clinical settings." | 1.36 | Influence of sex on the out-of-hospital management of chest pain. ( Armstrong, K; Facenda, K; Mechem, CC; Meisel, ZF; Peacock, N; Pollack, CV; Shofer, FS, 2010) |
| " Identified areas of improvement were the standardization of treatment protocols, use of risk assessment scores, appropriate dosing of anticoagulants, and improvement in patient treatment times." | 1.36 | Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. ( Berry, CA; Cannon, CP; Carter, RD; Cornish, J; Hoekstra, JW; Karcher, RB; Larson, DM; Mencia, WA; Stowell, SA, 2010) |
| "The prevalence of COPD was 5." | 1.36 | Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. ( Al Habib, K; Al Mahmeed, W; Al Suwaidi, J; Alsheikh-Ali, AA; Assad, N; El-Menyar, AA; Hadi, HA; Ridha, M; Singh, R; Zubaid, M, 2010) |
| "Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information." | 1.36 | Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010) |
| "Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial." | 1.36 | Emerging oral antiplatelet therapies for acute coronary syndromes. ( Pollack, CV, 2010) |
| "Mortality from acute coronary syndrome has historically been higher in women as compared with men." | 1.35 | Reduction in sex-based mortality difference with implementation of new cardiology guidelines. ( Cutlip, DE; Jotkowitz, A; Lieberman, N; Novack, V; Porath, A, 2008) |
| "The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy." | 1.35 | Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy. ( Fonville, S; Ramos, LM; Rinkel, GJ; van der Worp, HB, 2009) |
| "Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0." | 1.35 | Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. ( Abbas, A; Barth, JH; Cubbon, RM; Das, R; Gale, CP; Grant, PJ; Hall, AS; Kearney, MT; Morrell, C; Rajwani, A, 2008) |
| "6) by PFA-100], chronic use of aspirin [OR=0." | 1.34 | Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R, 2007) |
| " One major adverse clinical event (0." | 1.34 | Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. ( Davis, KE; Denardo, SJ; Tcheng, JE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 147 (15.65) | 29.6817 |
| 2010's | 607 (64.64) | 24.3611 |
| 2020's | 185 (19.70) | 2.80 |
| Authors | Studies |
|---|---|
| Vranckx, P | 9 |
| Valgimigli, M | 21 |
| Odutayo, A | 1 |
| Serruys, PW | 9 |
| Hamm, C | 8 |
| Steg, PG | 22 |
| Heg, D | 3 |
| Mc Fadden, EP | 1 |
| Onuma, Y | 6 |
| Benit, E | 2 |
| Janssens, L | 1 |
| Diletti, R | 1 |
| Ferrario, M | 3 |
| Huber, K | 17 |
| Räber, L | 3 |
| Windecker, S | 19 |
| Jüni, P | 5 |
| Ndrepepa, G | 4 |
| Neumann, FJ | 5 |
| Menichelli, M | 2 |
| Holdenrieder, S | 2 |
| Richardt, G | 2 |
| Mayer, K | 3 |
| Cassese, S | 4 |
| Xhepa, E | 2 |
| Kufner, S | 2 |
| Wiebe, J | 1 |
| Joner, M | 2 |
| Kessler, T | 1 |
| Laugwitz, KL | 2 |
| Schunkert, H | 2 |
| Kastrati, A | 7 |
| Serebruany, V | 1 |
| Tanguay, JF | 7 |
| Kubica, J | 5 |
| Adamski, P | 2 |
| Gorog, DA | 5 |
| Kubica, A | 2 |
| Jilma, B | 4 |
| Budaj, A | 10 |
| Siller-Matula, JM | 5 |
| Gurbel, PA | 16 |
| Alexopoulos, D | 5 |
| Badarienė, J | 2 |
| Dąbrowski, P | 1 |
| Dudek, D | 3 |
| Giannitsis, E | 4 |
| Horszczaruk, G | 1 |
| Jaguszewski, MJ | 1 |
| James, S | 8 |
| Jeong, YH | 7 |
| Kryjak, M | 1 |
| Niezgoda, P | 2 |
| Ostrowska, M | 2 |
| Patti, G | 4 |
| Romanek, J | 1 |
| Di Somma, S | 1 |
| Specchia, G | 2 |
| Tantry, U | 1 |
| Gąsior, M | 2 |
| Tycińska, A | 2 |
| Wojakowski, W | 2 |
| Buszko, K | 1 |
| Gil, R | 3 |
| Gruchała, M | 1 |
| Kasprzak, J | 2 |
| Kleinrok, A | 2 |
| Legutko, J | 2 |
| Lesiak, M | 2 |
| Navarese, EP | 6 |
| Cesaro, A | 2 |
| Gragnano, F | 3 |
| Calabrò, P | 5 |
| Moscarella, E | 3 |
| Santelli, F | 1 |
| Fimiani, F | 2 |
| Cavallari, I | 2 |
| Antonucci, E | 1 |
| Cirillo, P | 2 |
| Pignatelli, P | 1 |
| Palareti, G | 1 |
| Pelliccia, F | 1 |
| Bossone, E | 1 |
| Pengo, V | 2 |
| Gresele, P | 3 |
| Marcucci, R | 9 |
| Gupta, R | 1 |
| Lin, M | 1 |
| Mehta, A | 1 |
| Aedma, SK | 1 |
| Shah, R | 2 |
| Ranchal, P | 1 |
| Vyas, AV | 1 |
| Singh, S | 3 |
| Kluck, B | 1 |
| Combs, WG | 1 |
| Patel, NC | 1 |
| Rivolo, S | 1 |
| Di Fusco, M | 1 |
| Polanco, C | 1 |
| Kang, A | 1 |
| Dhanda, D | 1 |
| Savone, M | 1 |
| Skandamis, A | 1 |
| Kongnakorn, T | 1 |
| Soto, J | 1 |
| Kim, BG | 1 |
| Hong, SJ | 6 |
| Kim, BK | 6 |
| Lee, SJ | 4 |
| Ahn, CM | 6 |
| Shin, DH | 2 |
| Kim, JS | 8 |
| Ko, YG | 5 |
| Choi, D | 5 |
| Hong, MK | 6 |
| Jang, Y | 7 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 1 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 1 |
| Rodríguez-González, F | 1 |
| Tugores, A | 1 |
| Passacquale, G | 1 |
| Sharma, P | 1 |
| Perera, D | 1 |
| Ferro, A | 1 |
| Jackson, J | 1 |
| Alkhalil, M | 2 |
| Ratcovich, H | 1 |
| Wilkinson, C | 1 |
| Mehran, R | 21 |
| Kunadian, V | 4 |
| Kuzemczak, M | 1 |
| Bell, A | 1 |
| Stern, S | 1 |
| Welsford, M | 2 |
| Cantor, WJ | 2 |
| Goodman, SG | 18 |
| Welsh, RC | 4 |
| Dehghani, P | 1 |
| Lopes, R | 2 |
| Wojdyla, DM | 5 |
| Aronson, R | 7 |
| Granger, CB | 15 |
| Vora, AN | 6 |
| Vinereanu, D | 4 |
| Halvorsen, S | 5 |
| Parkhomenko, A | 6 |
| Alexander, JH | 12 |
| Goodman, S | 2 |
| Lahu, S | 1 |
| Bernlochner, I | 2 |
| Wöhrle, J | 1 |
| Witzenbichler, B | 5 |
| Hemetsberger, R | 1 |
| Akin, I | 2 |
| Gewalt, S | 1 |
| Valina, C | 1 |
| Sager, HB | 1 |
| Ibrahim, T | 1 |
| Schüpke, S | 1 |
| Marquis-Gravel, G | 2 |
| Robert-Halabi, M | 1 |
| Bainey, KR | 3 |
| Mehta, SR | 10 |
| D'Ascenzo, F | 6 |
| DE Filippo, O | 3 |
| Angelini, F | 1 |
| Piroli, F | 1 |
| DE Lio, G | 1 |
| Bocchino, PP | 1 |
| Baldetti, L | 2 |
| Melillo, F | 2 |
| Chieffo, A | 3 |
| Saglietto, A | 1 |
| Omedè, P | 3 |
| Montefusco, A | 2 |
| Conrotto, F | 2 |
| de Ferrari, GM | 3 |
| Tam, CF | 1 |
| Chan, YH | 1 |
| Wong, YK | 1 |
| Li, Z | 6 |
| Zhu, X | 1 |
| Su, KJ | 1 |
| Ganguly, A | 1 |
| Hwa, K | 1 |
| Ling, XB | 1 |
| Tse, HF | 1 |
| Sheng, XY | 1 |
| An, HJ | 1 |
| He, YY | 1 |
| Ye, YF | 1 |
| Zhao, JL | 1 |
| Li, S | 1 |
| Krackhardt, F | 1 |
| Jörnten-Karlsson, M | 1 |
| Waliszewski, M | 1 |
| Knutsson, M | 1 |
| Niklasson, A | 1 |
| Appel, KF | 1 |
| Degenhardt, R | 1 |
| Ghanem, A | 1 |
| Köhler, T | 1 |
| Ohlow, MA | 1 |
| Tschöpe, C | 1 |
| Theres, H | 1 |
| Vom Dahl, J | 2 |
| Karlson, BW | 1 |
| Maier, LS | 1 |
| Gargiulo, G | 4 |
| Serino, F | 1 |
| Esposito, G | 3 |
| Lee, YJ | 3 |
| Cho, JY | 3 |
| Yun, KH | 3 |
| Tao, L | 2 |
| Ren, S | 1 |
| Zhang, L | 7 |
| Liu, W | 2 |
| Zhao, Y | 3 |
| Chen, C | 3 |
| Mao, X | 1 |
| Chen, Z | 1 |
| Gu, X | 1 |
| Smits, PC | 3 |
| Frigoli, E | 1 |
| Bongiovanni, D | 1 |
| Tijssen, J | 1 |
| Hovasse, T | 1 |
| Mafragi, A | 1 |
| Ruifrok, WT | 1 |
| Karageorgiev, D | 1 |
| Aminian, A | 1 |
| Garducci, S | 1 |
| Merkely, B | 4 |
| Routledge, H | 1 |
| Ando, K | 3 |
| Diaz Fernandez, JF | 1 |
| Cuisset, T | 12 |
| Nesa Malik, FT | 1 |
| Halabi, M | 1 |
| Belle, L | 1 |
| Din, J | 1 |
| Beygui, F | 2 |
| Abhyankar, A | 1 |
| Reczuch, K | 1 |
| Pedrazzini, G | 1 |
| Hou, M | 1 |
| Hyun, K | 1 |
| Chew, DP | 2 |
| Kritharides, L | 1 |
| Amos, D | 1 |
| Brieger, D | 6 |
| Bahit, MC | 4 |
| Thomas, L | 2 |
| Jordan, JD | 1 |
| Kolls, BJ | 1 |
| Dombrowski, KE | 1 |
| Berwanger, O | 6 |
| Lopes, RD | 14 |
| Yang, J | 3 |
| Qi, G | 1 |
| Hu, F | 1 |
| Zhang, X | 4 |
| Xing, Y | 1 |
| Wang, P | 1 |
| Philipsen, L | 1 |
| Würtz, N | 1 |
| Polcwiartek, C | 1 |
| Kragholm, KH | 1 |
| Torp-Pedersen, C | 2 |
| Nielsen, RE | 1 |
| Jensen, SE | 1 |
| Attar, R | 2 |
| Obayashi, Y | 1 |
| Watanabe, H | 3 |
| Morimoto, T | 1 |
| Yamamoto, K | 1 |
| Natsuaki, M | 1 |
| Domei, T | 1 |
| Yamaji, K | 1 |
| Suwa, S | 1 |
| Isawa, T | 1 |
| Yoshida, R | 1 |
| Sakamoto, H | 1 |
| Akao, M | 1 |
| Hata, Y | 1 |
| Morishima, I | 1 |
| Tokuyama, H | 1 |
| Yagi, M | 1 |
| Suzuki, H | 1 |
| Wakabayashi, K | 1 |
| Suematsu, N | 1 |
| Inada, T | 1 |
| Tamura, T | 1 |
| Okayama, H | 1 |
| Abe, M | 1 |
| Kawai, K | 1 |
| Nakao, K | 1 |
| Tanabe, K | 2 |
| Ikari, Y | 2 |
| Morino, Y | 1 |
| Kadota, K | 1 |
| Furukawa, Y | 1 |
| Nakagawa, Y | 1 |
| Kimura, T | 4 |
| Pufulete, M | 4 |
| Harris, J | 3 |
| Pouwels, K | 1 |
| Reeves, BC | 3 |
| Lasserson, D | 3 |
| Loke, YK | 1 |
| Mumford, A | 3 |
| Mahadevan, K | 2 |
| Johnson, TW | 5 |
| Xu, S | 1 |
| Liang, Y | 1 |
| Chen, Y | 4 |
| Gao, H | 1 |
| Tan, Z | 1 |
| Wang, Q | 5 |
| Liu, Y | 3 |
| Zhu, B | 2 |
| Tao, F | 1 |
| Zhao, S | 1 |
| Yang, L | 2 |
| Zhang, Y | 6 |
| Wang, Z | 8 |
| Han, P | 1 |
| Zhang, A | 2 |
| Li, C | 5 |
| Lian, K | 1 |
| Rao, SV | 2 |
| Kirsch, B | 1 |
| Bhatt, DL | 32 |
| Coppolecchia, R | 1 |
| Eikelboom, J | 3 |
| James, SK | 7 |
| Jones, WS | 3 |
| Keller, L | 1 |
| Hermanides, RS | 1 |
| Campo, G | 2 |
| Ferreiro, JL | 3 |
| Shibasaki, T | 1 |
| Mundl, H | 4 |
| Li, X | 9 |
| Ye, Y | 2 |
| Xia, L | 1 |
| Zou, Y | 1 |
| Xu, Q | 2 |
| Yao, Y | 1 |
| Lv, Q | 3 |
| Jansky, P | 2 |
| Motovska, Z | 2 |
| Kroupa, J | 1 |
| Waldauf, P | 1 |
| Kafka, P | 1 |
| Knot, J | 1 |
| Jarkovsky, J | 1 |
| Alamin, MA | 1 |
| Al-Mashdali, A | 1 |
| Al Kindi, DI | 1 |
| Elshaikh, EA | 1 |
| Othman, F | 1 |
| Millesimo, M | 1 |
| Elia, E | 1 |
| Marengo, G | 1 |
| Raposeiras-Roubin, S | 3 |
| Wańha, W | 1 |
| Abu-Assi, E | 3 |
| Kinnaird, T | 4 |
| Ariza-Solé, A | 4 |
| Liebetrau, C | 1 |
| Manzano-Fernández, S | 5 |
| Iannaccone, M | 1 |
| Henriques, JPS | 2 |
| Templin, C | 4 |
| Wilton, SB | 1 |
| Velicki, L | 4 |
| Xanthopoulou, I | 4 |
| Correia, L | 1 |
| Cerrato, E | 7 |
| Rognoni, A | 5 |
| Nuñez-Gil, I | 2 |
| Song, X | 1 |
| Kawaji, T | 1 |
| Quadri, G | 5 |
| Huczek, Z | 3 |
| Paz, RC | 4 |
| Juanatey, JRG | 1 |
| Nie, SP | 1 |
| Kawashiri, MA | 1 |
| Dominguez-Rodriguez, A | 4 |
| Kang, J | 4 |
| Park, KW | 6 |
| Lee, H | 5 |
| Hwang, D | 3 |
| Yang, HM | 4 |
| Rha, SW | 3 |
| Bae, JW | 4 |
| Lee, NH | 2 |
| Hur, SH | 2 |
| Han, JK | 4 |
| Shin, ES | 5 |
| Koo, BK | 5 |
| Kim, HS | 6 |
| Case, BC | 1 |
| Torguson, R | 3 |
| Abramowitz, J | 1 |
| Shea, C | 1 |
| Zhang, C | 2 |
| Sutton, JA | 1 |
| Deksissa, T | 1 |
| Satler, LF | 3 |
| Ben-Dor, I | 1 |
| Bernardo, NL | 1 |
| Hashim, H | 1 |
| Rogers, T | 1 |
| Waksman, R | 5 |
| Peng, W | 4 |
| Lin, Y | 4 |
| Kanaoka, K | 2 |
| Iwanaga, Y | 2 |
| Nakai, M | 2 |
| Nishioka, Y | 2 |
| Myojin, T | 2 |
| Kubo, S | 2 |
| Okada, K | 2 |
| Soeda, T | 2 |
| Noda, T | 2 |
| Sakata, Y | 2 |
| Miyamoto, Y | 2 |
| Saito, Y | 3 |
| Imamura, T | 2 |
| Yu, Q | 1 |
| Wang, J | 4 |
| Yu, R | 1 |
| Li, J | 10 |
| Cheng, J | 1 |
| Hu, Y | 1 |
| Zheng, N | 1 |
| Zhang, Z | 3 |
| Wang, Y | 11 |
| Du, W | 1 |
| Zhu, K | 1 |
| Chen, X | 2 |
| Su, J | 1 |
| De Servi, S | 5 |
| Landi, A | 2 |
| Savonitto, S | 3 |
| De Luca, L | 5 |
| De Luca, G | 18 |
| Morici, N | 2 |
| Montalto, C | 1 |
| Crimi, G | 1 |
| Cattaneo, M | 4 |
| Carlin, S | 1 |
| de Vries, TAC | 1 |
| Anchidin, OI | 1 |
| Rosianu, SH | 1 |
| Nemes, A | 1 |
| Aldica, M | 1 |
| Blendea, D | 1 |
| Molnar, A | 1 |
| Moldovan, H | 1 |
| Pop, D | 1 |
| Malm, CJ | 2 |
| Alfredsson, J | 1 |
| Erlinge, D | 6 |
| Gudbjartsson, T | 1 |
| Gunn, J | 1 |
| Møller, CH | 1 |
| Nielsen, SJ | 2 |
| Sartipy, U | 2 |
| Tønnessen, T | 1 |
| Jeppsson, A | 2 |
| Greco, A | 1 |
| Finocchiaro, S | 1 |
| Angiolillo, DJ | 25 |
| Capodanno, D | 7 |
| Broderick, C | 1 |
| Kobayashi, S | 1 |
| Suto, M | 1 |
| Ito, S | 1 |
| Kobayashi, T | 2 |
| Cortellini, G | 1 |
| Raiteri, A | 1 |
| Galli, M | 1 |
| Lotrionte, M | 1 |
| Piscaglia, F | 1 |
| Romano, A | 1 |
| Zhou, S | 1 |
| Xiao, Y | 1 |
| Zhou, C | 2 |
| Zheng, Z | 1 |
| Jiang, W | 1 |
| Shen, Q | 1 |
| Zhu, C | 1 |
| Pan, H | 1 |
| Liu, C | 2 |
| Zeng, G | 1 |
| Ge, L | 1 |
| Ouyang, Z | 1 |
| Fu, G | 1 |
| Pan, G | 1 |
| Chen, F | 4 |
| Huang, L | 1 |
| Liu, Q | 1 |
| Caglioni, S | 1 |
| Serebruany, VL | 8 |
| Gurvich, ML | 1 |
| Marciniak, TA | 1 |
| Atar, D | 2 |
| Ten Haaf, ME | 1 |
| van Geuns, RJ | 1 |
| van der Linden, MMJM | 1 |
| de Vries, AG | 1 |
| Doevendans, PA | 1 |
| Appelman, Y | 2 |
| Boersma, E | 1 |
| Bianco, M | 4 |
| Mottola, FF | 1 |
| Giordana, F | 1 |
| Cinconze, S | 1 |
| Baralis, G | 1 |
| Verra, A | 1 |
| Musumeci, G | 6 |
| Rossini, R | 5 |
| Lee, B | 1 |
| Jun, EJ | 1 |
| Kim, B | 1 |
| Won, KB | 1 |
| Rhee, TM | 1 |
| Jeyalan, V | 1 |
| Markides, RIL | 1 |
| Farag, M | 1 |
| Wu, C | 2 |
| Qu, X | 1 |
| He, X | 1 |
| Ma, S | 1 |
| Qiu, M | 1 |
| Wang, X | 9 |
| De Caterina, R | 4 |
| Gong, X | 1 |
| Hua, R | 1 |
| Bai, J | 1 |
| Wu, T | 1 |
| Zhang, J | 5 |
| Zhang, W | 2 |
| Ying, L | 2 |
| Ke, Y | 1 |
| Liu, K | 1 |
| Zhang, B | 2 |
| Dong, P | 1 |
| Xiao, J | 1 |
| Zhu, L | 1 |
| Genç, S | 1 |
| Yeter, AS | 1 |
| Oğuz, AB | 1 |
| Koca, A | 1 |
| Polat, O | 1 |
| Günalp Eneyli, M | 1 |
| Kanagaratnam, P | 1 |
| Francis, DP | 1 |
| Chamie, D | 1 |
| Coyle, C | 1 |
| Marynina, A | 1 |
| Katritsis, G | 1 |
| Paiva, P | 1 |
| Szigeti, M | 1 |
| Cole, G | 1 |
| de Andrade Nunes, D | 1 |
| Howard, J | 1 |
| Esper, R | 1 |
| Khan, M | 1 |
| More, R | 1 |
| Barreto, G | 1 |
| Meneguz-Moreno, R | 1 |
| Arnold, A | 1 |
| Nowbar, A | 1 |
| Kaura, A | 1 |
| Mariveles, M | 1 |
| March, K | 1 |
| Shah, J | 1 |
| Nijjer, S | 1 |
| Lip, GYH | 5 |
| Mills, N | 1 |
| Camm, AJ | 1 |
| Cooke, GS | 1 |
| Corbett, SJ | 2 |
| Llewelyn, MJ | 1 |
| Ghanima, W | 1 |
| Toshner, M | 1 |
| Peters, N | 1 |
| Petraco, R | 1 |
| Al-Lamee, R | 1 |
| Boshoff, ASM | 1 |
| Durkina, M | 1 |
| Malik, I | 1 |
| Ruparelia, N | 2 |
| Cornelius, V | 1 |
| Shun-Shin, M | 1 |
| Shpigelman, J | 1 |
| Proshkina, A | 1 |
| Daly, MJ | 1 |
| Cox, D | 1 |
| Wang, CC | 1 |
| Zhao, Q | 3 |
| Guo, BY | 1 |
| Hao, J | 1 |
| Zhao, JJ | 1 |
| Ren, JL | 1 |
| Sun, YQ | 1 |
| Zhang, XR | 1 |
| Yang, XL | 1 |
| Liu, JM | 1 |
| Guimarães, PO | 2 |
| Franken, M | 1 |
| Tavares, CAM | 1 |
| Silveira, FS | 1 |
| Antunes, MO | 1 |
| Bergo, RR | 1 |
| Joaquim, RM | 1 |
| Hirai, JCS | 1 |
| Andrade, PB | 1 |
| Pitta, FG | 1 |
| Mariani, J | 1 |
| Nascimento, BR | 1 |
| de Paula, JET | 1 |
| Silveira, MS | 1 |
| Costa, TAO | 1 |
| Dall'Orto, FTC | 1 |
| Serpa, RG | 1 |
| Sampaio, FBA | 1 |
| Ohe, LN | 1 |
| Mangione, FM | 1 |
| Furtado, RHM | 2 |
| Sarmento-Leite, R | 1 |
| Monfardini, F | 1 |
| Assis, SRL | 1 |
| Nicolau, JC | 7 |
| Sposito, AC | 1 |
| Bacal, F | 1 |
| Lemos, PA | 1 |
| Chung, J | 1 |
| Yuan, X | 1 |
| Chu, Q | 1 |
| Chen, K | 1 |
| Zheng, Y | 2 |
| Hu, S | 2 |
| Li, Y | 10 |
| Lei, M | 1 |
| Yang, Y | 3 |
| An, L | 1 |
| Zhou, H | 1 |
| Zhao, Z | 1 |
| Nie, S | 3 |
| Hau, WK | 1 |
| Xue, Z | 1 |
| Pouwels, KB | 1 |
| Johnson, T | 1 |
| Sterne, J | 1 |
| Pithara, C | 2 |
| Reeves, B | 1 |
| Benedetto, U | 3 |
| Loke, Y | 2 |
| Doble, B | 2 |
| Hopewell-Kelly, N | 1 |
| Redwood, S | 2 |
| Wordsworth, S | 2 |
| Rogers, C | 1 |
| Ahrens, I | 1 |
| Ako, J | 2 |
| Geisler, T | 8 |
| Rubboli, A | 3 |
| Sibbing, D | 4 |
| Storey, RF | 21 |
| Tan, JWC | 1 |
| Ten Berg, JM | 6 |
| Vandenbriele, C | 1 |
| Tian, MY | 1 |
| Wang, XY | 1 |
| Guo, YF | 1 |
| van der Sangen, NMR | 1 |
| Küçük, IT | 1 |
| Sivanesan, S | 1 |
| Verburg, A | 1 |
| Azzahhafi, J | 1 |
| Arkenbout, EK | 1 |
| Kikkert, WJ | 2 |
| Pisters, R | 1 |
| Jukema, JW | 1 |
| Arslan, F | 1 |
| van 't Hof, A | 1 |
| Ilhan, M | 1 |
| Hoebers, LP | 1 |
| van der Schaaf, RJ | 1 |
| Damman, P | 2 |
| Woudstra, P | 1 |
| van de Hoef, TP | 1 |
| Bax, M | 1 |
| Anthonio, RL | 1 |
| Polad, J | 1 |
| Adriaenssens, T | 2 |
| Dewilde, W | 1 |
| Zivelonghi, C | 1 |
| Laanmets, P | 1 |
| Majas, R | 1 |
| Dijkgraaf, MGW | 1 |
| Claessen, BEPM | 1 |
| Almarzooq, ZI | 1 |
| Al-Roub, NM | 1 |
| Kinlay, S | 2 |
| Bono, J | 1 |
| Ricarte-Bratti, JP | 1 |
| Barcudi, R | 1 |
| Alenazy, FO | 1 |
| Harbi, MH | 1 |
| Kavanagh, DP | 1 |
| Price, J | 1 |
| Brady, P | 1 |
| Hargreaves, O | 1 |
| Harrison, P | 2 |
| Slater, A | 1 |
| Tiwari, A | 1 |
| Nicolson, PLR | 1 |
| Connolly, DL | 1 |
| Kirchhof, P | 1 |
| Kalia, N | 1 |
| Jandrot-Perrus, M | 1 |
| Mangin, PH | 1 |
| Watson, SP | 1 |
| Thomas, MR | 4 |
| Lee, SY | 3 |
| Kim, JW | 1 |
| Gao, ST | 1 |
| Ma, L | 3 |
| Kim, MC | 1 |
| Ahn, SG | 1 |
| Cho, KH | 1 |
| Sim, DS | 1 |
| Hong, YJ | 1 |
| Kim, JH | 3 |
| Jeong, MH | 1 |
| Lee, JW | 1 |
| Youn, YJ | 1 |
| Kim, HY | 1 |
| Yoo, KD | 1 |
| Jeon, DS | 1 |
| Chang, K | 1 |
| Ahn, Y | 1 |
| Ortega-Paz, L | 1 |
| Sabaté, M | 3 |
| Girotra, S | 1 |
| Stebbins, A | 1 |
| Wruck, L | 1 |
| Gupta, K | 2 |
| Farrehi, P | 1 |
| Benziger, CP | 1 |
| Effron, MB | 2 |
| Whittle, J | 1 |
| Muñoz, D | 1 |
| Kripalani, S | 1 |
| Anderson, RD | 1 |
| Jain, SK | 1 |
| Polonsky, TS | 1 |
| Ahmad, FS | 1 |
| Roe, MT | 17 |
| Rothman, RL | 1 |
| Harrington, RA | 12 |
| Hernandez, AF | 2 |
| Kovacevic, M | 1 |
| Pompei, G | 1 |
| Cayla, G | 6 |
| Lattuca, B | 1 |
| Takahashi, K | 4 |
| Chichareon, P | 2 |
| Kogame, N | 2 |
| Tomaniak, M | 3 |
| Modolo, R | 2 |
| Chang, CC | 2 |
| Komiyama, H | 1 |
| Soliman, O | 1 |
| Wykrzykowska, JJ | 1 |
| de Winter, RJ | 4 |
| Dominici, M | 1 |
| Buszman, P | 2 |
| Bolognese, L | 2 |
| Tumscitz, C | 1 |
| Stoll, HP | 1 |
| Colombo, A | 3 |
| Parkin, L | 1 |
| Quon, J | 1 |
| Sharples, K | 1 |
| Barson, D | 1 |
| Dummer, J | 1 |
| Dracoulakis, MDA | 1 |
| Gurbel, P | 4 |
| Martins, HS | 1 |
| Kalil Filho, R | 1 |
| Stoyko, OA | 1 |
| Shalaev, SV | 1 |
| Shrestha, A | 1 |
| Wilson, J | 1 |
| Stys, A | 2 |
| Wu, HY | 1 |
| Zhao, X | 5 |
| Qian, JY | 1 |
| Wang, QB | 1 |
| Ge, JB | 1 |
| Al-Zakwani, I | 1 |
| Al-Lawati, J | 2 |
| Alsheikh-Ali, AA | 4 |
| Almahmeed, W | 2 |
| Rashed, W | 1 |
| Al-Mulla, A | 1 |
| Zubaid, M | 3 |
| Darius, H | 9 |
| Averkov, O | 2 |
| Kong, DF | 2 |
| Kobalava, Z | 1 |
| Mehta, RH | 1 |
| Mirza, Z | 1 |
| Quadros, A | 1 |
| Thiele, H | 2 |
| Massaro, T | 2 |
| Jones-Burton, C | 1 |
| Heizer, G | 2 |
| Aschermann, M | 1 |
| Cura, F | 1 |
| Engstrøm, T | 1 |
| Fridrich, V | 1 |
| Kang, HJ | 2 |
| Leiva-Pons, JL | 4 |
| Lewis, BS | 2 |
| Malaga, G | 1 |
| Meneveau, N | 1 |
| Milicic, D | 1 |
| Morais, J | 3 |
| Potpara, TS | 3 |
| Raev, D | 1 |
| de Waha-Thiele, S | 2 |
| Xavier, D | 1 |
| Deliargyris, EN | 1 |
| Rademaker-Havinga, T | 1 |
| Dangas, GD | 1 |
| Mujovic, N | 2 |
| Proietti, M | 1 |
| Dagres, N | 1 |
| Hindricks, G | 1 |
| Collet, JP | 11 |
| Heidbuchel, H | 1 |
| Gimbel, ME | 2 |
| Vos, GJA | 1 |
| Nguyen, TA | 1 |
| Kelder, JC | 2 |
| Sobral Filho, DC | 1 |
| Monteiro Júnior, JGM | 1 |
| Bestari, MB | 1 |
| Joewono, IR | 1 |
| Shi, X | 2 |
| Xu, X | 2 |
| Charif, F | 1 |
| Hamdan, R | 1 |
| Youness, G | 1 |
| El Zein, A | 1 |
| Issa, M | 1 |
| Jassar, Y | 1 |
| Younes, M | 1 |
| Saab, M | 1 |
| Verdoia, M | 17 |
| Rolla, R | 13 |
| Negro, F | 3 |
| Tonon, F | 2 |
| Pergolini, P | 13 |
| Nardin, M | 12 |
| Marcolongo, M | 3 |
| Raposeiras Roubin, S | 1 |
| Peyracchia, M | 1 |
| Gravinese, C | 2 |
| Destefanis, P | 2 |
| Luciano, A | 2 |
| Rinaldi, M | 3 |
| Varbella, F | 5 |
| Boccuzzi, G | 3 |
| Montabone, A | 3 |
| Bernardi, A | 1 |
| Taha, S | 3 |
| Durante, A | 3 |
| Gili, S | 3 |
| Magnani, G | 5 |
| Autelli, M | 3 |
| Grosso, A | 3 |
| Blanco, PF | 3 |
| Giustetto, C | 1 |
| Garay, A | 3 |
| Queija, BC | 3 |
| Srdanovic, I | 1 |
| Fernández, MC | 3 |
| Pousa, IM | 3 |
| Gallo, D | 3 |
| Morbiducci, U | 3 |
| Lopez-Cuenca, Á | 1 |
| Cequier, A | 4 |
| Iñiguez-Romo, A | 3 |
| Pozzi, R | 3 |
| Assi, EA | 1 |
| Magrum, BG | 1 |
| Pickworth, KK | 1 |
| Liao, YWB | 1 |
| Wang, TKM | 1 |
| Söderberg, M | 1 |
| Holm, M | 2 |
| Gupta, A | 2 |
| Kobayashi, Y | 1 |
| de Castro, RL | 1 |
| de Alcantara Lima, N | 1 |
| da Costa Lino, DO | 1 |
| Bannon, SF | 1 |
| Guedeney, P | 2 |
| Montalescot, G | 15 |
| Kyyak, YH | 1 |
| Barnett, OY | 1 |
| Halkevych, MP | 1 |
| Labinska, OY | 1 |
| Kyyak, HY | 1 |
| Kysil, OY | 1 |
| Faggioni, M | 1 |
| Redfors, B | 2 |
| Crowley, A | 1 |
| Claessen, BE | 1 |
| Farhan, S | 3 |
| Mastoris, I | 1 |
| Maehara, A | 3 |
| Weisz, G | 5 |
| Généreux, P | 3 |
| Ben-Yehuda, O | 1 |
| Kirtane, AJ | 3 |
| Stone, GW | 9 |
| Topno, AP | 1 |
| Styczkiewicz, K | 1 |
| Styczkiewicz, M | 1 |
| Myćka, M | 1 |
| Mędrek, S | 1 |
| Kondraciuk, T | 1 |
| Czerkies-Bieleń, A | 1 |
| Wiśniewski, A | 1 |
| Szmit, S | 1 |
| Jankowski, P | 1 |
| Yang, C | 2 |
| Fan, Z | 1 |
| Limdi, NA | 1 |
| Cavallari, LH | 2 |
| Lee, CR | 1 |
| Hillegass, WB | 1 |
| Holmes, AM | 1 |
| Skaar, TC | 1 |
| Pisu, M | 1 |
| Dillon, C | 2 |
| Beitelshees, AL | 1 |
| Empey, PE | 1 |
| Duarte, JD | 2 |
| Diaby, V | 1 |
| Gong, Y | 1 |
| Johnson, JA | 1 |
| Graves, J | 1 |
| Garbett, S | 1 |
| Zhou, Z | 1 |
| Peterson, JF | 1 |
| Desta, DM | 1 |
| Nedi, T | 1 |
| Hailu, A | 1 |
| Atey, TM | 1 |
| Tsadik, AG | 1 |
| Asgedom, SW | 1 |
| Kasahun, GG | 1 |
| Ayalew, E | 1 |
| Martí, D | 1 |
| Carballeira, D | 1 |
| Morales, MJ | 1 |
| Concepción, R | 1 |
| Del Castillo, H | 1 |
| Marschall, A | 1 |
| Delgado-Calva, FA | 1 |
| Dejuán-Bitriá, C | 1 |
| Pérez-Guzmán, J | 1 |
| López-Soberón, E | 1 |
| Palazuelos, J | 1 |
| Álvarez-Antón, S | 1 |
| Luo, CF | 1 |
| Mo, P | 1 |
| Li, GQ | 1 |
| Liu, SM | 1 |
| Tang, C | 1 |
| Zhu, Y | 2 |
| Yang, X | 2 |
| Xu, B | 2 |
| Ye, C | 1 |
| Zhong, J | 1 |
| Yu, L | 2 |
| Khan, SU | 2 |
| Osman, M | 1 |
| Khan, MU | 2 |
| Khan, MS | 2 |
| Zhao, D | 4 |
| Mamas, MA | 1 |
| Savji, N | 1 |
| Al-Abdouh, A | 1 |
| Hasan, RK | 1 |
| Michos, ED | 2 |
| Hagiwara, H | 1 |
| Fukuta, H | 1 |
| Niimura, T | 1 |
| Zamami, Y | 1 |
| Ishizawa, K | 1 |
| Kimura, K | 4 |
| Kamiya, T | 1 |
| Ohte, N | 1 |
| Wojdyla, D | 2 |
| Riegel, B | 2 |
| Stephens-Shields, A | 1 |
| Jaskowiak-Barr, A | 1 |
| Daus, M | 1 |
| Kimmel, SE | 1 |
| Shoji, S | 1 |
| Sawano, M | 1 |
| Sandhu, AT | 1 |
| Heidenreich, PA | 1 |
| Shiraishi, Y | 1 |
| Ikemura, N | 1 |
| Ueno, K | 1 |
| Suzuki, M | 1 |
| Numasawa, Y | 1 |
| Fukuda, K | 1 |
| Kohsaka, S | 1 |
| Pivato, CA | 1 |
| Margonato, A | 1 |
| Godino, C | 2 |
| Moroni, F | 1 |
| Gallone, G | 1 |
| Pagnesi, M | 1 |
| Venuti, A | 1 |
| Beneduce, A | 1 |
| Calvo, F | 1 |
| Gramegna, M | 1 |
| Cappelletti, AM | 1 |
| Wang, L | 3 |
| Di, Y | 1 |
| Guo, T | 1 |
| Ming, JE | 1 |
| Kong, F | 1 |
| Yin, H | 2 |
| Xie, F | 1 |
| Yang, N | 1 |
| Ping, C | 1 |
| Hou, J | 2 |
| Shuvy, M | 1 |
| Peretz, A | 1 |
| Gotsman, I | 1 |
| Vorobeichik, D | 1 |
| Shlomo, N | 1 |
| Minha, S | 1 |
| Pereg, D | 2 |
| Franzone, A | 2 |
| McFadden, EP | 1 |
| Leonardi, S | 7 |
| Piccolo, R | 2 |
| Branca, M | 1 |
| Said, A | 1 |
| Keeney, S | 1 |
| Matka, M | 1 |
| Hafeez, A | 1 |
| George, J | 1 |
| Halalau, A | 1 |
| Gager, GM | 1 |
| Winter, MP | 1 |
| Hengstenberg, C | 1 |
| Lang, IM | 1 |
| Toma, A | 1 |
| Prüller, F | 1 |
| Wallner, M | 1 |
| Kolesnik, E | 1 |
| von Lewinski, D | 1 |
| Ramlakhan, KP | 1 |
| Johnson, MR | 1 |
| Roos-Hesselink, JW | 1 |
| Ilardi, F | 1 |
| Paolillo, R | 1 |
| Ferrone, M | 1 |
| Cimino, S | 1 |
| Giugliano, G | 1 |
| Schiattarella, GG | 1 |
| Verde, N | 1 |
| Stabile, E | 2 |
| Perrino, C | 1 |
| Coscioni, E | 1 |
| Morisco, C | 2 |
| Sanna, GD | 2 |
| Deriu, S | 1 |
| Uras, M | 1 |
| Murgia, A | 1 |
| Talanas, G | 1 |
| Moccia, E | 1 |
| Corda, G | 2 |
| Mura, E | 1 |
| Saba, PS | 1 |
| Parodi, G | 5 |
| Wu, H | 3 |
| Xiang, X | 1 |
| Li, D | 1 |
| Shen, S | 1 |
| Yuan, D | 1 |
| Guo, L | 4 |
| Wang, G | 3 |
| Zhang, H | 2 |
| Huang, Q | 1 |
| Yuan, Y | 2 |
| Cho, YH | 1 |
| Kim, YH | 1 |
| Suh, Y | 1 |
| Her, AY | 1 |
| Cho, S | 1 |
| Jeon, DW | 2 |
| Yoo, SY | 1 |
| Cho, DK | 4 |
| Hong, BK | 1 |
| Kwon, H | 1 |
| Nam, CM | 1 |
| O'Donoghue, ML | 1 |
| Murphy, SA | 6 |
| Sabatine, MS | 3 |
| Schlachtenberger, G | 1 |
| Deppe, AC | 1 |
| Gerfer, S | 1 |
| Choi, YH | 1 |
| Zeriouh, M | 1 |
| Liakopoulos, O | 1 |
| Wahlers, TCW | 1 |
| Weitz, JI | 1 |
| Heitmeier, S | 1 |
| Gioscia, R | 1 |
| Suryapranata, H | 15 |
| Kedhi, E | 5 |
| Baş, HA | 1 |
| Aksoy, F | 1 |
| Bağcı, A | 1 |
| Varol, E | 1 |
| Altınbaş, A | 1 |
| Chon, MK | 2 |
| Jung, SM | 1 |
| Lee, SH | 3 |
| Hwang, KW | 2 |
| Choi, JH | 4 |
| Park, YH | 3 |
| Chun, KJ | 3 |
| Jing, Q | 3 |
| Wang, B | 2 |
| Qiao, S | 1 |
| Chen, S | 1 |
| Han, Y | 6 |
| Boussofara, A | 1 |
| Laroussi, L | 1 |
| Baccouche, H | 1 |
| Bennour, E | 1 |
| Kasbaoui, S | 1 |
| Triki, H | 1 |
| Zied, EH | 1 |
| Kammoun, I | 1 |
| Halima, AB | 1 |
| Addad, F | 1 |
| Marrakchi, S | 1 |
| Romdhane, NB | 1 |
| Kachboura, S | 1 |
| Hertz, JT | 1 |
| Sakita, FM | 1 |
| Kweka, GL | 1 |
| Bloomfield, GS | 1 |
| Bartlett, JA | 1 |
| Tarimo, TG | 1 |
| Temu, G | 1 |
| Bettger, JP | 1 |
| Thielman, NM | 1 |
| Singh, M | 1 |
| Valavoor, S | 1 |
| Lone, AN | 1 |
| Khan, MZ | 1 |
| Mani, P | 1 |
| Kapadia, SR | 1 |
| Kalra, A | 1 |
| Ray, A | 1 |
| Najmi, A | 1 |
| Khandelwal, G | 1 |
| Jhaj, R | 1 |
| Sadasivam, B | 1 |
| Deoker, A | 1 |
| Lehker, A | 1 |
| Mukherjee, D | 2 |
| Willemsen, LM | 1 |
| Janssen, PWA | 1 |
| Peper, J | 1 |
| Soliman-Hamad, MA | 1 |
| van Straten, AHM | 1 |
| Klein, P | 1 |
| Hackeng, CM | 2 |
| Sonker, U | 1 |
| Bekker, MWA | 1 |
| von Birgelen, C | 2 |
| Brouwer, MA | 2 |
| van der Harst, P | 1 |
| Vlot, EA | 1 |
| Deneer, VHM | 1 |
| Chan Pin Yin, DRPP | 1 |
| Beukema, KF | 1 |
| Daeter, EJ | 1 |
| Tijssen, JGP | 1 |
| Rensing, BJWM | 1 |
| van Es, HW | 1 |
| Swaans, MJ | 1 |
| Dobesh, PP | 2 |
| Finks, SW | 1 |
| Trujillo, TC | 1 |
| Rhew, JY | 1 |
| Lim, YH | 1 |
| Bong, JM | 1 |
| Lee, BK | 1 |
| Scudiero, F | 1 |
| Valenti, R | 3 |
| Gori, AM | 5 |
| Migliorini, A | 3 |
| Vitale, R | 1 |
| Giusti, B | 5 |
| De Vito, E | 1 |
| Paniccia, R | 5 |
| Zirolia, D | 1 |
| Canonico, ME | 1 |
| Jacobsen, AP | 1 |
| Raber, I | 1 |
| McCarthy, CP | 1 |
| Blumenthal, RS | 1 |
| Cusack, RW | 1 |
| Serruys, PWJC | 1 |
| Wijns, W | 2 |
| McEvoy, JW | 1 |
| Hoffer, EP | 1 |
| Cao, D | 1 |
| Makkar, RR | 1 |
| Bangalore, S | 3 |
| Saito, S | 4 |
| Ge, J | 2 |
| Hermiller, J | 1 |
| Picon, H | 1 |
| Toelg, R | 1 |
| Maksoud, A | 1 |
| Chehab, BM | 1 |
| Wang, LJ | 1 |
| Li, Q | 2 |
| Tu, C | 1 |
| Zeng, Y | 1 |
| Moran, TB | 1 |
| Plana, JC | 1 |
| Xue, Y | 1 |
| Chen, J | 4 |
| Kawashima, H | 1 |
| Ono, M | 1 |
| Wang, R | 2 |
| Hara, H | 1 |
| Gao, C | 1 |
| Sharif, F | 1 |
| Thury, A | 1 |
| Walsh, S | 1 |
| Cotton, J | 1 |
| Carrie, D | 1 |
| Steinwender, C | 1 |
| Leibundgut, G | 1 |
| Wykrzykowska, J | 1 |
| Garg, S | 1 |
| Bavishi, C | 1 |
| Baber, U | 6 |
| Dangas, G | 3 |
| Cohen, DJ | 6 |
| Sharma, SK | 1 |
| Nicolas, J | 1 |
| Briguori, C | 1 |
| Cha, JY | 1 |
| Collier, T | 1 |
| Džavik, V | 1 |
| Escaned, J | 2 |
| Hamm, CW | 2 |
| Henry, T | 1 |
| Kaul, U | 1 |
| Kornowski, R | 1 |
| Krucoff, M | 1 |
| Marx, SO | 1 |
| Mehta, S | 1 |
| Moliterno, D | 1 |
| Ohman, EM | 17 |
| Oldroyd, K | 1 |
| Sardella, G | 2 |
| Sartori, S | 4 |
| Shlofmitz, R | 1 |
| Han, YL | 5 |
| Pocock, S | 2 |
| Gibson, CM | 12 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 2 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 1 |
| Santos, RCO | 1 |
| Bensenor, IM | 2 |
| Goulart, AC | 2 |
| Lotufo, PA | 2 |
| Santos, IS | 2 |
| Baos, S | 1 |
| Collett, L | 1 |
| Hutchinson, JL | 1 |
| Nkau, M | 1 |
| Molina, M | 1 |
| Aungraheeta, R | 1 |
| Reilly-Stitt, C | 1 |
| Bowles, R | 1 |
| Rogers, CA | 2 |
| Mundell, SJ | 1 |
| Baumbach, A | 1 |
| Mumford, AD | 2 |
| Tscharre, M | 3 |
| Wadowski, PP | 1 |
| Weikert, C | 1 |
| Pultar, J | 1 |
| Eichelberger, B | 1 |
| Panzer, S | 1 |
| Gremmel, T | 2 |
| de Ronde, MWJ | 1 |
| Creemers, EE | 1 |
| Van der Made, I | 1 |
| Meijering, R | 1 |
| Chan, MY | 3 |
| Hwee Tan, S | 1 |
| Tang Chin, C | 1 |
| Mark Richards, A | 1 |
| Troughton, RW | 1 |
| Yean Yip Fong, A | 1 |
| Yan, BP | 2 |
| Pinto-Sietsma, SJ | 1 |
| Ftouh, S | 1 |
| Lewis, S | 1 |
| Lovibond, K | 1 |
| Hijazi, Z | 2 |
| Sinnaeve, P | 2 |
| Lunardi, M | 1 |
| Lee, CY | 1 |
| Liu, KT | 1 |
| Lu, HT | 1 |
| Mohd Ali, R | 1 |
| Fong, AYY | 1 |
| Wan Ahmad, WA | 1 |
| Ge, Z | 1 |
| Gao, XF | 1 |
| Kan, J | 1 |
| Kong, XQ | 1 |
| Zuo, GF | 1 |
| Ye, F | 2 |
| Tian, NL | 1 |
| Lin, S | 1 |
| Liu, ZZ | 1 |
| Shao, YB | 1 |
| He, YQ | 1 |
| Wen, SY | 1 |
| Yang, Q | 1 |
| Xia, Y | 1 |
| Wang, ZZ | 1 |
| Xiao, PX | 1 |
| Li, F | 1 |
| Zeng, HS | 1 |
| Yang, S | 1 |
| Gao, DS | 1 |
| Qu, H | 1 |
| Qian, XS | 1 |
| Zhang, JJ | 1 |
| Chen, SL | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Nakashima, CAK | 1 |
| Dallan, LAO | 1 |
| Lisboa, LAF | 1 |
| Jatene, FB | 1 |
| Hajjar, LA | 1 |
| Soeiro, AM | 1 |
| Dalçoquio, TF | 1 |
| Baracioli, LM | 1 |
| Lima, FG | 1 |
| Giraldez, RRCV | 1 |
| Silva, BA | 1 |
| Costa, MSS | 1 |
| Strunz, CMC | 1 |
| Dallan, LRP | 1 |
| Barbosa, CJDG | 1 |
| Britto, FAB | 1 |
| Farkouh, ME | 2 |
| Sinnaeve, PR | 1 |
| Fuertes Ferre, G | 2 |
| Pérez Guerrero, A | 1 |
| Linares Vicente, JA | 1 |
| Jimeno Sánchez, J | 1 |
| Alonso-Ventura, V | 1 |
| Cubero Saldaña, JL | 1 |
| Galache Osuna, JG | 1 |
| Andrés Esteban, EM | 1 |
| Diarte de Miguel, JA | 1 |
| Ortas Nadal, MDR | 1 |
| Casasnovas Lenguas, JA | 1 |
| Jin, J | 2 |
| Zhuo, X | 1 |
| Xiao, M | 1 |
| Jiang, Z | 2 |
| Chen, L | 3 |
| Devi Shamloll, Y | 1 |
| Dong, Z | 1 |
| Zhai, H | 1 |
| Pan, L | 1 |
| Kamran, H | 1 |
| Jneid, H | 2 |
| Kayani, WT | 1 |
| Virani, SS | 2 |
| Levine, GN | 1 |
| Nambi, V | 2 |
| Khalid, U | 1 |
| Ho, MY | 1 |
| Chen, PW | 1 |
| Feng, WH | 1 |
| Su, CH | 1 |
| Huang, SW | 1 |
| Cheng, CW | 1 |
| Yeh, HI | 1 |
| Chen, CP | 2 |
| Huang, WC | 1 |
| Fang, CC | 1 |
| Lin, HW | 1 |
| Lin, SH | 1 |
| Hsieh, IC | 1 |
| Li, YH | 2 |
| Song, PS | 1 |
| Oh, JH | 3 |
| Song, YB | 3 |
| Choi, SH | 3 |
| Gwon, HC | 3 |
| Jeong, JO | 2 |
| Hahn, JY | 3 |
| Knijnik, L | 1 |
| Fernandes, M | 1 |
| Rivera, M | 1 |
| Cardoso, R | 1 |
| Goyal, A | 1 |
| Liberman, H | 1 |
| Sperling, LS | 1 |
| McDaniel, MC | 1 |
| Podhajski, P | 1 |
| Barańska, M | 1 |
| Umińska, JM | 1 |
| Pietrzykowski, Ł | 1 |
| Bartuś, S | 1 |
| Dobrzycki, S | 1 |
| Fidor, Ł | 1 |
| Gessek, J | 1 |
| Gierlotka, M | 1 |
| Gorący, J | 1 |
| Grzelakowski, P | 1 |
| Hajdukiewicz, T | 1 |
| Jaguszewski, M | 1 |
| Janion, M | 1 |
| Kern, A | 1 |
| Klecha, A | 1 |
| Kochman, W | 1 |
| Krakowiak, B | 1 |
| Nosal, M | 1 |
| Piotrowski, G | 1 |
| Przybylski, A | 1 |
| Roleder, T | 1 |
| Skonieczny, G | 1 |
| Sobieszek, G | 1 |
| Wojciechowski, D | 1 |
| Wójcik, J | 1 |
| Zielińska, M | 1 |
| Żurakowski, A | 1 |
| Colleran, R | 1 |
| Byrne, RA | 2 |
| Alvarez-Covarrubias, HA | 1 |
| Kuna, C | 1 |
| Rai, H | 1 |
| Liu, X | 3 |
| Xu, H | 2 |
| Geng, Q | 1 |
| Mak, WH | 1 |
| Ling, F | 1 |
| Su, Z | 1 |
| Yang, F | 1 |
| Zhang, T | 1 |
| Yang, H | 2 |
| Jia, H | 2 |
| Zhong, S | 1 |
| Bálint, A | 1 |
| Tornyos, D | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Kupó, P | 1 |
| Komócsi, A | 3 |
| Roberto, M | 1 |
| Radovanovic, D | 2 |
| Buttà, C | 1 |
| Tersalvi, G | 1 |
| Krüll, J | 1 |
| Erne, P | 2 |
| Rickli, H | 2 |
| Pedrazzini, GB | 1 |
| Moccetti, M | 1 |
| Wang, T | 1 |
| Bai, H | 1 |
| Zhu, W | 1 |
| Wu, J | 1 |
| Sun, L | 1 |
| Yu, A | 1 |
| Li, H | 2 |
| Wang, W | 3 |
| Man, F | 1 |
| Pan, Q | 1 |
| Björklund, E | 1 |
| Hansson, EC | 1 |
| Tygesen, H | 1 |
| Romlin, BS | 1 |
| Martinsson, A | 1 |
| Omerovic, E | 1 |
| Pivodic, A | 1 |
| Tantry, US | 11 |
| Povsic, TJ | 3 |
| White, J | 3 |
| Rockhold, F | 1 |
| Plotnikov, A | 2 |
| Strony, J | 3 |
| Sun, X | 1 |
| Husted, S | 8 |
| Tendera, M | 1 |
| Ardissino, D | 8 |
| Bueno, H | 1 |
| Claeys, MJ | 2 |
| Cornel, JH | 9 |
| Goto, S | 3 |
| Kiss, RG | 2 |
| Güray, Ü | 1 |
| Park, DW | 2 |
| Bode, C | 7 |
| Sacks, JH | 1 |
| Flueckiger, PB | 1 |
| Spandorfer, PR | 1 |
| Mahle, WT | 1 |
| Costello, BE | 1 |
| Qadir, MI | 1 |
| Rehman, A | 1 |
| HamidAkash, MS | 1 |
| Irfan, M | 1 |
| Baber, M | 1 |
| Hussain, SB | 1 |
| Elliott, JM | 2 |
| Wang, TK | 1 |
| Gamble, GD | 1 |
| Williams, MJ | 1 |
| Matsis, P | 1 |
| Troughton, R | 2 |
| Hamer, A | 1 |
| Devlin, G | 1 |
| Mann, S | 1 |
| Richards, M | 1 |
| French, JK | 1 |
| White, HD | 15 |
| Ellis, CJ | 1 |
| Rashid, A | 1 |
| Hwang, I | 1 |
| Fan, TM | 1 |
| Khouzam, RN | 2 |
| Reed, GL | 1 |
| Huynh, K | 1 |
| Lindholm, D | 1 |
| Hagström, E | 2 |
| Becker, RC | 10 |
| Cannon, CP | 17 |
| Himmelmann, A | 4 |
| Katus, HA | 4 |
| Maurer, G | 1 |
| López-Sendón, JL | 1 |
| Siegbahn, A | 4 |
| Wallentin, L | 11 |
| Daffara, V | 1 |
| Marino, P | 11 |
| Bellomo, G | 10 |
| Carriero, A | 5 |
| Nakamura, S | 1 |
| Rowland, SM | 1 |
| Handler, A | 1 |
| Al-Khalidi, HR | 1 |
| Krucoff, MW | 3 |
| Vogel, B | 1 |
| Deharo, P | 3 |
| Quilici, J | 9 |
| Deffarges, S | 1 |
| Bassez, C | 2 |
| Bonnet, G | 3 |
| Fourcade, L | 3 |
| Mouret, JP | 1 |
| Lambert, M | 2 |
| Verdier, V | 3 |
| Morange, PE | 7 |
| Alessi, MC | 10 |
| Bonnet, JL | 10 |
| Wilson, S | 1 |
| Newby, DE | 2 |
| Ovrakh, T | 1 |
| Serik, S | 1 |
| Kochubiei, O | 1 |
| Dalby, AJ | 4 |
| Gottlieb, S | 5 |
| Cyr, DD | 2 |
| Magnus Ohman, E | 2 |
| McGuire, DK | 3 |
| Ruzyllo, W | 5 |
| Wiviott, SD | 9 |
| Winters, KJ | 7 |
| Fox, KAA | 1 |
| Armstrong, PW | 11 |
| Prabhakaran, D | 10 |
| Paravattil, B | 1 |
| Elewa, H | 1 |
| Lowenstern, A | 2 |
| Neely, M | 2 |
| Sun, JL | 1 |
| Egger, F | 2 |
| Machata, M | 1 |
| Rohla, M | 2 |
| Michael, N | 1 |
| Neumayr, M | 1 |
| Zweiker, R | 1 |
| Hajos, J | 1 |
| Adlbrecht, C | 1 |
| Suppan, M | 1 |
| Helmreich, W | 1 |
| Eber, B | 1 |
| Weiss, TW | 2 |
| Gonzini, L | 2 |
| Cavallini, C | 2 |
| Mauro, C | 1 |
| Cacciavillani, L | 1 |
| Nakamura, M | 4 |
| Iijima, R | 1 |
| Shinke, T | 2 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 2 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 2 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 3 |
| Schellenberg, A | 1 |
| Shmyr, D | 1 |
| Koziol, K | 1 |
| Martens, B | 1 |
| Kosar, L | 1 |
| Jiang, M | 1 |
| You, JHS | 1 |
| Koscielny, J | 2 |
| von Heymann, C | 2 |
| Zeymer, U | 11 |
| Cremer, J | 2 |
| Spannagl, M | 2 |
| Labenz, J | 2 |
| Goss, F | 2 |
| Bank, S | 1 |
| Jana, P | 1 |
| Girish, GV | 1 |
| Sinha, AK | 1 |
| Maiti, S | 1 |
| Yılmaz, MB | 1 |
| Newby, LK | 2 |
| Feghaly, J | 1 |
| Al Hout, AR | 1 |
| Mercieca Balbi, M | 1 |
| Schäfer, A | 3 |
| Bauersachs, J | 2 |
| Barbieri, L | 10 |
| Schaffer, A | 8 |
| Ahmad, T | 1 |
| Davies, R | 1 |
| Alagona, P | 2 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Spartalis, E | 1 |
| Damaskos, C | 1 |
| Athanasiou, A | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| Chang, AM | 1 |
| Litt, HI | 1 |
| Snyder, BS | 1 |
| Gatsonis, C | 1 |
| Greco, EM | 1 |
| Miller, CD | 1 |
| Singh, H | 1 |
| O'Conor, KJ | 1 |
| Hollander, JE | 5 |
| Fluschnik, N | 1 |
| Becher, PM | 1 |
| Schnabel, R | 1 |
| Blankenberg, S | 1 |
| Westermann, D | 2 |
| Tilemann, L | 1 |
| Mohr, SK | 1 |
| Preusch, M | 1 |
| Chorianopoulos, E | 1 |
| Müller, OJ | 1 |
| Stähli, BE | 1 |
| Landmesser, U | 1 |
| Hammett, CJ | 1 |
| Amerena, J | 1 |
| Sindone, A | 1 |
| Thompson, PL | 2 |
| Worthley, MI | 1 |
| Aylward, PE | 4 |
| Xing, L | 1 |
| Yamamoto, E | 1 |
| Sugiyama, T | 1 |
| Wang, C | 1 |
| Li, L | 5 |
| Xu, M | 1 |
| Liu, H | 3 |
| Bryniarski, K | 1 |
| Zhang, S | 4 |
| Yu, B | 1 |
| Jang, IK | 1 |
| Camoin-Jau, L | 4 |
| Fernandez, M | 1 |
| Ibrahim, M | 1 |
| Suchon, P | 1 |
| Ruivo, C | 1 |
| Sá, FM | 1 |
| Santos, LG | 1 |
| Correia, J | 1 |
| Belo, A | 1 |
| Gaubert, M | 1 |
| Resseguier, N | 1 |
| Laine, M | 2 |
| Bonello, L | 6 |
| Paganelli, F | 4 |
| Ueland, T | 1 |
| Åkerblom, A | 2 |
| Ghukasyan, T | 1 |
| Michelsen, AE | 1 |
| Aukrust, P | 1 |
| Bertilsson, M | 1 |
| Kontny, F | 1 |
| de Carvalho, LP | 1 |
| Fong, A | 1 |
| Chin, CT | 3 |
| Poh, SC | 1 |
| Mejin, M | 1 |
| Huang, N | 1 |
| Seneviratna, A | 1 |
| Lee, CH | 1 |
| Low, AF | 1 |
| Tan, HC | 1 |
| Chan, SP | 1 |
| Frampton, C | 1 |
| Richards, AM | 1 |
| Yang, BS | 2 |
| Wang, XZ | 2 |
| Ge, ML | 1 |
| Jing, QM | 2 |
| Ma, YY | 2 |
| Liu, HW | 1 |
| Xu, K | 4 |
| Gao, R | 2 |
| Wu, Y | 1 |
| Su, G | 1 |
| Yuan, Z | 2 |
| Liu, L | 2 |
| Shen, L | 2 |
| Leonsson-Zachrisson, M | 1 |
| Udell, JA | 3 |
| Fonarow, GC | 4 |
| Maddox, TM | 1 |
| Frank Peacock, W | 1 |
| Laskey, WK | 1 |
| Grau-Sepulveda, MV | 1 |
| Smith, EE | 1 |
| Peterson, ED | 6 |
| Lee, JB | 2 |
| Doh, JH | 2 |
| Kim, SH | 2 |
| Bae, JH | 1 |
| Kim, BO | 1 |
| Cho, JH | 1 |
| Suh, IW | 1 |
| Kim, DI | 1 |
| Park, HK | 1 |
| Park, JS | 1 |
| Choi, WG | 1 |
| Lee, WS | 1 |
| Choi, KH | 1 |
| Park, TK | 2 |
| Lee, JM | 2 |
| Yang, JH | 2 |
| Nusdeo, G | 1 |
| Terrosu, P | 1 |
| Chi, G | 1 |
| Jamil, A | 1 |
| Radulovic, M | 1 |
| Jamil, U | 1 |
| Balouch, MA | 1 |
| Marszalek, J | 1 |
| Karimi, Z | 1 |
| Pahlavani, S | 1 |
| Jafarizade, M | 1 |
| Shaukat, H | 1 |
| Kumar, S | 1 |
| Kalayci, A | 1 |
| Zhao, G | 1 |
| Zhou, M | 1 |
| Ma, C | 1 |
| Huo, Y | 1 |
| Smith, SC | 1 |
| Liu, J | 8 |
| Hao, Y | 1 |
| Taubert, KA | 1 |
| Morgan, L | 1 |
| Zhu, J | 1 |
| Niu, J | 1 |
| He, L | 1 |
| Qin, S | 1 |
| Fang, S | 1 |
| Ertaş, FS | 1 |
| Tokgozoglu, L | 1 |
| Tsukiyama, Y | 1 |
| Kozuki, A | 1 |
| Otake, H | 1 |
| Kijima, Y | 2 |
| Masano, T | 1 |
| Nagoshi, R | 1 |
| Shibata, H | 1 |
| Takeshige, R | 1 |
| Yanaka, KI | 1 |
| Shite, J | 1 |
| Hirata, KI | 1 |
| Wang, A | 1 |
| Wu, A | 1 |
| Newman, MF | 1 |
| Smith, PK | 2 |
| Duong, M | 1 |
| Abouelfath, A | 1 |
| Lassalle, R | 1 |
| Droz, C | 1 |
| Blin, P | 1 |
| Moore, N | 1 |
| Gulizia, MM | 2 |
| Colivicchi, F | 3 |
| Abrignani, MG | 1 |
| Ambrosetti, M | 1 |
| Aspromonte, N | 2 |
| Barile, G | 1 |
| Caporale, R | 2 |
| Casolo, G | 2 |
| Chiuini, E | 1 |
| Di Lenarda, A | 1 |
| Faggiano, P | 1 |
| Gabrielli, D | 1 |
| Geraci, G | 2 |
| La Manna, AG | 1 |
| Maggioni, AP | 2 |
| Marchese, A | 1 |
| Massari, FM | 1 |
| Mureddu, GF | 2 |
| Nardi, F | 1 |
| Panno, AV | 1 |
| Pedretti, RFE | 1 |
| Piredda, M | 1 |
| Pusineri, E | 1 |
| Riccio, C | 1 |
| Scotto Di Uccio, F | 1 |
| Urbinati, S | 1 |
| Zito, GB | 1 |
| Basra, SS | 2 |
| Wang, TY | 3 |
| Simon, DN | 1 |
| Chiswell, K | 1 |
| Alam, M | 1 |
| Denktas, AE | 1 |
| Deswal, A | 1 |
| Bozkurt, B | 1 |
| Ballantyne, CM | 1 |
| Liaw, D | 2 |
| Lee, Y | 1 |
| Park, HC | 1 |
| Shin, J | 1 |
| Galeazzi, R | 1 |
| Olivieri, F | 1 |
| Spazzafumo, L | 1 |
| Rose, G | 1 |
| Montesanto, A | 1 |
| Giovagnetti, S | 1 |
| Cecchini, S | 1 |
| Malatesta, G | 1 |
| Di Pillo, R | 1 |
| Antonicelli, R | 1 |
| Velázquez de Campos, O | 1 |
| Mazlan-Kepli, W | 1 |
| Dawson, J | 1 |
| Berry, C | 2 |
| Walters, M | 1 |
| Gibler, WB | 3 |
| Racadio, JM | 1 |
| Hirsch, AL | 1 |
| Roat, TW | 1 |
| Bliden, KP | 1 |
| Schrage, B | 1 |
| Fan, Y | 3 |
| Zhu, T | 2 |
| Kong, D | 2 |
| Meng, H | 1 |
| Ye, S | 2 |
| Ji, Y | 1 |
| Calnan, MW | 1 |
| Crawford, AN | 1 |
| Iliescu, C | 2 |
| Balanescu, DV | 1 |
| Donisan, T | 1 |
| Giza, DE | 1 |
| Muñoz Gonzalez, ED | 1 |
| Cilingiroglu, M | 1 |
| Song, J | 1 |
| Mukerji, SS | 1 |
| Lopez-Mattei, JC | 1 |
| Kim, PY | 1 |
| Palaskas, N | 1 |
| Mouhayar, EN | 1 |
| Durand, JB | 3 |
| Marmagkiolis, K | 1 |
| Fathy, S | 1 |
| Shahin, MH | 1 |
| Langaee, T | 1 |
| Khalil, BM | 1 |
| Saleh, A | 1 |
| Sabry, NA | 1 |
| Schaalan, MF | 1 |
| El Wakeel, LL | 1 |
| Dondi, L | 1 |
| Pedrini, A | 1 |
| Ronconi, G | 1 |
| Calabria, S | 1 |
| Cimminiello, C | 1 |
| Martini, N | 1 |
| Yan, G | 1 |
| De Rosa, R | 1 |
| Palmerini, T | 2 |
| Piscione, F | 1 |
| Tubaro, M | 2 |
| Falaschi, G | 1 |
| Frelinger, AL | 1 |
| Gachet, C | 1 |
| Noris, P | 1 |
| Mezzano, D | 1 |
| Weidmann, L | 1 |
| Obeid, S | 1 |
| Mach, F | 4 |
| Shahin, M | 1 |
| Yousif, N | 1 |
| Denegri, A | 1 |
| Muller, O | 2 |
| Matter, CM | 3 |
| Lüscher, TF | 4 |
| Lee, W | 1 |
| Suh, JW | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Boden, WE | 7 |
| Malinova, LI | 1 |
| Furman, NV | 1 |
| Dolotovskaya, PV | 1 |
| Chernousova, LA | 1 |
| Denisova, TP | 1 |
| Gong, W | 1 |
| Fan, J | 1 |
| Wei, Y | 1 |
| Ferlini, M | 1 |
| Mauri, S | 1 |
| Demarchi, A | 1 |
| Portolan, M | 1 |
| Visconti, LO | 1 |
| Lin, Z | 1 |
| Xuan, J | 1 |
| Tello-Montoliu, A | 2 |
| Albaladejo, P | 1 |
| Hernández-Romero, D | 1 |
| Taboada, R | 1 |
| Albacete, CL | 1 |
| Arribas, JM | 1 |
| Jara, R | 1 |
| Veliz, A | 1 |
| López-García, C | 1 |
| Cánovas, S | 1 |
| Valdés, M | 4 |
| Rivera-Caravaca, JM | 1 |
| Marín, F | 5 |
| Rinaldi, MJ | 1 |
| Gohs, FX | 1 |
| Brodie, BR | 1 |
| Stuckey, TD | 1 |
| McAndrew, T | 1 |
| Metzger, DC | 1 |
| Golfeyz, S | 1 |
| Aoi, S | 1 |
| Harrington, M | 1 |
| Reynard, C | 1 |
| Morris, N | 2 |
| Moss, P | 1 |
| Jarman, H | 1 |
| Body, R | 1 |
| Jackson, M | 1 |
| Callaghan, S | 1 |
| Stapleton, J | 1 |
| Bolton, S | 1 |
| Austin, D | 2 |
| Muir, DF | 1 |
| Sutton, AGC | 1 |
| Wright, RA | 1 |
| Williams, PD | 1 |
| Hall, JA | 1 |
| Carter, J | 1 |
| de Belder, MA | 1 |
| Swanson, N | 1 |
| Rico-Mesa, JS | 1 |
| Uribe, C | 1 |
| Prasad, M | 1 |
| Luis, SA | 1 |
| De Lorenzo, A | 1 |
| Dutra, M | 1 |
| Mattos, MA | 1 |
| Rey, HCV | 1 |
| Tibirica, E | 1 |
| Freynhofer, MK | 2 |
| Hein-Rothweiler, R | 1 |
| Haller, PM | 1 |
| Aradi, D | 3 |
| Dézsi, DA | 1 |
| Gross, L | 1 |
| Orban, M | 1 |
| Trenk, D | 4 |
| Toth-Gayor, GG | 1 |
| Massberg, S | 2 |
| Lisowska, A | 1 |
| Makarewicz-Wujec, M | 1 |
| Dworakowska, AM | 1 |
| Kozłowska-Wojciechowska, M | 1 |
| Oldgren, J | 3 |
| Hohnloser, SH | 1 |
| Nordaby, M | 1 |
| Brueckmann, M | 1 |
| Kleine, E | 1 |
| Sumaya, W | 1 |
| Kristensen, SD | 4 |
| Bertaina, M | 1 |
| Fioravanti, F | 1 |
| Bongiovanni, F | 1 |
| Gaita, F | 1 |
| Biscaglia, S | 1 |
| Tizzani, E | 1 |
| Corleto, A | 1 |
| Giolitto, S | 1 |
| Lo Savio, L | 1 |
| George, S | 1 |
| Onwordi, ENC | 1 |
| Gamal, A | 1 |
| Zaman, A | 1 |
| Zheng, W | 1 |
| Tian, J | 1 |
| Xie, L | 1 |
| Mao, Q | 1 |
| Tong, W | 1 |
| Zhou, D | 1 |
| Azzalini, L | 1 |
| Yang, M | 2 |
| Xu, L | 2 |
| Zhu, H | 1 |
| Wang, F | 1 |
| Hu, X | 1 |
| Chan, NC | 1 |
| Chopra, AM | 1 |
| Díez-Villanueva, P | 2 |
| Córdoba-Soriano, JG | 2 |
| Lee, JKT | 1 |
| Al-Ahmad, M | 1 |
| Ferraris, VA | 1 |
| Mehta, M | 1 |
| Kowalski, ML | 1 |
| Cortese, M | 1 |
| D Ascenzo, F | 1 |
| Ashby, D | 1 |
| Lyon, C | 1 |
| Koyabu, Y | 1 |
| Abe, S | 1 |
| Sakuma, M | 1 |
| Kanaya, T | 1 |
| Obi, S | 1 |
| Yoneda, S | 1 |
| Toyoda, S | 1 |
| Nakajima, T | 1 |
| Inoue, T | 1 |
| Crisci, M | 1 |
| Di Maio, M | 1 |
| Diana, V | 1 |
| Pariggiano, I | 1 |
| Di Maio, D | 1 |
| Concilio, C | 1 |
| Taglialatela, V | 1 |
| Cirillo, PL | 1 |
| Rockhold, FW | 1 |
| Plotnikov, AN | 1 |
| Sterne, JAC | 1 |
| Zheng, L | 1 |
| Xiang, L | 1 |
| Hao, Z | 1 |
| Sulzgruber, P | 1 |
| Niessner, A | 1 |
| Bruno, V | 1 |
| Hübl, W | 1 |
| Willheim, M | 1 |
| Wojta, J | 2 |
| Geppert, A | 2 |
| Wester, A | 1 |
| Mohammad, MA | 1 |
| Andell, P | 1 |
| Hofmann, R | 1 |
| Jensen, J | 1 |
| Szummer, K | 3 |
| Koul, S | 3 |
| de Groot, NL | 1 |
| van Haalen, HG | 1 |
| Spiegel, BM | 1 |
| Laine, L | 3 |
| Lanas, A | 2 |
| Focks, JJ | 1 |
| Siersema, PD | 1 |
| van Oijen, MG | 1 |
| Fugon, L | 1 |
| Beguin, S | 1 |
| Carrieri, P | 1 |
| Echavarría-Pinto, M | 1 |
| Gorgadze, T | 1 |
| Gonzalo, N | 1 |
| Hernández, R | 1 |
| Jiménez-Quevedo, P | 1 |
| Alfonso, F | 2 |
| Bañuelos, C | 1 |
| Nuñez-Gil, IJ | 1 |
| Ibañez, B | 1 |
| Fernández, C | 1 |
| Fernandez-Ortiz, A | 1 |
| García, E | 1 |
| Macaya, C | 2 |
| Mellstrom, C | 1 |
| Chua, TS | 1 |
| Matchar, DB | 1 |
| Turkmen, S | 1 |
| Fettser, DV | 3 |
| Kagliian, KÉ | 1 |
| Serchelik, A | 1 |
| Arystanova, AZh | 1 |
| Tekin, K | 1 |
| Balli, M | 1 |
| Batyraliev, TA | 3 |
| Samko, AN | 2 |
| Sidorenko, BA | 3 |
| Caglar, I | 1 |
| Vural, A | 2 |
| Ungan, I | 1 |
| Ugurlucan, M | 1 |
| Karakaya, O | 1 |
| Torngren, K | 1 |
| Ohman, J | 2 |
| Salmi, H | 1 |
| Larsson, J | 1 |
| Blancas Gómez-Casero, R | 1 |
| Quintana Díaz, M | 1 |
| Chana García, M | 1 |
| Martín Parra, C | 1 |
| López Matamala, B | 1 |
| Estébanez Montiel, B | 1 |
| Ballesteros Ortega, D | 1 |
| Martínez González, O | 1 |
| Vigil Escribano, D | 1 |
| Prieto Valderrey, F | 1 |
| Marina Martínez, L | 1 |
| Castro Gallego, O | 1 |
| Chakrabarti, AK | 1 |
| Mega, J | 1 |
| Bassand, JP | 6 |
| Verheugt, FW | 5 |
| Cohen, M | 5 |
| Mohanavelu, S | 2 |
| Burton, P | 3 |
| Stone, G | 1 |
| Braunwald, E | 11 |
| Mazurov, AV | 4 |
| Khaspekova, SG | 3 |
| Yakushkin, VV | 1 |
| Khachikyan, MV | 1 |
| Zyuryaev, IT | 1 |
| Ruda, MY | 2 |
| Duan, Z | 1 |
| Hu, K | 1 |
| DiNicolantonio, JJ | 5 |
| Tomek, A | 2 |
| Berger, JS | 2 |
| Stevens, SR | 1 |
| Hochman, JS | 3 |
| Martinez, F | 4 |
| Fox, KA | 14 |
| Yan, RT | 1 |
| Gore, JM | 3 |
| Polasek, P | 1 |
| Lai, K | 1 |
| Baer, C | 1 |
| Goldberg, RJ | 3 |
| Pinter, A | 1 |
| Ahmad, K | 1 |
| Kornder, JM | 1 |
| Yan, AT | 2 |
| Can, MM | 1 |
| Pershukov, IV | 1 |
| Kuliczkowski, W | 1 |
| Aronow, WS | 2 |
| López, J | 1 |
| Morales, C | 1 |
| Avanzas, P | 1 |
| Callejo, F | 1 |
| Hernández-Vaquero, D | 1 |
| Llosa, JC | 1 |
| Nagashima, Z | 2 |
| Tsukahara, K | 3 |
| Morita, S | 2 |
| Endo, T | 2 |
| Sugano, T | 2 |
| Hibi, K | 3 |
| Himeno, H | 2 |
| Fukui, K | 2 |
| Umemura, S | 3 |
| Ottani, F | 1 |
| Norgard, NB | 2 |
| El-Menyar, A | 2 |
| Ahmed, E | 1 |
| Albinali, H | 1 |
| Al-Thani, H | 1 |
| Gehani, A | 1 |
| Singh, R | 3 |
| Al Suwaidi, J | 4 |
| Bell, AD | 1 |
| Ackman, ML | 1 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 5 |
| Wong, G | 1 |
| Serikawa, T | 1 |
| Miura, S | 1 |
| Okabe, M | 1 |
| Hongo, H | 1 |
| Tokutome, M | 1 |
| Yoshikawa, T | 1 |
| Takesue, K | 1 |
| Adachi, S | 1 |
| Osaka, K | 1 |
| Matsukawa, R | 1 |
| Yanagi, D | 1 |
| Nozoe, M | 1 |
| Kozai, T | 1 |
| Hironaga, K | 1 |
| Saku, K | 1 |
| Yamamoto, Y | 1 |
| Gulba, D | 1 |
| Chiang, FT | 1 |
| Shyu, KG | 1 |
| Wu, CJ | 2 |
| Mar, GY | 1 |
| Hou, CJ | 1 |
| Li, AH | 1 |
| Wen, MS | 1 |
| Lai, WT | 2 |
| Lin, SJ | 1 |
| Kuo, CT | 1 |
| Kuo, C | 1 |
| Hwang, JJ | 1 |
| Gasche, D | 1 |
| Ulle, T | 1 |
| Meier, B | 2 |
| Greiner, RA | 1 |
| Niazi, AK | 2 |
| Lavie, CJ | 2 |
| O'Keefe, JH | 2 |
| Meier, P | 3 |
| Acharji, S | 1 |
| Lakshmanadoss, U | 1 |
| Rudzinski, W | 1 |
| Stapleton, DD | 1 |
| Kaluski, E | 1 |
| Varenhorst, C | 2 |
| Jensevik, K | 2 |
| Jernberg, T | 3 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Held, C | 4 |
| Lagerqvist, B | 3 |
| Jayasinghe, R | 1 |
| Markham, R | 1 |
| Adsett, G | 1 |
| Bosch, X | 3 |
| Marrugat, J | 3 |
| Sanchis, J | 3 |
| Lip, G | 1 |
| Franchi, F | 2 |
| Rollini, F | 3 |
| Muñiz-Lozano, A | 1 |
| Cho, JR | 2 |
| Kohli, P | 1 |
| Antman, EM | 4 |
| Kronish, IM | 4 |
| Rieckmann, N | 4 |
| Burg, MM | 3 |
| Alcántara, C | 1 |
| Davidson, KW | 4 |
| Feres, F | 3 |
| Costa, RA | 2 |
| Abizaid, A | 2 |
| Leon, MB | 1 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 1 |
| Negoita, M | 1 |
| Liu, M | 2 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Zhang, YY | 1 |
| Zhou, X | 1 |
| Ji, WJ | 1 |
| Shi, R | 1 |
| Lu, RY | 1 |
| Li, JL | 1 |
| Yang, GH | 1 |
| Luo, T | 1 |
| Zhang, JQ | 1 |
| Zhao, JH | 1 |
| Jiang, TM | 1 |
| Li, YM | 1 |
| Sevimli, S | 1 |
| Karakoyun, S | 1 |
| Bakirci, EM | 1 |
| Topcu, S | 1 |
| Kalkan, K | 1 |
| Borekci, A | 1 |
| Vançelik, S | 1 |
| Berkenboom, G | 1 |
| Coufal, Z | 1 |
| Belger, M | 2 |
| Sartral, M | 2 |
| Norrbacka, K | 1 |
| Bakhai, A | 3 |
| Cully, M | 1 |
| Mahla, E | 1 |
| Lin, CF | 1 |
| Shen, LJ | 1 |
| Hsiao, FY | 4 |
| Gau, CS | 2 |
| Wu, FL | 1 |
| del Castillo-Carnevali, H | 1 |
| Barrios Alonso, V | 1 |
| Zamorano Gómez, JL | 1 |
| Kotha, J | 1 |
| Smyth, SS | 1 |
| Moliterno, DJ | 5 |
| Rorick, TL | 1 |
| Moccetti, T | 1 |
| Dery, JP | 1 |
| Thomas, GS | 1 |
| Hord, E | 1 |
| Judge, HM | 1 |
| Chen, E | 2 |
| Mahaffey, KW | 5 |
| Tricoci, P | 4 |
| Jennings, LK | 3 |
| Arntz, HR | 2 |
| Boudriot, E | 1 |
| Garlichs, C | 1 |
| Hoffmann, S | 1 |
| Ince, H | 1 |
| Klingenheben, T | 1 |
| Weil, J | 1 |
| Zugck, C | 1 |
| Helms, TM | 1 |
| Silber, S | 1 |
| Wijeyeratne, YD | 2 |
| May, JA | 1 |
| Johnson, A | 1 |
| Heptinstall, S | 2 |
| Fox, SC | 1 |
| Good, RI | 1 |
| McGarrity, A | 1 |
| Sheehan, R | 1 |
| James, TE | 1 |
| Miller, H | 1 |
| Stephens, J | 1 |
| Watkins, S | 1 |
| McConnachie, A | 1 |
| Goodall, AH | 1 |
| Oldroyd, KG | 1 |
| Pankert, M | 2 |
| Morange, P | 1 |
| Huang, Z | 1 |
| Van de Werf, F | 5 |
| Rorick, T | 1 |
| Dalén, M | 2 |
| van der Linden, J | 2 |
| Lindvall, G | 2 |
| Ivert, T | 1 |
| Dasbiswas, A | 1 |
| Rao, MS | 1 |
| Babu, PR | 1 |
| Vijayvergiya, R | 1 |
| Nayak, R | 1 |
| Dani, S | 1 |
| Tyagi, S | 1 |
| Hiremath, S | 1 |
| Patel, T | 1 |
| Alexander, T | 1 |
| Prakash, VS | 1 |
| Singh, DP | 1 |
| Yadav, MK | 1 |
| Pathak, K | 1 |
| Srivastava, A | 1 |
| Hirschl, MM | 1 |
| Singh, D | 1 |
| Vacek, JL | 2 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Chen, SC | 1 |
| Lee, CM | 1 |
| Hsu, WW | 1 |
| Viswanathan, GN | 2 |
| Marshall, SM | 2 |
| Balasubramaniam, K | 2 |
| Badimon, JJ | 3 |
| Zaman, AG | 2 |
| Choi, JL | 1 |
| Kim, BR | 1 |
| Kim, JE | 1 |
| Woo, KS | 1 |
| Kim, KH | 1 |
| Kim, JM | 1 |
| Kim, MH | 2 |
| Han, JY | 1 |
| Whitmore, TJ | 1 |
| O'Shea, JP | 1 |
| Starac, D | 1 |
| Edwards, MG | 1 |
| Waterer, GW | 1 |
| Bhatty, S | 1 |
| Ali, A | 1 |
| Shetty, R | 1 |
| Sumption, KF | 1 |
| Cowley, MJ | 1 |
| Jovin, IS | 1 |
| Neuenschwander, FC | 1 |
| Lima Filho, A | 1 |
| Moreira, CM | 1 |
| Santos, ES | 1 |
| Reis, HJ | 1 |
| Romano, ER | 1 |
| Mattos, LA | 1 |
| Andrade, JP | 1 |
| Bonaca, MP | 1 |
| Held, P | 1 |
| Jensen, EC | 1 |
| Greene, SJ | 1 |
| Alkhawam, L | 1 |
| Vaduganathan, M | 2 |
| Isshiki, T | 2 |
| Ogawa, H | 4 |
| Nanto, S | 2 |
| Takayama, M | 2 |
| Kitagawa, K | 2 |
| Nishikawa, M | 3 |
| Miyazaki, S | 2 |
| Oestreich, JH | 1 |
| Chatterjee, S | 1 |
| Packard, KA | 1 |
| Biondi-Zoccai, G | 2 |
| Fuchs, FD | 1 |
| Levitan, B | 1 |
| Poulos, C | 1 |
| Brett Hauber, A | 1 |
| Berlin, JA | 1 |
| Christodoulidis, G | 1 |
| Stimpfle, F | 1 |
| Karathanos, A | 1 |
| Droppa, M | 1 |
| Metzger, J | 1 |
| Rath, D | 1 |
| Müller, K | 2 |
| Tavlaki, E | 1 |
| Schäffeler, E | 1 |
| Winter, S | 1 |
| Schwab, M | 1 |
| Gawaz, M | 4 |
| Fedor, M | 1 |
| Samoš, M | 1 |
| Šimonová, R | 1 |
| Fedorová, J | 1 |
| Škorňová, I | 1 |
| Duraj, L | 1 |
| Staško, J | 1 |
| Kovář, F | 1 |
| Mokáň, M | 1 |
| Kubisz, P | 1 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Lopez-Sendon, J | 5 |
| Ramos, Y | 1 |
| Widimsky, P | 5 |
| Santilli, F | 1 |
| Paloscia, L | 1 |
| Liani, R | 1 |
| Di Nicola, M | 1 |
| Di Marco, M | 1 |
| Lattanzio, S | 1 |
| La Barba, S | 1 |
| Pascale, S | 1 |
| Mascellanti, M | 1 |
| Davì, G | 1 |
| Ye, J | 1 |
| Wen, Z | 1 |
| Ding, J | 1 |
| Kunapuli, SP | 1 |
| Luo, X | 1 |
| Ding, Z | 1 |
| Molina-Cuadrado, E | 1 |
| Mateo-Carrasco, H | 1 |
| Nieto-Guindo, P | 1 |
| Rodríguez-Gómez, P | 1 |
| Arima, Y | 1 |
| Hokimoto, S | 1 |
| Akasaka, T | 1 |
| Mizobe, K | 1 |
| Kaikita, K | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Yildiz, M | 1 |
| Yildiz, BS | 1 |
| Gursoy, MO | 1 |
| Koziolova, NA | 1 |
| Okura, H | 1 |
| Kataoka, T | 1 |
| Yoshiyama, M | 2 |
| Yoshikawa, J | 1 |
| Yoshida, K | 1 |
| Schreiber, P | 1 |
| Fauchère, I | 1 |
| Wyss, C | 1 |
| Griffiths, B | 1 |
| Lesosky, M | 1 |
| Ntsekhe, M | 1 |
| Simms, AD | 1 |
| Weston, CF | 1 |
| West, RM | 2 |
| Hall, AS | 3 |
| Batin, PD | 2 |
| Timmis, A | 1 |
| Hemingway, H | 1 |
| Fox, K | 1 |
| Gale, CP | 3 |
| Rubattu, S | 1 |
| De Giusti, M | 1 |
| Farcomeni, A | 1 |
| Abbolito, S | 1 |
| Comito, F | 1 |
| Cangianiello, S | 1 |
| Greco, ES | 1 |
| Dito, E | 1 |
| Pagliaro, B | 1 |
| Cotugno, M | 1 |
| Stanzione, R | 1 |
| Marchitti, S | 1 |
| Bianchi, F | 1 |
| Di Castro, S | 1 |
| Battistoni, A | 1 |
| Burocchi, S | 1 |
| Caprinozzi, M | 1 |
| Pierelli, G | 1 |
| Sciarretta, S | 1 |
| Volpe, M | 1 |
| Vengoechea, F | 1 |
| Nührenberg, T | 1 |
| Stratz, C | 1 |
| Valina, CM | 1 |
| Hochholzer, W | 1 |
| Li, K | 1 |
| Sun, H | 1 |
| Zhang, D | 1 |
| Wang, H | 1 |
| Li, W | 1 |
| Ni, Z | 1 |
| Xia, K | 1 |
| Almendro-Delia, M | 1 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 1 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Bauer, T | 3 |
| Ismail, S | 1 |
| Lee, YM | 1 |
| Patel, M | 1 |
| Ardati, AK | 1 |
| Olivier, CB | 1 |
| Diehl, P | 1 |
| Moser, M | 1 |
| Christ, G | 1 |
| Francesconi, M | 1 |
| Dechant, C | 1 |
| Grohs, K | 1 |
| Podczeck-Schweighofer, A | 1 |
| Kander, T | 1 |
| Brokopp, J | 1 |
| Lood, C | 1 |
| Schött, U | 1 |
| Qi, Y | 2 |
| Sun, J | 2 |
| Nachmias, B | 1 |
| Leibowitz, D | 1 |
| Thompson, AG | 1 |
| Judkins, C | 1 |
| Hobl, EL | 1 |
| Schmid, RW | 1 |
| Stimpfl, T | 1 |
| Ebner, J | 1 |
| Bates, ER | 2 |
| Anderson, JL | 1 |
| Lopez Sendon, JL | 1 |
| Kupsky, DF | 1 |
| Tweet, MS | 1 |
| Anavekar, NS | 1 |
| Geersing, GJ | 1 |
| Kappelle, LJ | 1 |
| Braun, OÖ | 2 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Tydén, P | 1 |
| Scherstén, F | 2 |
| Jovinge, S | 1 |
| Svensson, PJ | 2 |
| Gustav Smith, J | 1 |
| van der Pals, J | 2 |
| Bakheet, MF | 1 |
| Pearce, LA | 1 |
| Hart, RG | 1 |
| Oliveras Vilà, T | 1 |
| Ferrer Massot, M | 1 |
| Curós Abadal, A | 1 |
| Rueda Sobella, F | 1 |
| Serra Flores, J | 1 |
| Carrillo Suárez, X | 1 |
| Bayes-Genis, A | 1 |
| Sáez, ME | 1 |
| González-Pérez, A | 1 |
| Johansson, S | 2 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Ziuriaev, IT | 2 |
| Iakushkin, VV | 2 |
| Sirotkina, OV | 1 |
| Ruda, MIa | 2 |
| Natarajan, D | 1 |
| Ferrer Gracia, MC | 1 |
| Calvo Cebollero, I | 1 |
| Gencer, B | 2 |
| Rodondi, N | 2 |
| Auer, R | 2 |
| Klingenberg, R | 1 |
| Nanchen, D | 2 |
| Carballo, D | 1 |
| Vogt, P | 1 |
| Carballo, S | 1 |
| Meyer, P | 1 |
| Lhermusier, T | 1 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Yeh, RW | 3 |
| Mauri, L | 3 |
| Weeks, PA | 1 |
| Sieg, A | 1 |
| Paruthi, C | 1 |
| Rajapreyar, I | 1 |
| Tataris, KL | 1 |
| Mercer, MP | 1 |
| Govindarajan, P | 1 |
| Bultas, J | 1 |
| Costa, F | 1 |
| Ando, G | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Rajpurohit, N | 1 |
| Ayaz, SZ | 1 |
| Yee, J | 1 |
| Khan, MA | 1 |
| Kafkas, NV | 1 |
| Liakos, CI | 1 |
| Mouzarou, AG | 1 |
| Monitillo, F | 1 |
| Iacoviello, M | 1 |
| Caldarola, P | 1 |
| Valle, R | 1 |
| Chiatto, M | 1 |
| Sharma, A | 1 |
| Ferguson, C | 1 |
| Bomb, R | 1 |
| Oliphant, CS | 1 |
| Cecchi, E | 2 |
| Chiostri, M | 1 |
| Mecarocci, V | 1 |
| Spini, V | 1 |
| Innocenti, L | 1 |
| Calabretta, R | 1 |
| Cordisco, A | 1 |
| Romano, SM | 1 |
| Abbate, R | 7 |
| Gensini, GF | 6 |
| Giglioli, C | 3 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Wiegerinck, EM | 1 |
| Ussia, GP | 1 |
| Sharma, S | 1 |
| Baan, J | 1 |
| Eltchaninoff, H | 1 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Tamburino, C | 1 |
| Poliacikova, P | 1 |
| Blanchard, D | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Xian, Y | 1 |
| McCoy, LA | 1 |
| Henry, TD | 2 |
| Bach, RG | 1 |
| Zettler, ME | 1 |
| Baker, BA | 1 |
| Yudi, MB | 1 |
| Eccleston, D | 2 |
| Andrianopoulos, N | 1 |
| Farouque, O | 1 |
| Duffy, SJ | 1 |
| Brennan, A | 1 |
| Reid, C | 1 |
| Clark, DJ | 1 |
| Ajani, AE | 2 |
| Lettieri, C | 2 |
| Limbruno, U | 1 |
| Senni, M | 2 |
| Guagliumi, G | 1 |
| Valsecchi, O | 1 |
| Sartori, C | 2 |
| Fanari, Z | 1 |
| Weiss, S | 1 |
| Weintraub, WS | 2 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Cao, H | 1 |
| Yahia, DH | 1 |
| Lishner, M | 1 |
| Elis, A | 1 |
| Brener, SJ | 2 |
| Mintz, GS | 1 |
| de Bruyne, B | 1 |
| Ferreira-González, I | 1 |
| Carrillo, X | 1 |
| Martín, V | 1 |
| de la Torre Hernández, JM | 1 |
| Baz, JA | 1 |
| Navarro Manchón, J | 1 |
| Masotti, M | 1 |
| Cárdenas, M | 1 |
| Alfonso Manterola, F | 1 |
| Petricevic, M | 1 |
| Boban, M | 1 |
| Mihaljevic, MZ | 1 |
| Biocina, B | 1 |
| Pereira, M | 1 |
| Lopes-Conceição, L | 1 |
| Bennett, K | 1 |
| Dias, P | 1 |
| Laszczynska, O | 1 |
| Lunet, N | 1 |
| Azevedo, A | 1 |
| Golukhova, EZ | 1 |
| Grigorian, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Fortmann, S | 1 |
| Grove, EL | 2 |
| Würtz, M | 1 |
| Tan, NS | 1 |
| Ganjehei, L | 1 |
| Dong, W | 1 |
| Wan, Z | 1 |
| Cong, H | 1 |
| Hong, T | 1 |
| Yin, T | 1 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Rigg, K | 1 |
| Hogg, K | 1 |
| Acibuca, A | 1 |
| Gerede, DM | 1 |
| Vurgun, VK | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Kline, KP | 1 |
| Conti, CR | 1 |
| Winchester, DE | 1 |
| Medagama, A | 1 |
| Bandara, R | 1 |
| De Silva, C | 1 |
| Galgomuwa, MP | 1 |
| Ikeda, Y | 2 |
| Tanaka, Y | 1 |
| Valli, G | 1 |
| De Marco, F | 1 |
| Spina, MT | 1 |
| Valeriano, V | 1 |
| Rosa, A | 1 |
| Minerva, V | 1 |
| Mirante, E | 1 |
| Ruggieri, MP | 1 |
| Pugliese, FR | 1 |
| Han, DC | 1 |
| Sohn, CB | 1 |
| Hwang, J | 1 |
| Kim, IS | 1 |
| Lee, SM | 1 |
| Han, J | 1 |
| Noh, M | 1 |
| Kim, CH | 1 |
| Corbí-Pascual, M | 1 |
| López-Neyra, I | 1 |
| Navarro-Cuartero, J | 1 |
| Hidalgo-Olivares, V | 1 |
| Barrionuevo-Sánchez, MI | 1 |
| Prieto-Mateos, D | 1 |
| Gutiérrez-Díez, A | 1 |
| Gallardo-López, A | 1 |
| Fuentes-Manso, R | 1 |
| Gómez-Pérez, A | 1 |
| Lafuente-Gormaz, C | 1 |
| Jiménez-Mazuecos, J | 1 |
| Garcia-Garcia, HM | 1 |
| van Es, GA | 1 |
| Lansky, AJ | 1 |
| Ayele, GM | 1 |
| Schneider, DJ | 1 |
| Chava, S | 1 |
| Cook, KA | 1 |
| White, AA | 1 |
| Pursnani, A | 1 |
| Celeng, C | 1 |
| Schlett, CL | 1 |
| Mayrhofer, T | 1 |
| Zakroysky, P | 1 |
| Ferencik, M | 1 |
| Fleg, JL | 1 |
| Bamberg, F | 1 |
| Truong, QA | 1 |
| Udelson, JE | 1 |
| Nagurney, JT | 1 |
| Hoffmann, U | 1 |
| Grifoni, E | 1 |
| Antoniucci, D | 4 |
| Wilczynski, M | 1 |
| Wybraniec, MT | 1 |
| Milewski, K | 1 |
| Sanak, M | 1 |
| Wita, K | 1 |
| Buldak, Ł | 1 |
| Kondys, M | 1 |
| Bochenek, A | 1 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Saito, M | 1 |
| Ohshima, K | 1 |
| Ikeda, S | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Guthrie, RM | 1 |
| Beauloye, C | 1 |
| Vrolix, M | 1 |
| van de Borne, P | 1 |
| Vandendriessche, E | 1 |
| Welker, J | 1 |
| Cornuz, J | 1 |
| Mărginean, A | 1 |
| Bănescu, C | 1 |
| Moldovan, V | 1 |
| Scridon, A | 1 |
| Mărginean, M | 1 |
| Bălaşa, R | 1 |
| Maier, S | 1 |
| Ţăruşi, M | 1 |
| Dobreanu, M | 1 |
| Gouda, P | 1 |
| Bainey, K | 1 |
| Welsh, R | 2 |
| Antuña, P | 1 |
| Múgica, MV | 1 |
| Belver, MT | 1 |
| Aguilar, R | 1 |
| Chong Tou, TJ | 1 |
| Liu, PM | 1 |
| Wang, JF | 2 |
| Sio Cham, ZC | 1 |
| O U, YF | 1 |
| Lei Sio, ZW | 1 |
| Lei Put, PZ | 1 |
| Lei Sok, SM | 1 |
| Zhou, SX | 1 |
| Wu, W | 2 |
| Rayner-Hartley, E | 1 |
| Chou, A | 1 |
| Saw, J | 1 |
| Sedlak, T | 1 |
| Geissel, W | 1 |
| Uchida, K | 1 |
| Karube, N | 1 |
| Ebina, T | 1 |
| Imoto, K | 1 |
| Neely, B | 5 |
| Neely, ML | 4 |
| Mancone, M | 1 |
| Faz, GT | 1 |
| Park, Y | 2 |
| Thano, E | 1 |
| Hu, J | 1 |
| Kureti, M | 1 |
| Aggarwal, N | 1 |
| Durairaj, A | 1 |
| Been, L | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 3 |
| Suryadevara, S | 1 |
| Antoun, P | 1 |
| Bass, TA | 4 |
| Fanaroff, AC | 1 |
| Corbalán, R | 3 |
| Schiele, F | 2 |
| Ruiz-Nodar, JM | 1 |
| Jayakumar, T | 1 |
| Yang, CH | 1 |
| Geraldine, P | 1 |
| Yen, TL | 1 |
| Sheu, JR | 1 |
| Giustino, G | 1 |
| Ariti, C | 1 |
| Litherland, C | 1 |
| Kini, AS | 1 |
| Fromonot, J | 1 |
| Dignat-Georges, F | 1 |
| Rossi, P | 1 |
| Mottola, G | 1 |
| Kipson, N | 1 |
| Ruf, J | 1 |
| Guieu, R | 1 |
| Trantalis, G | 1 |
| Katsi, V | 1 |
| Toutouzas, K | 1 |
| Tousoulis, D | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Becher, A | 1 |
| Jennings, E | 1 |
| Westergaard, M | 1 |
| Cryer, BL | 1 |
| Hsieh, WH | 2 |
| Doros, G | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Hafley, G | 1 |
| Sidhu, MS | 1 |
| Bagai, A | 2 |
| Eikelboom, JW | 5 |
| Mancini, GB | 1 |
| Cohen, EA | 1 |
| Vijayaraghavan, R | 1 |
| Cheema, AN | 1 |
| Niznick, J | 1 |
| Llitjos, JF | 1 |
| Sideris, G | 1 |
| Voicu, S | 1 |
| Bal Dit Sollier, C | 1 |
| Deye, N | 1 |
| Megarbane, B | 1 |
| Drouet, L | 1 |
| Henry, P | 1 |
| Dillinger, JG | 1 |
| Smagulova, G | 1 |
| Kulmurzaeva, N | 1 |
| Seytmaganbetova, N | 1 |
| Kurmanalina, G | 1 |
| Talipova, I | 1 |
| Dadjou, Y | 1 |
| Safavi, S | 1 |
| Kojuri, J | 1 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Asher, E | 2 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Sabbag, A | 1 |
| Mazin, I | 1 |
| Shlezinger, M | 1 |
| Atar, S | 1 |
| Zahger, D | 1 |
| Polak, A | 1 |
| Beigel, R | 3 |
| Matetzky, S | 4 |
| Borzi, M | 1 |
| Menozzi, A | 2 |
| Scherillo, M | 1 |
| Ledda, A | 1 |
| Tarantini, G | 1 |
| Gerometta, P | 1 |
| Formigli, D | 1 |
| Romeo, F | 1 |
| Di Bartolomeo, R | 1 |
| Zang, H | 1 |
| Zhao, W | 1 |
| Tsoumani, ME | 1 |
| Tatsidou, PT | 1 |
| Ntalas, IV | 1 |
| Goudevenos, JA | 2 |
| Tselepis, AD | 3 |
| Marino, BC | 1 |
| Marcolino, MS | 1 |
| Reis Júnior, Rdos S | 1 |
| França, AL | 1 |
| Passos, PF | 1 |
| Lemos, TR | 1 |
| Antunes, Ide O | 1 |
| Ferreira, CG | 1 |
| Antunes, AP | 1 |
| Ribeiro, AL | 1 |
| Knežević, B | 1 |
| Musić, L | 1 |
| Batrićević, G | 1 |
| Bošković, A | 1 |
| Bulatović, N | 1 |
| Nenezić, A | 1 |
| Vujović, J | 1 |
| Kalezić, M | 1 |
| Cui, M | 1 |
| Tu, CC | 1 |
| Chen, EZ | 1 |
| Wang, XL | 1 |
| Tan, SC | 1 |
| Jackson, LR | 1 |
| Piccini, JP | 1 |
| Ueno, T | 1 |
| Koiwaya, H | 1 |
| Sasaki, KI | 1 |
| Katsuki, Y | 1 |
| Katsuda, Y | 1 |
| Murasato, Y | 1 |
| Shimamatsu, J | 1 |
| Umeji, K | 1 |
| Otsuka, Y | 1 |
| Kawasaki, T | 1 |
| Shibata, Y | 1 |
| Fukumoto, Y | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Lee, SW | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Kaul, P | 1 |
| Knight, JD | 1 |
| Anstrom, KJ | 1 |
| Gašparović, V | 2 |
| McCollam, P | 2 |
| Fakhouri, W | 1 |
| Cowper, P | 1 |
| Davidson-Ray, L | 1 |
| Clapp-Channing, N | 1 |
| Mark, DB | 1 |
| Manzo-Silberman, S | 1 |
| Nicaise-Roland, P | 1 |
| Neukirch, C | 1 |
| Tubach, F | 1 |
| Huisse, MG | 1 |
| Chollet-Martin, S | 1 |
| Abergel, H | 1 |
| Driss, F | 1 |
| Alfaiate, T | 1 |
| Ajzenberg, N | 1 |
| Ariotti, S | 1 |
| Santucci, A | 1 |
| Baldo, A | 1 |
| Marino, M | 1 |
| Koh, JS | 1 |
| Ahn, JH | 1 |
| Kang, MG | 1 |
| Kim, K | 1 |
| Jang, JY | 1 |
| Park, HW | 1 |
| Park, JR | 1 |
| Hwang, SJ | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Gherli, R | 1 |
| Mariscalco, G | 1 |
| Onorati, F | 1 |
| Perrotti, A | 1 |
| Chocron, S | 1 |
| Verhoye, JP | 1 |
| Gulbins, H | 1 |
| Reichart, D | 1 |
| Svenarud, P | 2 |
| Faggian, G | 1 |
| Santarpino, G | 1 |
| Fischlein, T | 1 |
| Maselli, D | 1 |
| Dominici, C | 1 |
| Musumeci, F | 1 |
| Rubino, AS | 1 |
| Mignosa, C | 1 |
| De Feo, M | 1 |
| Bancone, C | 1 |
| Gatti, G | 1 |
| Maschietto, L | 1 |
| Santini, F | 1 |
| Nicolini, F | 1 |
| Gherli, T | 1 |
| Zanobini, M | 1 |
| Kinnunen, EM | 1 |
| Ruggieri, VG | 1 |
| Rosato, S | 1 |
| Biancari, F | 1 |
| Lev, EI | 1 |
| Gunarathne, A | 1 |
| Hussain, S | 1 |
| Gershlick, AH | 1 |
| Rosa, GM | 1 |
| Bianco, D | 1 |
| Valbusa, A | 1 |
| Massobrio, L | 1 |
| Chiarella, F | 1 |
| Brunelli, C | 1 |
| Myat, A | 1 |
| Kinsara, AJ | 1 |
| Doly, JS | 1 |
| Lorian, E | 1 |
| Desormais, I | 1 |
| Constans, J | 1 |
| Bura Rivière, A | 1 |
| Lacroix, P | 1 |
| Petrie, CJ | 1 |
| Zhang, P | 1 |
| Huang, X | 1 |
| Shen, C | 1 |
| Jakubowski, JA | 3 |
| Choi, HK | 1 |
| Ghim, JL | 1 |
| Shon, J | 1 |
| Choi, YK | 1 |
| Jung, JA | 1 |
| Ferri, LA | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 2 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Tondi, S | 1 |
| Toso, A | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Moffa, N | 1 |
| Webster, TD | 1 |
| Vaishnava, P | 1 |
| Eagle, KA | 5 |
| Santos, RC | 1 |
| Kisukuri, AL | 1 |
| Brandão, RM | 1 |
| Sitnik, D | 1 |
| Staniak, HL | 1 |
| Bittencourt, MS | 1 |
| Wimmer, NJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Gagnon, DR | 1 |
| Quach, L | 1 |
| Ly, S | 1 |
| Do, JM | 1 |
| Ostrowski, S | 1 |
| Michael Gaziano, J | 1 |
| Faxon, DP | 3 |
| Luchessi, AD | 1 |
| Concheiro, M | 1 |
| Germano, JF | 1 |
| Silbiger, VN | 1 |
| Bortolin, RH | 1 |
| Cruz, A | 1 |
| Quintela, O | 1 |
| Brion, M | 1 |
| Carracedo, A | 1 |
| Iñiguez, A | 2 |
| Bravo, M | 1 |
| López-Rivadulla, M | 1 |
| Hirata, RD | 1 |
| Sousa, AG | 1 |
| Hirata, MH | 1 |
| Carrero, JJ | 2 |
| Evans, M | 2 |
| Spaak, J | 2 |
| Ho, HH | 1 |
| Mok, KH | 1 |
| Petzold, T | 1 |
| Thienel, M | 1 |
| Konrad, I | 1 |
| Schubert, I | 1 |
| Regenauer, R | 1 |
| Hoppe, B | 1 |
| Lorenz, M | 1 |
| Eckart, A | 1 |
| Chandraratne, S | 1 |
| Lennerz, C | 1 |
| Kolb, C | 1 |
| Braun, D | 1 |
| Jamasbi, J | 1 |
| Brandl, R | 1 |
| Braun, S | 1 |
| Siess, W | 1 |
| Schulz, C | 1 |
| Pocock, SJ | 1 |
| Badimon, J | 1 |
| Zafar, MU | 2 |
| Chandrasekhar, J | 1 |
| Aquino, M | 1 |
| Wonnacott, D | 1 |
| Berringer, R | 1 |
| Mirra, M | 1 |
| Kola, N | 1 |
| Mattiello, G | 1 |
| Spinelli, L | 1 |
| Hauguel-Moreau, M | 1 |
| Boccara, F | 1 |
| Boyd, A | 1 |
| Salem, JE | 1 |
| Brugier, D | 1 |
| Curjol, A | 1 |
| Hulot, JS | 1 |
| Kerneis, M | 1 |
| Galier, S | 1 |
| Cohen, A | 1 |
| Silvain, J | 4 |
| van Diepen, S | 1 |
| Fuster, V | 3 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Yonetsu, T | 1 |
| Lee, T | 1 |
| Murai, T | 1 |
| Kanno, Y | 1 |
| Hamaya, R | 1 |
| Ichijo, S | 1 |
| Niida, T | 1 |
| Hada, M | 1 |
| Araki, M | 1 |
| Matsuda, J | 1 |
| Usui, E | 1 |
| Hoshino, M | 1 |
| Kanaji, Y | 1 |
| Kakuta, T | 1 |
| Hohlfeld, T | 1 |
| Erbel, R | 1 |
| Münzel, T | 1 |
| Zahn, R | 4 |
| Roitenberg, A | 1 |
| Breitenstein, S | 1 |
| Pap, ÁF | 1 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Gilard, M | 1 |
| Morice, MC | 1 |
| Sangiorgi, D | 1 |
| Angelini, GD | 1 |
| Yildirim, A | 2 |
| Lübbers, HT | 1 |
| Gesheff, T | 1 |
| Barbour, C | 1 |
| Iorio, A | 1 |
| Colombo, P | 1 |
| Rigattieri, S | 1 |
| Dossena, C | 1 |
| Anzuini, A | 1 |
| Khedri, M | 1 |
| Jacobson, SH | 1 |
| Stefanescu Schmidt, AC | 1 |
| Kereiakes, DJ | 1 |
| Cutlip, DE | 2 |
| D'Agostino, RB | 1 |
| Massaro, JM | 1 |
| Wilson, SJ | 1 |
| Dawson, D | 1 |
| Irving, J | 1 |
| Sheikh Rezaei, S | 1 |
| Geroldinger, A | 1 |
| Heinze, G | 1 |
| Reichardt, B | 1 |
| Wolzt, M | 1 |
| Lim, SW | 1 |
| Oh, SK | 1 |
| Kim, BS | 1 |
| Lee, JH | 1 |
| Park, TH | 1 |
| Saucedo, JF | 2 |
| Novack, V | 1 |
| Jotkowitz, A | 1 |
| Lieberman, N | 1 |
| Porath, A | 1 |
| Papathanasiou, AI | 1 |
| Mikhailidis, DP | 1 |
| Nappi, J | 1 |
| Gutterman, D | 1 |
| Lincoff, AM | 2 |
| Popma, JJ | 1 |
| Steg, G | 1 |
| Guyatt, GH | 1 |
| Cundiff, DK | 1 |
| Vasilieva, E | 1 |
| Kasyanova, O | 1 |
| Shpektor, A | 1 |
| Barker, CM | 1 |
| Price, MJ | 2 |
| Antonino, MJ | 1 |
| Pastor, FJ | 1 |
| Cambronero, F | 1 |
| Caro, C | 1 |
| Pascual-Figal, DA | 1 |
| Garrido, IP | 1 |
| Pinar, E | 1 |
| Wang, S | 2 |
| Ma, Y | 1 |
| Luan, B | 1 |
| Wang, D | 2 |
| Ren, YH | 2 |
| Yang, TS | 1 |
| Gai, LY | 1 |
| Liu, HB | 2 |
| Wang, HY | 1 |
| Wang, CY | 2 |
| Xu, XL | 1 |
| Xin, YH | 1 |
| Li, RB | 1 |
| Li, HY | 1 |
| Lin, L | 1 |
| Liu, CX | 1 |
| Frere, C | 5 |
| Uhry, S | 2 |
| Wu, TG | 1 |
| Huang, WG | 1 |
| Wei, JR | 1 |
| Chen, SW | 1 |
| Zhao, J | 1 |
| Huang, LP | 1 |
| Wang, LX | 1 |
| Hoekstra, J | 1 |
| Giugliano, R | 1 |
| Manoukian, SV | 1 |
| Pollack, CV | 7 |
| Hirsch, A | 2 |
| Windhausen, F | 2 |
| Tijssen, JG | 4 |
| Oude Ophuis, AJ | 1 |
| van der Giessen, WJ | 1 |
| van der Zee, PM | 1 |
| Ramsdale, DR | 1 |
| Rao, A | 1 |
| Asghar, O | 1 |
| Ramsdale, KA | 1 |
| McKay, E | 1 |
| van der Worp, HB | 1 |
| Fonville, S | 1 |
| Ramos, LM | 1 |
| Rinkel, GJ | 1 |
| Halperin, JL | 1 |
| Roldán, V | 1 |
| Chrolavicius, S | 3 |
| Diaz, R | 3 |
| Jolly, S | 2 |
| Rupprecht, HJ | 4 |
| Yusuf, S | 3 |
| Yong, G | 1 |
| Rankin, J | 1 |
| Ferguson, L | 1 |
| Thom, J | 1 |
| French, J | 2 |
| Dick, R | 1 |
| Hockings, B | 1 |
| Walters, D | 1 |
| Whelan, A | 1 |
| Riezebos, RK | 1 |
| Ronner, E | 1 |
| Ter Bals, E | 1 |
| Slagboom, T | 1 |
| Kiemeneij, F | 1 |
| Amoroso, G | 1 |
| Patterson, MS | 1 |
| Suttorp, MJ | 1 |
| Laarman, GJ | 1 |
| Heer, T | 1 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Towae, F | 1 |
| Senges, J | 2 |
| Schwarz, M | 1 |
| Saurbier, B | 1 |
| Vermeer, NS | 1 |
| Bajorek, BV | 1 |
| Toth, PP | 1 |
| De Labriolle, A | 1 |
| Lemesle, G | 1 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Suddath, WO | 2 |
| Kent, KM | 2 |
| Pichard, AD | 2 |
| Dalmau, G | 1 |
| Gaig, P | 1 |
| Gázquez, V | 1 |
| Mercé, J | 1 |
| Freedman, JE | 1 |
| Foussas, SG | 1 |
| Zairis, MN | 1 |
| Tsirimpis, VG | 1 |
| Makrygiannis, SS | 1 |
| Patsourakos, NG | 1 |
| Adamopoulou, EN | 1 |
| Mytas, DZ | 1 |
| Prekates, AA | 1 |
| Perdiou, AJ | 1 |
| Tsoukanas, VK | 1 |
| Argyrakis, SK | 1 |
| Slattery, D | 1 |
| Emanuelsson, H | 3 |
| Katus, H | 1 |
| Skene, A | 1 |
| Harrington, R | 1 |
| Becker, R | 1 |
| Shu, Q | 1 |
| Tang, X | 1 |
| Ionescu, CN | 1 |
| Chrissoheris, M | 1 |
| Caraccciolo, EA | 1 |
| Spinler, SA | 1 |
| Cross, J | 1 |
| Papathanasiou, A | 1 |
| Goudevenos, J | 1 |
| Bonvini, RF | 1 |
| Reny, JL | 1 |
| Zeller, T | 1 |
| Fontana, P | 1 |
| Gaborit, B | 3 |
| Bali, L | 3 |
| Poyet, R | 2 |
| Faille, D | 1 |
| Ou, FS | 1 |
| Perez de Prado, A | 1 |
| Cuellas, C | 1 |
| Diego, A | 1 |
| de Miguel, A | 1 |
| Samaniego, B | 1 |
| Alonso-Orcajo, N | 1 |
| Carbonell, R | 1 |
| Pascual, C | 1 |
| Fernandez-Vazquez, F | 1 |
| Calabozo, RG | 1 |
| Overbaugh, KJ | 1 |
| Podolec, J | 1 |
| Gajos, G | 1 |
| Budziaszek, Ł | 1 |
| Czaniecka, M | 1 |
| Kleczkoska, A | 1 |
| Zmudka', K | 1 |
| Małek, LA | 1 |
| Bilińska, ZT | 1 |
| Sitkiewicz, D | 1 |
| Kłopotowski, M | 1 |
| Witkowski, A | 2 |
| Ruzyłło, W | 1 |
| Sarkees, ML | 1 |
| Bavry, AA | 1 |
| Robinson, A | 1 |
| Das, K | 1 |
| Koshy, SK | 1 |
| Das, P | 1 |
| Cools, F | 2 |
| Crea, F | 3 |
| Dellborg, M | 1 |
| Mohan, P | 2 |
| Ruda, M | 2 |
| Verheugt, F | 1 |
| Bjessmo, S | 1 |
| Lindvall, B | 1 |
| Sellers, MB | 1 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Mega, JL | 1 |
| Poulter, R | 1 |
| Misselwitz, F | 1 |
| Hricak, V | 1 |
| Barnathan, ES | 1 |
| Bordes, P | 1 |
| Markov, V | 1 |
| Oppenheimer, L | 1 |
| Acikel, S | 2 |
| Yildirir, A | 1 |
| Aydinalp, A | 2 |
| Bal, U | 1 |
| Kaynar, G | 1 |
| Ozin, B | 2 |
| Muderrisoglu, H | 2 |
| Kireyev, D | 1 |
| Yun, EC | 1 |
| Page, BJ | 1 |
| Rogowski, W | 1 |
| Burch, J | 1 |
| Palmer, S | 1 |
| Craigs, C | 1 |
| Golder, S | 1 |
| Woolacott, N | 1 |
| Mauskopf, JA | 2 |
| Boye, KS | 1 |
| Schmitt, C | 2 |
| Birt, J | 1 |
| Juniper, MD | 1 |
| Kittisupamongkol, W | 1 |
| Pride, YB | 1 |
| Buros, JL | 1 |
| Zorkun, C | 1 |
| Tariq, MU | 1 |
| Aksu, H | 1 |
| Ozer, O | 1 |
| Unal, H | 1 |
| Hobikoglu, G | 1 |
| Norgaz, T | 1 |
| Buturak, A | 1 |
| Soylu, O | 1 |
| Narin, A | 1 |
| Bandinelli, B | 1 |
| Valente, S | 2 |
| Lazzeri, C | 1 |
| Mannini, L | 1 |
| Ranjith, MP | 1 |
| Divya, R | 1 |
| Mehta, VK | 1 |
| Krishnan, MG | 1 |
| KamalRaj, R | 1 |
| Kavishwar, A | 1 |
| Ray, MJ | 1 |
| Juneja, M | 1 |
| Bett, N | 1 |
| Walters, DL | 3 |
| Fermann, GJ | 1 |
| Raja, AS | 1 |
| Hoekstra, JW | 3 |
| Milford-Beland, S | 1 |
| Diercks, DB | 1 |
| Peacock, WF | 3 |
| Summers, R | 1 |
| Aranki, SF | 1 |
| Body, SC | 1 |
| Depta, JP | 2 |
| Bertrand, OF | 1 |
| Rodés-Cabau, J | 1 |
| Rinfret, S | 1 |
| Larose, E | 1 |
| Bagur, R | 1 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| Costerousse, O | 1 |
| De Larochellière, R | 1 |
| Roy, L | 1 |
| Stellos, K | 3 |
| Bigalke, B | 3 |
| Stakos, D | 1 |
| Henkelmann, N | 1 |
| Raymond, C | 1 |
| Menon, V | 1 |
| Shankarappa, RK | 1 |
| Panneerselvam, A | 1 |
| Dwarakaprasad, R | 1 |
| Karur, S | 1 |
| Krishnanaik, GB | 1 |
| Nanjappa, MC | 1 |
| Kasprzak, M | 1 |
| Koziński, M | 2 |
| Bielis, L | 1 |
| Boinska, J | 1 |
| Plazuk, W | 1 |
| Marciniak, A | 1 |
| Budzyński, J | 1 |
| Siller-Matula, J | 2 |
| Rość, D | 1 |
| Fitchett, D | 1 |
| Fremes, S | 1 |
| Mazer, D | 1 |
| Bittira, B | 1 |
| Brister, S | 1 |
| Graham, J | 2 |
| Gupta, M | 1 |
| Karkouti, K | 1 |
| Lee, A | 1 |
| Love, M | 1 |
| McArthur, R | 1 |
| Peterson, M | 1 |
| Yau, T | 1 |
| Abdallah, M | 1 |
| Karrowni, W | 1 |
| Shamseddeen, W | 1 |
| Itani, S | 1 |
| Kobeissi, L | 1 |
| Ghazzal, Z | 1 |
| Alam, S | 1 |
| Dakik, HA | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Chhatriwalla, AK | 1 |
| Dracup, K | 1 |
| McKinley, S | 1 |
| Moser, DK | 1 |
| Meischke, H | 1 |
| Doering, LV | 1 |
| Davidson, P | 1 |
| Paul, SM | 1 |
| Baker, H | 1 |
| Pelter, M | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Robinson, D | 2 |
| Hussain, J | 1 |
| Ramanath, VS | 1 |
| Armstrong, DF | 1 |
| Grzybowski, M | 1 |
| Rahnama-Mohagdam, S | 1 |
| Tamhane, UU | 1 |
| Gordon, K | 1 |
| Froehlich, JB | 2 |
| Jackson, EA | 1 |
| Meisel, ZF | 1 |
| Armstrong, K | 1 |
| Mechem, CC | 1 |
| Shofer, FS | 2 |
| Peacock, N | 1 |
| Facenda, K | 1 |
| Solomon, S | 1 |
| Yamashita, T | 1 |
| Yajima, J | 1 |
| Oikawa, Y | 1 |
| Ogasawara, K | 1 |
| Sagara, K | 1 |
| Kirigaya, H | 1 |
| Koike, A | 1 |
| Nagashima, K | 1 |
| Ohtsuka, T | 1 |
| Uejima, T | 1 |
| Suzuki, S | 1 |
| Sawada, H | 1 |
| Aizawa, T | 1 |
| Yamaguchi, T | 1 |
| Kato, K | 1 |
| Yamaguchi, H | 1 |
| Jensen, P | 1 |
| Hamilos, M | 1 |
| Delrue, M | 1 |
| Verhamme, K | 1 |
| Bartunek, J | 1 |
| Saut, N | 1 |
| Eijgelsheim, M | 1 |
| Barbato, E | 1 |
| Pattanaik, S | 1 |
| Malhotra, S | 1 |
| Sharma, YP | 1 |
| Ahluwalia, J | 1 |
| Bhalla, A | 1 |
| Pandhi, P | 1 |
| Atar, I | 1 |
| Gulmez, O | 1 |
| Atar, A | 1 |
| Bozbas, H | 1 |
| Ozgul, A | 1 |
| Ertan, C | 1 |
| Ren, WL | 1 |
| Song, LF | 1 |
| Liang, YQ | 1 |
| Li, RJ | 1 |
| Yin, ZN | 1 |
| Xu, YY | 1 |
| Hu, DY | 1 |
| Larson, DM | 1 |
| Carter, RD | 1 |
| Cornish, J | 1 |
| Karcher, RB | 1 |
| Mencia, WA | 1 |
| Berry, CA | 1 |
| Stowell, SA | 1 |
| Takakuwa, KM | 1 |
| Lin, GM | 1 |
| Han, CL | 1 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Gebel, JM | 1 |
| Chu, JW | 1 |
| Wong, CK | 1 |
| Chambers, J | 1 |
| Wout, JV | 1 |
| Herbison, P | 1 |
| Tang, EW | 1 |
| Hadi, HA | 1 |
| Al Mahmeed, W | 1 |
| El-Menyar, AA | 1 |
| Ridha, M | 1 |
| Assad, N | 1 |
| Al Habib, K | 1 |
| Morel, O | 1 |
| Kessler, L | 1 |
| Ohlmann, P | 1 |
| Bareiss, P | 1 |
| Fuchs, I | 1 |
| Spiel, AO | 1 |
| Frossard, M | 1 |
| Derhaschnig, U | 1 |
| Riedmüller, E | 1 |
| Eshtehardi, P | 1 |
| Cook, S | 1 |
| Billinger, M | 1 |
| Togni, M | 1 |
| Garachemani, A | 1 |
| Hess, OM | 1 |
| Wenaweser, P | 1 |
| Glauser, J | 1 |
| Emerman, CL | 1 |
| Daudelin, DH | 1 |
| Sayah, AJ | 1 |
| Kwong, M | 1 |
| Restuccia, MC | 1 |
| Porcaro, WA | 1 |
| Ruthazer, R | 1 |
| Goetz, JD | 1 |
| Lane, WM | 1 |
| Beshansky, JR | 1 |
| Selker, HP | 1 |
| Erdem, G | 1 |
| Flather, MD | 1 |
| Ambrosio, G | 1 |
| Steinhubl, S | 1 |
| Tritto, I | 1 |
| Zuchi, C | 1 |
| Bertrand, ME | 1 |
| Moses, JW | 1 |
| Jim, MH | 1 |
| Yung, AS | 1 |
| Tang, GK | 1 |
| Fan, KY | 1 |
| Chow, WH | 1 |
| Yusuf, SW | 2 |
| Bathina, JD | 1 |
| Daher, IN | 2 |
| Cheng, CI | 1 |
| Kuan, PL | 1 |
| Lei, MH | 1 |
| Liau, CS | 1 |
| Ueng, KC | 1 |
| Liu, F | 2 |
| Cui, W | 1 |
| Xie, RQ | 1 |
| Yang, XC | 1 |
| Lu, JC | 1 |
| Zheng, HM | 1 |
| Ren, XJ | 1 |
| Gratsianskiĭ, NA | 1 |
| Pevzner, DV | 1 |
| Staroverov, II | 1 |
| Frolova, NS | 1 |
| Nguyen, HL | 1 |
| Gurfinkel, EP | 1 |
| Spencer, FA | 1 |
| Reed, G | 1 |
| Quill, A | 1 |
| Anderson, FA | 2 |
| Tebaldi, M | 1 |
| Merino, A | 1 |
| Roldán, I | 1 |
| Worner, F | 1 |
| Danchin, N | 1 |
| Aïssaoui, N | 1 |
| Aichele, S | 1 |
| Herkommer, M | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| May, AE | 1 |
| Flather, M | 2 |
| Bhattacharya, R | 1 |
| Pani, A | 1 |
| Dutta, D | 1 |
| Basak, S | 1 |
| Gangopadhyay, S | 1 |
| Das Baksi, S | 1 |
| Sarkar, RN | 1 |
| Tsai, YW | 2 |
| Wen, YW | 2 |
| Huang, WF | 2 |
| Chen, PF | 2 |
| Kuo, KN | 1 |
| Jolly, SS | 1 |
| Joyner, CD | 2 |
| Avezum, A | 2 |
| Di Pasquale, G | 2 |
| Niemela, K | 2 |
| Gao, P | 1 |
| Afzal, R | 1 |
| Pogue, J | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Husted, SE | 3 |
| Nielsen, HK | 2 |
| Laizure, SC | 1 |
| Parker, RB | 1 |
| Pham, SV | 1 |
| Pham, PC | 1 |
| Pham, PM | 1 |
| Miller, JM | 1 |
| Pham, PT | 1 |
| Pham, PA | 1 |
| Shimbo, D | 1 |
| Burg, M | 1 |
| Aragam, KG | 1 |
| Tentzeris, I | 2 |
| Jarai, R | 1 |
| Brozovic, I | 1 |
| Smetana, P | 1 |
| Rich, JD | 1 |
| Qin, J | 1 |
| Giugliano, RP | 2 |
| O'Connor, RE | 1 |
| Bossaert, L | 1 |
| Brooks, SC | 1 |
| Diercks, D | 1 |
| Feitosa-Filho, G | 1 |
| Nolan, JP | 1 |
| Vanden Hoek, TL | 1 |
| Wong, A | 1 |
| Woolfrey, K | 1 |
| Pechlaner, C | 1 |
| Abergel, E | 1 |
| Nikolsky, E | 1 |
| Sambu, N | 1 |
| Warner, T | 1 |
| Curzen, N | 2 |
| Menown, IB | 1 |
| Ivandic, B | 1 |
| Frey, N | 1 |
| Park, JH | 1 |
| Lim, DS | 1 |
| Merella, P | 1 |
| Casu, G | 1 |
| Meloni, I | 1 |
| Vassiliou, VS | 1 |
| Padrini, R | 1 |
| Elhadad, S | 1 |
| Rangé, G | 1 |
| Vicaut, E | 2 |
| Masumura, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Ağırbaşlı, M | 1 |
| Güvenç, H | 1 |
| Cinçin, A | 1 |
| Li, XY | 1 |
| Lorgis, L | 2 |
| Richard, C | 1 |
| Zeller, M | 2 |
| Gudjoncik, A | 1 |
| Buffet, P | 2 |
| L'Huillier, I | 2 |
| Cottin, Y | 2 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Gaglia, MA | 1 |
| Vassiliou, V | 1 |
| Gaspar, A | 1 |
| Ribeiro, S | 1 |
| Nabais, S | 1 |
| Rocha, S | 1 |
| Azevedo, P | 1 |
| Pereira, MA | 1 |
| Brandāo, A | 1 |
| Salgado, A | 1 |
| Correia, A | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Disney, BR | 1 |
| Watson, RD | 1 |
| Blann, AD | 1 |
| Lip, GY | 1 |
| Anderson, MR | 1 |
| Vik-Mo, H | 1 |
| Topçuoglu, MA | 1 |
| Arsava, EM | 1 |
| Ay, H | 1 |
| Ferrieres, J | 1 |
| Srour, JF | 1 |
| Smetana, GW | 1 |
| Barthelemy, O | 1 |
| Connor, S' | 1 |
| Payot, L | 1 |
| Bellemain-Appaix, A | 1 |
| Aout, M | 1 |
| Vestergaard, P | 1 |
| Steinberg, TH | 1 |
| Schwarz, P | 1 |
| Jørgensen, NR | 1 |
| Phillippe, HM | 1 |
| Baty, SR | 1 |
| Griffith, CB | 1 |
| Good, CW | 1 |
| Berger, PB | 3 |
| Lancaster, GI | 1 |
| Srivastava, AV | 1 |
| Zarich, SW | 1 |
| Schwarz, AK | 1 |
| Hochadel, M | 1 |
| Kerber, S | 1 |
| Hauptmann, KE | 1 |
| Glunz, HG | 1 |
| Mudra, H | 1 |
| Zhao, M | 1 |
| Chen, YD | 1 |
| Sun, ZJ | 1 |
| Chen, JS | 1 |
| Huang, TT | 1 |
| Guo, YS | 1 |
| Xie, YJ | 1 |
| Persson, J | 1 |
| Lindbäck, J | 1 |
| Hofman-Bang, C | 1 |
| Stenestrand, U | 1 |
| Samnegard, A | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Mantovani, F | 2 |
| Demola, MA | 1 |
| Rajan, L | 1 |
| Jünger, C | 1 |
| Bestehorn, K | 1 |
| Gitt, A | 1 |
| Fernando, H | 1 |
| Bassler, N | 1 |
| Habersberger, J | 1 |
| Sheffield, LJ | 1 |
| Sharma, R | 1 |
| Dart, AM | 1 |
| Peter, KH | 1 |
| Shaw, JA | 1 |
| Gassanov, N | 1 |
| Caglayan, E | 1 |
| Erdmann, E | 1 |
| Er, F | 2 |
| Ranasinghe, I | 1 |
| Alprandi-Costa, B | 1 |
| Chow, V | 1 |
| Waites, J | 1 |
| Counsell, JT | 1 |
| Bailey, AL | 1 |
| Campbell, CL | 1 |
| Chaplin, WF | 1 |
| Schwartz, JE | 2 |
| Kilaru, R | 1 |
| He, Y | 1 |
| Keltai, M | 2 |
| Pais, P | 1 |
| White, H | 4 |
| Geraldes, M | 1 |
| Lawrence, J | 1 |
| Ahmad, WA | 1 |
| Ramesh, SV | 1 |
| Zambahari, R | 1 |
| Hinneburg, I | 1 |
| Spectre, G | 1 |
| Mosseri, M | 1 |
| Abdelrahman, NM | 1 |
| Briskin, E | 1 |
| Bulut, A | 1 |
| Loncar, S | 1 |
| Varon, D | 3 |
| Alcalai, R | 1 |
| Mullins, CD | 1 |
| Höchtl, T | 1 |
| Schrör, K | 1 |
| Hoshida, S | 1 |
| Yuasa, F | 1 |
| Lim, YJ | 1 |
| Iwasaka, J | 1 |
| Iwasaka, T | 1 |
| Traynor, K | 1 |
| Metcalfe, E | 1 |
| Das, R | 2 |
| Kilcullen, N | 1 |
| Morrell, C | 2 |
| Crook, R | 1 |
| Barth, JH | 2 |
| Grosdidier, C | 1 |
| Molines, L | 1 |
| Golubeva, NV | 1 |
| Awad, HH | 1 |
| Bonafede, M | 1 |
| Jing, Y | 1 |
| Gdovin Bergeson, J | 1 |
| Liffmann, D | 1 |
| Makenbaeva, D | 1 |
| Deitelzweig, SB | 1 |
| Minarelli, M | 1 |
| Buonamici, P | 2 |
| Hoang, C | 1 |
| Kolenic, G | 1 |
| Kline-Rogers, E | 2 |
| Erickson, SR | 1 |
| Looi, KL | 1 |
| Chow, KL | 1 |
| Looi, JL | 1 |
| Lee, M | 1 |
| Halliday, S | 1 |
| Ellis, C | 1 |
| Ford, JA | 1 |
| Bell, J | 1 |
| Edwards, C | 1 |
| Nikolaou, NI | 1 |
| Vrints, CJ | 1 |
| Syed, FA | 1 |
| Bett, JH | 1 |
| O'Connor, SA | 2 |
| Graham, JB | 1 |
| Bae, JP | 1 |
| Ramaswamy, K | 1 |
| Zagar, AJ | 1 |
| Magnuson, EA | 1 |
| Meadows, ES | 1 |
| Fauchier, L | 1 |
| Clementy, N | 1 |
| Harrison, RW | 1 |
| Horrow, J | 1 |
| Lassila, R | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Ng, FH | 2 |
| Tunggal, P | 1 |
| Chu, WM | 2 |
| Lam, KF | 2 |
| Li, A | 1 |
| Chan, K | 1 |
| Lau, YK | 2 |
| Kng, C | 1 |
| Keung, KK | 1 |
| Kwan, A | 1 |
| Wong, BC | 2 |
| Lina, D | 1 |
| Conte, G | 1 |
| Zhang, YX | 1 |
| Lu, CY | 1 |
| Zhou, SH | 1 |
| Xue, Q | 1 |
| Gao, L | 1 |
| Tian, JW | 1 |
| Gao, W | 1 |
| Chen, R | 1 |
| Zhai, JY | 1 |
| Li, LJ | 1 |
| Hod, H | 3 |
| Buber, J | 1 |
| Vatury, O | 1 |
| Pfisterer, M | 1 |
| Kaiser, C | 1 |
| Jeger, R | 1 |
| Ishida, M | 1 |
| Iino, K | 1 |
| Okawa, M | 1 |
| Kosaka, T | 1 |
| Ito, H | 1 |
| AlHabib, KF | 1 |
| Al-Motarreb, A | 1 |
| Hersi, A | 1 |
| Al Faleh, H | 1 |
| Asaad, N | 1 |
| Al Saif, S | 1 |
| Sulaiman, K | 1 |
| Amin, H | 1 |
| AlQahtani, A | 1 |
| Al-Sagheer, NQ | 1 |
| Geeganage, CM | 1 |
| Diener, HC | 1 |
| Algra, A | 1 |
| Topol, EJ | 1 |
| Dengler, R | 1 |
| Markus, HS | 1 |
| Bath, MW | 1 |
| Bath, PM | 1 |
| Cequier, AR | 1 |
| Feng, XR | 1 |
| Liu, ML | 1 |
| Tian, QP | 1 |
| Liu, QZ | 1 |
| Porto, I | 2 |
| D'Amario, D | 1 |
| Stakos, DA | 1 |
| Tziakas, DN | 1 |
| Contractor, H | 1 |
| Lynch, DR | 1 |
| Khan, FH | 1 |
| Vaidya, D | 1 |
| Williams, MS | 1 |
| Binda, G | 1 |
| Häuptle, R | 1 |
| Weilenmann, D | 1 |
| Schneider, T | 1 |
| Haile, SR | 1 |
| Ammann, P | 1 |
| Knellwolf, C | 1 |
| Borovicka, J | 1 |
| Guan, SY | 1 |
| Wang, SL | 1 |
| Liu, XD | 1 |
| Niccoli, G | 1 |
| Giubilato, S | 1 |
| Leo, A | 1 |
| Cosentino, N | 1 |
| Fracassi, F | 1 |
| Cataneo, L | 1 |
| Leone, AM | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| Biasucci, LM | 1 |
| Narducci, ML | 1 |
| Pulcinelli, FM | 2 |
| Stauffer, JC | 1 |
| Goy, JJ | 1 |
| Duvoisin, N | 1 |
| Azmoon, S | 1 |
| Daraban, N | 1 |
| Abbasi, N | 1 |
| Lei, X | 1 |
| Bessereau, J | 2 |
| Oshchepkova, EV | 1 |
| Dmitriev, VA | 1 |
| Gridnev, VI | 1 |
| Dovgalevskiĭ, PIa | 1 |
| Goodnough, LT | 1 |
| Levy, JH | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Barillà, F | 1 |
| Mangieri, E | 1 |
| Torromeo, C | 1 |
| Tanzilli, G | 1 |
| Dominici, T | 1 |
| Pellicano, M | 1 |
| Paravati, V | 1 |
| Acconcia, MC | 1 |
| Gaudio, C | 1 |
| Tsantes, A | 1 |
| Ikonomidis, I | 1 |
| Papadakis, I | 1 |
| Kottaridi, C | 1 |
| Tsante, A | 1 |
| Kalamara, E | 1 |
| Kardoulaki, A | 1 |
| Kopterides, P | 1 |
| Kapsimali, V | 1 |
| Karakitsos, P | 1 |
| Lekakis, J | 1 |
| Travlou, A | 1 |
| Guimarães, HP | 1 |
| Laranjeira, LN | 1 |
| Cavalcanti, AB | 1 |
| Kodama, AA | 1 |
| Zazula, AD | 1 |
| Santucci, EV | 1 |
| Victor, E | 1 |
| Tenuta, M | 1 |
| Carvalho, V | 1 |
| Mira, VL | 1 |
| Pieper, KS | 1 |
| Weber, B | 1 |
| Mota, LH | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Renda, G | 2 |
| Joshi, R | 1 |
| Ahmad, S | 1 |
| Sébastien, A | 1 |
| Kar, S | 1 |
| Matsuura, E | 1 |
| Guyer, K | 1 |
| Yamamoto, H | 1 |
| Lopez, LR | 1 |
| Isordia-Salas, I | 1 |
| Olalde-Román, MJ | 1 |
| Santiago-Germán, D | 1 |
| de la Peña, NC | 1 |
| Valencia-Sánchez, JS | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Deng, J | 1 |
| Barron, T | 1 |
| Clawson, J | 1 |
| Scott, G | 1 |
| Patterson, B | 1 |
| Shiner, R | 1 |
| Wrigley, F | 1 |
| Gummett, J | 1 |
| Olola, CH | 1 |
| Limper, U | 1 |
| Lynch, J | 1 |
| Yano, H | 1 |
| Vatankulu, MA | 1 |
| Tasal, A | 1 |
| Erdoğan, E | 1 |
| Göktekin, Ö | 1 |
| Lamberts, M | 1 |
| Olesen, JB | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Kristensen, SL | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Hansen, ML | 1 |
| Sallum, RH | 1 |
| Katona, B | 1 |
| Maya, J | 1 |
| Ranganathan, G | 1 |
| Xu, Y | 1 |
| Mwamburi, M | 1 |
| Fassa, AA | 1 |
| Urban, P | 1 |
| Vavalle, JP | 1 |
| Clemmensen, P | 1 |
| Topacio, GO | 1 |
| Pavlides, G | 1 |
| Goudev, AR | 1 |
| Oto, A | 1 |
| Tseng, CD | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Brown, EB | 1 |
| Lokhnygina, Y | 1 |
| Mannacio, VA | 1 |
| Di Tommaso, L | 1 |
| Antignan, A | 1 |
| De Amicis, V | 1 |
| Vosa, C | 1 |
| Sciahbasi, A | 1 |
| Rizzello, V | 1 |
| Giampaoli, S | 1 |
| Greco, C | 1 |
| Di Chiara, A | 1 |
| Lioy, E | 1 |
| Boccanelli, A | 1 |
| Filipiak, KJ | 1 |
| Kochman, J | 1 |
| Michalak, M | 1 |
| Grabowski, M | 1 |
| Opolski, G | 1 |
| Fefer, P | 2 |
| Shenkman, B | 2 |
| Shechter, M | 1 |
| Savion, N | 2 |
| Horiuchi, H | 1 |
| Schechter, CB | 1 |
| Elefteriades, JA | 1 |
| Sadanandan, S | 1 |
| Singh, IM | 1 |
| Edmondson, D | 1 |
| Smith, JG | 1 |
| Wieloch, M | 1 |
| Lumsden, J | 1 |
| Rydell, E | 1 |
| Buffon, A | 1 |
| Obonska, K | 1 |
| Rychter, M | 1 |
| Sukiennik, A | 1 |
| Baglikov, AN | 1 |
| Rafal'skiĭ, VV | 1 |
| Qiao, R | 1 |
| Brown, E | 1 |
| Salama, MM | 1 |
| Morad, AR | 1 |
| Saleh, MA | 1 |
| Sabri, NA | 1 |
| Zaki, MM | 1 |
| ElSafady, LA | 1 |
| Secco, GG | 1 |
| Iorio, S | 1 |
| Santos-Gallego, C | 1 |
| Vorchheimer, DA | 1 |
| Viles-Gonzalez, JF | 1 |
| Elmariah, S | 1 |
| Giannarelli, C | 1 |
| Small, DS | 1 |
| Dziewierz, A | 1 |
| Brzeziński, M | 1 |
| Rakowski, T | 1 |
| Rodrigo, C | 1 |
| Amarasuriya, M | 1 |
| Wickramasinghe, S | 1 |
| Constantine, GR | 1 |
| Htun, WW | 1 |
| Steinhubl, SR | 3 |
| Loh, JP | 1 |
| Pendyala, LK | 1 |
| Kitabata, H | 1 |
| Oz, F | 1 |
| Gul, S | 1 |
| Kaya, MG | 1 |
| Yazici, M | 1 |
| Bulut, I | 1 |
| Elitok, A | 1 |
| Ersin, G | 1 |
| Abakay, O | 1 |
| Akkoyun, CD | 1 |
| Oncul, A | 1 |
| Cetinkaya, E | 1 |
| Gibson, MC | 1 |
| Oflaz, H | 1 |
| Wordsworth, DR | 1 |
| Halsey, T | 1 |
| Griffiths, R | 1 |
| Parker, MJ | 1 |
| Nadatani, Y | 1 |
| Watanabe, T | 1 |
| Tanigawa, T | 1 |
| Sogawa, M | 1 |
| Yamagami, H | 1 |
| Shiba, M | 1 |
| Watanabe, K | 1 |
| Tominaga, K | 1 |
| Fujiwara, Y | 1 |
| Arakawa, T | 1 |
| Christiansen, EH | 1 |
| Jensen, LO | 1 |
| Thayssen, P | 1 |
| Tilsted, HH | 1 |
| Krusell, LR | 1 |
| Hansen, KN | 1 |
| Kaltoft, A | 1 |
| Maeng, M | 1 |
| Bøtker, HE | 1 |
| Terkelsen, CJ | 1 |
| Villadsen, AB | 1 |
| Ravkilde, J | 1 |
| Aarøe, J | 1 |
| Madsen, M | 1 |
| Thuesen, L | 1 |
| Lassen, JF | 1 |
| Rembold, CM | 1 |
| Brüggenjürgen, B | 1 |
| Lindgren, P | 1 |
| Ehlken, B | 1 |
| Willich, SN | 1 |
| Niruntraporn, S | 1 |
| Chaiyakunapruk, N | 1 |
| Nathisuwan, S | 1 |
| Thamlikitkul, V | 1 |
| Nguyen, MC | 1 |
| Lim, YL | 1 |
| Walton, A | 1 |
| Lefkovits, J | 1 |
| Agnelli, G | 1 |
| Gulba, DC | 1 |
| Allegrone, J | 1 |
| Kapp, M | 1 |
| Göhring-Frischholz, K | 1 |
| Daub, K | 1 |
| Dösch, C | 1 |
| Langer, H | 1 |
| Herdeg, C | 1 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Beer, JC | 1 |
| Nguyen, C | 1 |
| Schaad, F | 1 |
| Obbee, P | 1 |
| Lagrost, AC | 1 |
| Vikman, S | 1 |
| Airaksinen, KE | 1 |
| Tierala, I | 1 |
| Peuhkurinen, K | 1 |
| Majamaa-Voltti, K | 1 |
| Niemelä, M | 1 |
| Asplund, S | 1 |
| Huhtala, H | 1 |
| Brulotte, S | 1 |
| Sénéchal, M | 1 |
| Poirier, P | 1 |
| Nguyen, CM | 1 |
| Lemieux, A | 1 |
| Magne, J | 1 |
| Bergeron, S | 1 |
| Riddell, JW | 1 |
| Chiche, L | 1 |
| Plaud, B | 1 |
| Hamon, M | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Tcheng, JE | 1 |
| Ibuki, C | 1 |
| van der Stelt, CA | 1 |
| van Werkum, JW | 1 |
| Seesing, TH | 1 |
| Berg, JM | 1 |
| Cubbon, RM | 1 |
| Rajwani, A | 1 |
| Abbas, A | 1 |
| Grant, PJ | 1 |
| Kearney, MT | 1 |
| Ferrario, C | 1 |
| Renders, F | 1 |
| Cairoli, A | 1 |
| Vuffray, A | 1 |
| Spertini, O | 1 |
| Angelillo-Scherrer, A | 1 |
| Bhavsar, J | 1 |
| Montgomery, D | 1 |
| Saab, F | 1 |
| Motivala, A | 1 |
| Parekh, V | 1 |
| Del Valle, J | 1 |
| Mann, KG | 1 |
| Michelson, AD | 3 |
| Scirica, BM | 1 |
| Peters, G | 1 |
| McCabe, CH | 2 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Kolm, P | 1 |
| Veledar, E | 1 |
| O'Brien, JA | 1 |
| Saracini, C | 1 |
| Sestini, I | 1 |
| Schreiner, GC | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Einav, Y | 1 |
| Lubetsky, A | 1 |
| Simmons, BB | 1 |
| Salzman, BE | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Krasopoulos, G | 1 |
| Brister, SJ | 1 |
| Beattie, WS | 1 |
| Buchanan, MR | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Thomas, J | 1 |
| Brady, WJ | 1 |
| Shen, LH | 1 |
| von Lewinski, F | 1 |
| Riggert, J | 1 |
| Paulus, W | 1 |
| Gladding, P | 1 |
| Webster, M | 1 |
| Ormiston, J | 1 |
| Olsen, S | 1 |
| Hankey, GJ | 1 |
| Langton, PE | 1 |
| Kapoor, JR | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Thomas, D | 1 |
| Angiolillo, D | 2 |
| Bates, E | 2 |
| Bhatt, D | 2 |
| Furman, MI | 2 |
| Peterson, E | 2 |
| Wiviott, S | 2 |
| Varas-Lorenzo, C | 1 |
| Castellsague, J | 1 |
| Stang, MR | 1 |
| Tomas, L | 1 |
| Aguado, J | 1 |
| Perez-Gutthann, S | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| Camoin, L | 1 |
| Juhan-Vague, I | 1 |
| Goyal, SK | 1 |
| Punnam, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Evaluation of an Electronic Device Based Support Tool for ACS Patients: Brilique (Ticagrelor) Treatment Adherence (eMocial)[NCT02615704] | 677 participants (Actual) | Observational | 2016-02-11 | Completed | |||
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen[NCT03023020] | 4,579 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent[NCT03462498] | Phase 4 | 3,008 participants (Actual) | Interventional | 2018-04-02 | Active, not recruiting | ||
| ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study[NCT02619760] | Phase 4 | 3,045 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction[NCT04304534] | Phase 2 | 1,601 participants (Actual) | Interventional | 2020-06-17 | Completed | ||
| Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)[NCT04702113] | 300 participants (Actual) | Interventional | 2020-12-03 | Completed | |||
| GLOBAL LEADERS Adjudication Sub-Study[NCT03231059] | 7,365 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| [NCT02494895] | Phase 4 | 3,056 participants (Anticipated) | Interventional | 2015-08-01 | Recruiting | ||
| Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020] | Phase 4 | 374 participants (Anticipated) | Interventional | 2023-08-28 | Recruiting | ||
| Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk.[NCT03431142] | Phase 4 | 7,700 participants (Anticipated) | Interventional | 2018-02-12 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)[NCT02352402] | Phase 3 | 487 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES ([NCT02193971] | Phase 4 | 3,384 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | ||
| XIENCE 28 Global Study[NCT03355742] | 963 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.[NCT03218787] | 2,047 participants (Actual) | Interventional | 2017-07-19 | Completed | |||
| XIENCE 28 USA Study[NCT03815175] | 1,605 participants (Actual) | Interventional | 2019-02-25 | Completed | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Platelet Function Evaluation in Patients With Acute Coronary Syndromes on Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy With Aspirin and a Potent P2Y12 Inhibitor[NCT05767723] | Phase 4 | 48 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-[NCT03971500] | 3,710 participants (Actual) | Interventional | 2019-08-20 | Active, not recruiting | |||
| The Importance of Evaluation of Platelet Aggregability in the Release of Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome With Dual Antiplatelet Therapy.[NCT02516267] | 190 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents[NCT02079194] | 3,000 participants (Actual) | Interventional | 2014-03-18 | Active, not recruiting | |||
| Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)[NCT01701453] | 2,712 participants (Actual) | Interventional | 2012-08-31 | Active, not recruiting | |||
| Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study[NCT04718025] | Phase 3 | 4,500 participants (Anticipated) | Interventional | 2022-02-07 | Recruiting | ||
| National Registry of Acute Myocardial Infarction in Switzerland[NCT01305785] | 60,000 participants (Anticipated) | Observational | 1997-01-31 | Recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute [NCT02073565] | 572 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry[NCT02015624] | 2,597 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome[NCT02041650] | Phase 4 | 250 participants (Anticipated) | Interventional | 2014-08-31 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)[NCT01870921] | Phase 4 | 2,004 participants (Actual) | Interventional | 2013-06-26 | Completed | ||
| Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome[NCT02306616] | 124,363 participants (Actual) | Observational | 2014-11-30 | Completed | |||
| [NCT01075867] | 2,498 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study[NCT01968499] | 1,805 participants (Actual) | Observational [Patient Registry] | 2011-03-31 | Completed | |||
| Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform[NCT02311231] | Phase 4 | 6,012 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans[NCT02587260] | Phase 4 | 54 participants (Actual) | Interventional | 2015-12-17 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome[NCT00809965] | Phase 3 | 15,526 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-07-31 | Recruiting | |||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acut[NCT00527943] | Phase 3 | 12,944 participants (Actual) | Interventional | 2007-12-01 | Terminated (stopped due to The trial was terminated at the request of the Data and Safety Monitoring Board.) | ||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Drug Drug Interactions of Antiplatelet Drugs and Morphine[NCT01369186] | Phase 4 | 95 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Rule Out Myocardial Ischemia/Infarction by Computer Assisted Tomography[NCT01084239] | Phase 3 | 1,000 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients[NCT01171404] | 10,568 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study[NCT02016170] | 82 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention[NCT04005729] | Phase 4 | 30 participants (Actual) | Interventional | 2019-07-01 | Completed | ||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| Aspirin DesensitizAtion in PatienTs With Coronary artEry Disease: Results of a Multi Center Registry: the ADAPTED Registry[NCT02848339] | 330 participants (Actual) | Observational [Patient Registry] | 2010-05-31 | Completed | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease[NCT01373632] | Phase 4 | 570 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300] | Phase 2 | 1,741 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597] | Phase 2 | 3,490 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Reducing Prehospital Delay in Acute Myocardial Infarction[NCT00734760] | 3,522 participants (Actual) | Interventional | 2001-02-28 | Completed | |||
| Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome[NCT00684203] | Phase 2 | 120 participants (Actual) | Interventional | 2006-12-01 | Completed | ||
| Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain[NCT01665521] | 282 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| The British Heart Foundation Older Patients With Non-ST SEgmeNt elevatIOn myocaRdial Infarction Randomized Interventional TreAtment Trial[NCT03052036] | 1,518 participants (Actual) | Interventional | 2016-11-30 | Active, not recruiting | |||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| The HEART Pathway: Bridging the Gap Between Operations, Research, and Education[NCT02056964] | 14,717 participants (Actual) | Observational | 2013-11-30 | Completed | |||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome[NCT00831441] | Phase 3 | 7,484 participants (Actual) | Interventional | 2009-03-31 | Terminated | ||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction[NCT00683111] | Phase 4 | 500 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes[NCT00958958] | 1,150 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease[NCT01254981] | Phase 4 | 2,504 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Effects of Low and High Doses of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes and Possible Influence of the Glycemic Control.[NCT01397513] | Phase 4 | 48 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Beijing Tiantan Hospital,Capital Medical University.[NCT02317445] | 472 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
(NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 10 |
| Asundexian 20 mg | 7 |
| Asundexian 50 mg | 10 |
| Placebo | 7 |
"CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.~Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.~ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 27 |
| Asundexian 20 mg | 24 |
| Asundexian 50 mg | 22 |
| Placebo | 22 |
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 7 |
| Asundexian 20 mg | 4 |
| Asundexian 50 mg | 5 |
| Placebo | 2 |
Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 18 |
| Asundexian 20 mg | 20 |
| Asundexian 50 mg | 18 |
| Placebo | 17 |
"ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 5 |
| Asundexian 50 mg | 4 |
| Placebo | 4 |
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 0 |
| Placebo | 2 |
All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 30 |
| Asundexian 20 mg | 32 |
| Asundexian 50 mg | 42 |
| Placebo | 36 |
| Pooled Asundexian | 104 |
Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 5 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 3 |
| Placebo | 5 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 43 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 13 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 30 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 27 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 6 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 9 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 5 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 45 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 121 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 55 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 42 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 44 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 61 | 27 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 19 | 7 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 44 | 20 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2 | 5 | 10 | 15 | 40 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 54 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 48 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 26 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 67 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding or autopsy or imaging confirmation" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 66 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI: CK-MB > URL or Troponin > URL with baseline value < UR~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.4 | 6.7 | 4.0 | 3.6 | 5.8 | 6.9 |
"Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: ICH; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood or packed RBC within 48h;Chest tube output ≥ 2L within 24h~Type 5: Fatal bleeding~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.1 | 3.9 | 2.7 | 5.4 | 6.0 | 7.7 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 64 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 40 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 24 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 8 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 15 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 14 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 103 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 46 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 57 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 68 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 49 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 69 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 34 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 77 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 38 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 39 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.5 | 4.3 | 4.1 | 2.6 | 2.7 | 3.9 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 6.7 | 4.3 | 6.7 | 6.0 | 7.9 | 8.4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.2 | 0.0 | 2.7 | 3.4 | 5.5 | 4.4 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 7.1 | 6.5 | 6.8 | 5.4 | 6.8 | 10.1 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2.5 | 2.2 | 1.4 | 3.1 | 2.0 | 3.7 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 4.9 | 4.3 | 5.5 | 2.3 | 5.2 | 7.0 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year. (NCT02073565)
Timeframe: 1 year follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Combo | 20 |
| Everolimus Eluting Stent (EES) | 12 |
Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR. (NCT02073565)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combo | 12 |
| Everolimus Eluting Stent (EES) | 8 |
The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers. (NCT02073565)
Timeframe: 1 year
| Intervention | Healthy Tissue Strut Coverage (>40 µm) % (Mean) |
|---|---|
| Combo | 91.27 |
| Everolimus Eluting Stent (EES) | 74.82 |
Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations. (NCT02073565)
Timeframe: Day of device implantation, 30 days, 12 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Baseline HAMA Responders | 30 day HAMA Responders | 1 Year HAMA Responders | |
| Combo | 0 | 0 | 0 |
| Everolimus Eluting Stent (EES) | 0 | 0 | 0 |
Combination of CV death, MI, and stroke (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 85 |
SAEs except the blending events which have aleady been reported as SAEs. (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 116 |
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Fatal/life threatening | Major | Major + minor | Major + minor + minimal | |
| Ticargrelor | 17 | 27 | 93 | 426 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.4 |
| Rivaroxaban 2.5 mg Bid | 6.1 |
| Rivaroxaban 5 mg Bid | 6.1 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.5 |
| Rivaroxaban 2.5 mg Bid | 6.3 |
| Rivaroxaban 5 mg Bid | 6.3 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 7.6 |
| Rivaroxaban 2.5 mg Bid | 7.1 |
| Rivaroxaban 5 mg Bid | 7.2 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 8.7 |
| Rivaroxaban 2.5 mg Bid | 7.3 |
| Rivaroxaban 5 mg Bid | 7.6 |
The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment. (NCT00809965)
Timeframe: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 9.4 |
| Rivaroxaban 2.5 mg Bid | 8.5 |
| Rivaroxaban 5 mg Bid | 8.2 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
The time (in days) from study start to death from any cause was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who died from any cause within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 6.1 |
| Vorapaxar | 6.5 |
The time (in days) from study start to first experience of a stroke was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced a stroke within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 2.1 |
| Vorapaxar | 1.9 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause Death, MI, stroke, or UCR I within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 20.8 |
| Vorapaxar | 19.6 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: all-cause death, MI, stroke, RIR, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). The Kaplan-Meier estimate reports the percentage of participants who experienced all-cause death, MI, stroke, RIR, or UCR within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 21.5 |
| Vorapaxar | 20.6 |
The time (in days) from study start to the first occurrence of an MI was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced an MI within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 12.5 |
| Vorapaxar | 11.1 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), and/or stroke. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the secondary composite efficacy endpoint within 2 years from randomization. (NCT00527943)
Timeframe: up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 16.4 |
| Vorapaxar | 14.7 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with re-hospitalization (RIR), and/or urgent coronary revascularization (UCR). A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced at least 1 of the components of the primary composite efficacy endpoint within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 19.9 |
| Vorapaxar | 18.5 |
"Adverse events were categorized as bleeding events if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria as major, minor or other. Clinically Significant Bleeding was defined as the composite of TIMI Major bleeding, TIMI Minor bleeding, or bleeding that required unplanned medical or surgical treatment or unplanned laboratory evaluation even if it did not meet the criteria for TIMI major or minor bleeding. The Kaplan-Meier estimate reports the percentage of participants who experienced clinically significant bleeding within 2 years from randomization." (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 14.6 |
| Vorapaxar | 19.5 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death or MI. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death or MI within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 14.9 |
| Vorapaxar | 13.5 |
The time (in days) from study start to the CV death (if reported) was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 3.8 |
| Vorapaxar | 3.8 |
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 19.2 |
| Vorapaxar | 17.5 |
The time (in days) from study start to the first occurrence of RIR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced RIR within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 1.5 |
| Vorapaxar | 1.6 |
The time (in days) from study start to the first occurrence of UCR was recorded. A CEC reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced UCR within 2 years from randomization. (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 3.5 |
| Vorapaxar | 3.8 |
"Adverse events were categorized as bleeding events if the intensity of the event was other or more than would be normally expected in the given situation (eg, mild nosebleed in a person who does not normally have nosebleeds, greater bruising than expected for a given injury, greater volume of blood loss than expected for a given procedure). The investigator graded the intensity of bleeding events according to the GUSTO cooperative group criteria as follows: Mild , Moderate or Severe and the grading was adjudicated by the CEC. The Kaplan-Meier estimate reports the percentage of participants who experienced GUSTO moderate or severe bleeding within 2 years from randomization." (NCT00527943)
Timeframe: Up to 2 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 5.8 |
| Vorapaxar | 7.6 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
Total cost during index hospitalization (NCT01084239)
Timeframe: Duration of stay in the hospital during the initial visit
| Intervention | US Dollars (Mean) |
|---|---|
| Cardiac CT | 4026 |
| Standard of Care | 3874 |
Number of patients with diagnostic testing (CCTA, ETT, SPECT, stress echocardiography, and invasive coronary angiography) (NCT01084239)
Timeframe: Duration of stay in the hospital during the initial visit
| Intervention | participants (Number) |
|---|---|
| Cardiac CT | 492 |
| Standard of Care | 390 |
(NCT01084239)
Timeframe: Duration of stay in the hospital during the initial visit
| Intervention | hours (Mean) |
|---|---|
| Cardiac CT | 23.2 |
| Standard of Care | 30.8 |
Major Adverse Cardiovascular Events, All though these events are called MACE they do not qualify as adverse or serious adverse events. As these events are expected in some individuals in this population. Only MACE that occured within 72 hours after hospital discharge were considered serious adverse events in this trial. There were no such events. (NCT01084239)
Timeframe: 72 hours after discharge up to 28 days after enrollment.
| Intervention | events (Number) |
|---|---|
| Cardiac CT | 6 |
| Standard of Care | 2 |
Direct discharge from Emergency Department (NCT01084239)
Timeframe: Duration of stay in the hospital during the initial visit
| Intervention | participants (Number) |
|---|---|
| Cardiac CT | 233 |
| Standard of Care | 62 |
(NCT01084239)
Timeframe: Time from ED arrival to first positive test (all tests except Echocardiography Rest and including troponins ) if discharge diagnosis is ACS, otherwise time to performance of last test (all tests except Echocardiography Rest and including troponins ).
| Intervention | hours (Mean) |
|---|---|
| Cardiac CT | 10.4 |
| Standard of Care | 18.7 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
The secondary hypothesis of our study was that after 1 week of randomized treatment PRI levels would be non-inferior in patients switched from prasugrel to ticagrelor (two arms combined) compared with patients remaining on prasugrel. VASP was measured by quantitative flow cytometry using commercially available labelled monoclonal antibodies. (NCT02016170)
Timeframe: 7 days
| Intervention | PRI (Least Squares Mean) |
|---|---|
| Ticagrelor | 25 |
| Prasugrel | 36 |
The primary hypothesis of our study was that after 1 week of randomized treatment PRU levels would be non-inferior in patients switched from prasugrel to ticagrelor (two arms combined) compared with patients remaining on prasugrel. (NCT02016170)
Timeframe: 7 days
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Ticagrelor | 45 |
| Prasugrel | 63 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 6.1 |
| Apixaban 2.5mg BID | 15.1 |
| Apixaban 10mg QD | 17.6 |
| Apixaban 10mg BID | 24.2 |
| Apixaban 20 mg QD | 23.9 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.5 |
| Apixaban 2.5mg BID | 20.6 |
| Apixaban 10mg QD | 22.5 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 5.0 |
| Apixaban 10mg QD | 5.6 |
| Apixaban 10mg BID | 7.8 |
| Apixaban 20 mg QD | 7.3 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.0 |
| Apixaban 2.5mg BID | 5.7 |
| Apixaban 10mg QD | 7.9 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.0 |
| Apixaban 2.5mg BID | 0.8 |
| Apixaban 10mg QD | 0.0 |
| Apixaban 10mg BID | 2.9 |
| Apixaban 20 mg QD | 4.1 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 1.6 |
| Apixaban 10mg QD | 1.9 |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 54 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 20 |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 19 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 83 |
| Riva 5 mg Total Daily Dose (TDD) | 23 |
| Riva 10 mg TDD | 55 |
| Riva 15 mg TDD | 27 |
| Riva 20 mg TDD | 36 |
The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 63 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 21 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 88 |
| Riva 5 mg Total Daily Dose (TDD) | 24 |
| Riva 10 mg TDD | 71 |
| Riva 15 mg TDD | 35 |
| Riva 20 mg TDD | 48 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 66 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 22 |
The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 18 |
| Riva 5 mg Total Daily Dose (TDD) | 11 |
| Riva 10 mg TDD | 9 |
| Riva 15 mg TDD | 4 |
| Riva 20 mg TDD | 9 |
The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 36 |
| Riva 5 mg Total Daily Dose (TDD) | 17 |
| Riva 10 mg TDD | 109 |
| Riva 15 mg TDD | 43 |
| Riva 20 mg TDD | 89 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose PCI | 40 |
| Vorapaxar 40 mg Loading Dose PCI | 30 |
| Placebo/Placebo PCI | 21 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal MI, nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 6 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 15 |
| Placebo/Placebo Non-PCI | 1 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading/maintenance dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg/1 mg PCI | 21 |
| Vorapaxar 20 mg/2.5 mg PCI | 19 |
| Vorapaxar 40 mg/1 mg PCI | 16 |
| Vorapaxar 40 mg/2.5 mg PCI | 14 |
| Placebo/Placebo PCI | 21 |
Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants who required a subsequent hospitalization. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 30
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 0 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1 |
| Placebo/Placebo Non-PCI | 0 |
Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants that required blood transfusion. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 2 |
| Placebo/Placebo Non-PCI | 0 |
Participant blood samples were collected at baseline and at the time of hospital discharge to determine the mean serum level of CD40 ligand. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline | Time of Hospital Discharge | |
| Placebo/Placebo Non-PCI | 11.1 | 12.9 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 8.4 | 10.1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 4.6 | 7.1 |
Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of CD40 ligand present. CD40 ligand is a protein primarily found on activated T-cells, with higher levels indicating better immunological health. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline (n=37, 34, 21) | Day 30 (n=35, 34, 31) | Day 60 (n=30, 25, 13) | |
| Placebo/Placebo PCI | 4.8 | 6.2 | 5.7 |
| Vorapaxar 1 mg Maintenance Dose PCI | 5.6 | 5.9 | 5.6 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 6.9 | 5.9 | 5.4 |
Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of membrane-bound P-selectin. Membrane-bound P-selectin was measured using flow cytometry and a monoclonal antibody to P-selectin. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | Arbitrary Units (Mean) | ||
|---|---|---|---|
| Baseline (n=4, 4, 3) | Day 30 (n=3, 4, 3) | Day 60 (n=2, 3, 1) | |
| Placebo/Placebo PCI | 15.9 | 18.8 | 19.4 |
| Vorapaxar 1 mg Maintenance Dose PCI | 24.8 | 20.6 | 25.0 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 16.5 | 16.4 | 14.9 |
Participant blood samples were collected at Baseline and on Days 30 and 60 to evaluate the median level of hs-CRP. hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| Baseline (n=37, 34, 21) | Day 30 (n=35, 34, 21) | Day 60 (n=30, 25, 13) | |
| Placebo/Placebo PCI | 1.78 | 2.99 | 1.27 |
| Vorapaxar 1 mg Maintenance Dose PCI | 1.30 | 1.28 | 1.20 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 2.00 | 1.01 | 0.79 |
Participant blood samples were collected at baseline and at the time of hospital discharge to determine the median serum level of hs-CRP. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | mg/L (Median) | |
|---|---|---|
| Baseline | Time of Hospital Discharge | |
| Placebo/Placebo Non-PCI | 6.94 | 3.96 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 2.57 | 3.56 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1.05 | 2.65 |
Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring blood transfusion, bleeding requiring hospitalization, and TIMI major bleeding. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Intracranial hemorrhage | Bleeding requiring transfusion | Bleeding requiring hospitalization | Major TIMI bleeding | |
| Placebo/Placebo Non-PCI | 0 | 0 | 0 | 0 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 0 | 1 | 0 | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1 | 2 | 1 | 2 |
Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring hospitalization, or TIMI major bleeding. Analysis of data was by loading/maintenance dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Phase | Post-Hospital Discharge | |
| Placebo/Placebo PCI | 0 | 0 |
| Vorapaxar 20 mg/1 mg PCI | 3 | 1 |
| Vorapaxar 20 mg/2.5 mg PCI | 0 | 0 |
| Vorapaxar 40 mg/1 mg PCI | 2 | 2 |
| Vorapaxar 40 mg/2.5 mg PCI | 0 | 0 |
Blood samples were collected from participants at Baseline and Days 30, 60, 74, 90, and 121 to determine the extent of inhibition of platelet aggregation induced by thrombin-receptor agonist peptide (TRAP). Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60, Day 74, Day 90, Day 121
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 74 (follow-up period) | Day 90 (follow-up period) | Day 121 (follow-up period) | |
| Placebo/Placebo PCI | 3 | 3 | 1 | 3 | 3 | 3 |
| Vorapaxar 1 mg Maintenance Dose PCI | 5 | 5 | 3 | 5 | 5 | 5 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 4 | 4 | 3 | 4 | 4 | 4 |
Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo magnetic resonance imaging [MRI]), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to <5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major TIMI Bleeding Events | Minor TIMI Bleeding Events | Non-TIMI Bleeding Events | |
| Placebo/Placebo PCI | 0 | 2 | 11 |
| Vorapaxar 1 mg Maintenance Dose PCI | 2 | 5 | 22 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 0 | 3 | 17 |
Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo MRI), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to <5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major TIMI Events | Minor TIMI Events | Non-TIMI Bleeding Events | |
| Placebo/Placebo Non-PCI | 0 | 0 | 1 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 1 | 0 | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 2 | 0 | 8 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 16.33 |
| Apixaban 5 mg BID | 39.98 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 13.96 |
| Apixaban 5 mg BID | 13.20 |
"Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.~CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination)." (NCT00831441)
Timeframe: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 15.65 |
| Apixaban 5 mg BID | 15.48 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 14.27 |
| Apixaban 5 mg BID | 13.97 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 17.95 |
| Apixaban 5 mg BID | 16.92 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.29 |
| Apixaban 5 mg BID | 6.15 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.04 |
| Apixaban 5 mg BID | 5.13 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 0.91 |
| Apixaban 5 mg BID | 2.40 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 9.20 |
| Apixaban 5 mg BID | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.21 |
| Apixaban 5 mg BID | 1.61 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 1.85 |
| Apixaban 5 mg BID | 1.65 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 4.21 |
| Apixaban 5 mg BID | 3.95 |
260 reviews available for aspirin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di | 2023 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet | 2022 |
Evidence base for the management of women with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ma | 2022 |
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hum | 2022 |
The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Canada; Clopidogrel; Drug Therapy, Combination; | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarctio | 2023 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans | 2022 |
Cardiovascular mortality in patients with acute and chronic coronary syndrome: insights from the clinical evidence on ticagrelor.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2022 |
A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet | 2022 |
Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
Topics: Acute Coronary Syndrome; Arrhythmias, Cardiac; Aspirin; Fibrinolytic Agents; Humans; Lipids; Non-ST | 2023 |
Intravenous immunoglobulin for the treatment of Kawasaki disease.
Topics: Acute Coronary Syndrome; Aspirin; Child; Fever; Humans; Immunoglobulins, Intravenous; Inflammation; | 2023 |
Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemia; Percutan | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Inf | 2023 |
Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Corona | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Int | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; H | 2023 |
Tailoring antiplatelet therapy in older patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Dual Ant | 2023 |
Management of Antiplatelet Agents in Patients with History of Coronary Artery Disease in Various Medical Conditions.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Humans; Myocardial Ischemia; Platelet Agg | 2019 |
Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS tr
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrino | 2020 |
Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2019 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug | 2020 |
Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fi | 2020 |
Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; | 2021 |
[Antithrombotic therapy after acute coronary syndromes: is it possible to identify the PEGASUS and COMPASS patient?]
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Humans; Patient Selection; Platelet Ag | 2020 |
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fibrinolytic Agent | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage | 2020 |
Pregnancy and cardiovascular disease.
Topics: Acute Coronary Syndrome; Antihypertensive Agents; Aortic Dissection; Arrhythmias, Cardiac; Aspirin; | 2020 |
Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet | 2020 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percu | 2020 |
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; | 2020 |
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Humans; Incidence; Myocardial Infarction; Per | 2020 |
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coron | 2021 |
Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Agents; Humans; Platelet Aggregation Inhibitors; Pr | 2020 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2020 |
Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or Is Reappraisal Warranted?
Topics: Acute Coronary Syndrome; Aspirin; Chronic Disease; Humans; Middle Aged; Platelet Aggregation Inhibit | 2020 |
Management of Patients with Acute Coronary Syndrome and Cancer.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Humans; Neoplasms; Platelet Aggregation I | 2020 |
Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Blood C | 2021 |
Dual Antiplatelet Therapy De-escalation Strategies.
Topics: Acute Coronary Syndrome; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Graft Oc | 2021 |
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage | 2021 |
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2021 |
Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting.
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Drug-Eluting Stents; Dual Anti-Platelet Therapy; D | 2021 |
Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; | 2022 |
New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet The | 2021 |
Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Dose-Response Relationship, Drug; Platelet A | 2017 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggr | 2017 |
Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2017 |
Duration of dual antiplatelet therapy after coronary stent insertion: Does the benefit of extended therapy outweigh the risk?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Human | 2016 |
Aspirin safety in glucose-6-phosphate dehydrogenase deficiency patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Huma | 2017 |
The Benefits and Risks of Oral Antiplatelet Therapy in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiology; Evidence-Based M | 2017 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; D | 2018 |
Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Factors; F | 2018 |
Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aftercare; Aspirin; Cardiac Catheterization; Continuity of Patient Care; Co | 2018 |
Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Humans; Percutaneou | 2018 |
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Topics: Acute Coronary Syndrome; Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Ther | 2018 |
[Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Co | 2018 |
[Bleeding risk in patients with acute coronary syndromes treated with antiplatelet agents: incidence, prognosis and clinical evaluation. From research to clinical practice].
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Platelet | 2018 |
Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; H | 2019 |
De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review.
Topics: Acute Coronary Syndrome; Aspirin; Diamines; Humans; Percutaneous Coronary Intervention; Platelet Agg | 2019 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrino | 2019 |
Meta-Analysis of Acetylsalicylic Acid Desensitization in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Plate | 2019 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Apical hypertrophic cardiomyopathy--case report and review of the literature.
Topics: Acute Coronary Syndrome; Aspirin; Cardiomyopathy, Hypertrophic; Echocardiography; Electrocardiograph | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Int | 2013 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topi | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clinical Trials as Topic; Clopidogrel; Drug Therapy, C | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Dis | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Cli | 2013 |
Cangrelor: a review on pharmacology and clinical trial development.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Aspirin; Clinical Trials as Topic; Drug T | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Interactions; Drug Therapy, Combination; Hem | 2014 |
[Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dr | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogr | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2014 |
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Percutaneous Coronary In | 2014 |
[Antiplatelet drugs].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; P | 2014 |
Recent developments in antiplatelet therapy after percutaneus coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2014 |
[Antiplatelet therapy in atherosclerosis of various localizations: acute and stable States].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Drug Therapy, Combination; Drug-Related Side Effe | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; My | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary D | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi | 2014 |
Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Genotype; Humans; Patient Selection; Phenotype; Platelet Aggregati | 2014 |
[Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].
Topics: Acute Coronary Syndrome; Aspirin; Cardiology; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; | 2015 |
[Acetylsalicylic acid desensitization in the new era of percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Percu | 2015 |
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Th | 2015 |
Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardi | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypa | 2015 |
Review of acute coronary syndromes: diagnosis and management of unstable angina and non ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angiotensin-Converting Enzym | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2015 |
Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Dru | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.
Topics: Acute Coronary Syndrome; Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Fibrinolytic Age | 2015 |
Oral dual antiplatelet therapy: what have we learnt from recent trials?
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Drug Therapy, Combination; Drug-Eluting Sten | 2016 |
Trends in pharmacological therapy following an acute coronary syndrome in Portugal: a systematic review.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; C | 2016 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary | 2015 |
Aspirin dosing in cardiovascular disease prevention and management: an update.
Topics: Acute Coronary Syndrome; Aspirin; Humans | 2015 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Which form of aspirin is the fastest to inhibit platelet aggregation in emergency department patients with non-ST segment elevation myocardial infarction?
Topics: Acute Coronary Syndrome; Aspirin; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Hu | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2015 |
Rapid Aspirin Challenge in Patients with Aspirin Allergy and Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Immun | 2016 |
The use of dual antiplatelet therapy in high-risk patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Humans; P | 2015 |
Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Percu | 2016 |
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Drug Therapy, | 2016 |
Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2017 |
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Hem | 2016 |
[Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].
Topics: Acute Coronary Syndrome; Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Patient Care Team; Pl | 2016 |
Immature Platelets: Clinical Relevance and Research Perspectives.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Humans; Megakaryocytes; RNA, Messeng | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; P | 2016 |
Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Causality; Comorbidity; Dose-Response | 2017 |
Spontaneous coronary artery dissection: Case report and review of the literature.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopi | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Dise | 2017 |
Duration of dual antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Coronary Thrombosis; Drug Administration Schedule | 2017 |
Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Hirud | 2008 |
Acute and long-term antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Plate | 2008 |
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platele | 2008 |
Current antiplatelet therapies: benefits and limitations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Dru | 2008 |
Clinical profile of prasugrel, a novel thienopyridine.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary | 2008 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardio | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Com | 2008 |
Advances in antiplatelet therapy for ACS and PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angina, Unstable; Aspirin; Blood Platelets; Cardia | 2008 |
[Anticoagulant and thrombolytic agents in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight | 2008 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2009 |
Variability in responsiveness to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet A | 2009 |
Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug | 2009 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Humans; Plate | 2009 |
Aspirin resistance in cardiovascular disease: pathogenesis, diagnosis and clinical impact.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Cardiovascular Diseases; Drug Interactions; Drug Resistan | 2009 |
Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2009 |
Acute coronary syndrome.
Topics: Acute Coronary Syndrome; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biom | 2009 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2008 |
Acute coronary syndrome (unstable angina and non-ST elevation MI).
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Oral; Angina, Unstable; Aspirin; Calcium Cha | 2009 |
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emerg | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
Medical therapy in acute coronary syndromes: which medicines and at what doses?
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensins; Anticoagulants; Aspirin; Enzyme | 2009 |
The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; F | 2009 |
Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cost-Benefit Analysis; Guideline Adherence; Humans; Platelet Aggre | 2009 |
Antiplatelet resistance--fact or myth?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chronic Disease; Hemorrhage; Humans; Platele | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon; Aspirin; Clinical Trials | 2009 |
Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Humans; Platelet Ag | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trial | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D | 2010 |
Aspirin for acute coronary syndromes: have we learned the correct dose yet?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiovascular Diseases; Humans; Platelet Aggrega | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; A | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Hepa | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopi | 2010 |
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2010 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty; Aspirin; Drug Interactions; Humans; Medication Adherence; Plat | 2011 |
[Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Evidence-Based Medicine; Fibrino | 2010 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet | 2010 |
Clopidogrel withdrawal: is there a "rebound" phenomenon?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration S | 2011 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; | 2010 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; | 2011 |
Antiplatelet resistance in stroke.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Resistance; Humans; P | 2011 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Pa | 2011 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial I | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug | 2011 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2011 |
Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Aspirin; Coronary Artery Disease; Humans; Mo | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activa | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactio | 2012 |
The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Dr | 2011 |
Triple antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Plate | 2011 |
Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Huma | 2012 |
Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hum | 2011 |
Clopidogrel and PPI interaction: clinically relevant or not?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; | 2012 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Integrin beta3; Platelet Aggregation Inhibitors; Platelet | 2012 |
Promises of PAR-1 inhibition in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Plate | 2012 |
[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cilostazol; Clopidogrel; Diabetes Complicati | 2010 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Mechanisms of platelet activation in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Drug Design; Drug Therapy, Combination; | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatme | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effec | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Dr | 2013 |
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hem | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Coronary Art | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Coronary Arte | 2012 |
Stents and antiplatelet therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug-Eluting Stents; | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Clopidogrel: the data, the experience, and the controversies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2012 |
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Purinerg | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; | 2013 |
Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Humans; Platelet Ag | 2013 |
Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Fibrin; Humans; Plaque, Atherosclerotic; Platel | 2014 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperaz | 2013 |
To statin or to non-statin in coronary disease--considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; | 2007 |
Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Platelets; Combi | 2006 |
[Management coronary syndrome in the acute phase].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2007 |
[Long-term management of post acute coronary syndrome with oral antiplatelet therapy].
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Human | 2007 |
Coronary stents and noncardiac surgery.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Plate | 2007 |
[Unstable angina].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Corona | 2007 |
Management of an acute coronary syndrome in a patient with severe haemophilia A.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemophi | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Death, Sudden, Cardiac; Drug Resistance; | 2008 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Haemorrhagic stroke during anti-platelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cerebral Hemorrhage; Clinical Trials as Topic; Humans; Intracrania | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
[Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drugs, | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
Antiplatelet drug nonresponsiveness.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet A | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Art | 2008 |
Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Contraindica | 2008 |
Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2008 |
Managing antiplatelet therapy in the ACS patient: straight from the emergency department to you.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Humans; Platelet Activation; Plate | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
182 trials available for aspirin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual An | 2021 |
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Com | 2021 |
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Hum | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2022 |
Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Epidermal Growth Factor; Humans; Interleukin-6; Percuta | 2022 |
Results from the "Me & My Heart" (eMocial) Study: a Randomized Evaluation of a New Smartphone-Based Support Tool to Increase Therapy Adherence of Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Medication Adherence; Smartphone; Ticagrelor | 2023 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarcti | 2022 |
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrha | 2022 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; | 2022 |
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hem | 2022 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2023 |
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Humans; Percutaneous Coronary Intervention | 2023 |
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggre | 2023 |
Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneou | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combin | 2023 |
A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial.
Topics: Acute Coronary Syndrome; Aspirin; Bayes Theorem; COVID-19; Hemorrhage; Humans; SARS-CoV-2; Treatment | 2023 |
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2023 |
Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOP-CABG trial study.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Double-Blind Method; Humans; Platelet Aggr | 2023 |
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Corona | 2023 |
P2Y
Topics: Acute Coronary Syndrome; Aspirin; C-Reactive Protein; Colchicine; Humans; Percutaneous Coronary Inte | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combinat | 2019 |
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; | 2019 |
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Continuity of Patient Care; Dose-Response Relation | 2019 |
Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Female; F | 2020 |
A behavioral economics-based telehealth intervention to improve aspirin adherence following hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Economics, Behavioral; Female; Humans; Male; Medication Adherence; | 2020 |
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized
Topics: Acute Coronary Syndrome; Adult; Area Under Curve; Asian People; Aspirin; Clopidogrel; Cross-Over Stu | 2020 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S | 2020 |
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting | 2020 |
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Dual | 2020 |
ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Administra | 2021 |
Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Double-Blind M | 2020 |
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy | 2020 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Stenosis; Drug-Eluting Stents; Dual Anti-Platelet T | 2021 |
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2020 |
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.
Topics: Acute Coronary Syndrome; Aged; Arachidonic Acid; Aspirin; Drug Therapy, Combination; Dual Anti-Plate | 2020 |
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Drug-Eluting Stents; Dual Anti-Platel | 2021 |
Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Coagulation Tests; Blood Transfusion; Coronary Artery | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Dru | 2017 |
Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronar
Topics: Acute Coronary Syndrome; Albumins; Anticoagulants; Antigens, CD34; Aspirin; Biocompatible Materials; | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combina | 2017 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Typ | 2017 |
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship, | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopido | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
[After the GEMINI-ACS-1 trial].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Humans; Rivaroxaban; Thrombosis | 2017 |
Impact of Coronary Computed Tomography Angiography Findings on Initiation of Cardioprotective Medications.
Topics: Acute Coronary Syndrome; Adult; Angina Pectoris; Aspirin; Clinical Decision-Making; Computed Tomogra | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; | 2018 |
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Capsules; Clopidogrel; Double-Blind Method; | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; | 2018 |
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Com | 2018 |
Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Aspirin; Blood Platelets; China; Clopidogrel; | 2018 |
Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Dose-Response Relations | 2018 |
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrha | 2018 |
Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up St | 2018 |
Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiogr | 2018 |
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Circadian Rhythm; Cl | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fib | 2019 |
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Doub | 2019 |
Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial.
Topics: Acute Coronary Syndrome; Aged; Appointments and Schedules; Aspirin; Drug Administration Schedule; Du | 2020 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedul | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug T | 2019 |
Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Male; Medication Adherence; Middle Aged; Mot | 2013 |
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Managem | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Te | 2013 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Cytochrome P-450 C | 2014 |
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Blood Platelets; Cells, C | 2014 |
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aspirin; Dose-Response Relationship, Drug; Doub | 2014 |
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind | 2013 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; P | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; C | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions.
Topics: Acute Coronary Syndrome; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Female; Humans; Male; Mid | 2014 |
Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Adolescent; Adult; Aged; Aspirin; Chewing Gum; Female | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationshi | 2015 |
Effect of Prior Aspirin Treatment on Patients With Acute Coronary Syndromes: Insights From the PROSPECT Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Fema | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggreg | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind | 2016 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combi | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combin | 2016 |
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Incidence; Male; Middle Aged; Myocardial Inf | 2016 |
Use of Coronary Computed Tomographic Angiography Findings to Modify Statin and Aspirin Prescription in Patients With Acute Chest Pain.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Chest Pain; Coronary Angiography; Decision Making; Di | 2016 |
Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Enoxaparin; Eptifibatide; Female; Fibrinol | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationshi | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relations | 2016 |
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Hu | 2016 |
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Gastr | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Ca | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therap | 2016 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Japan | 2017 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syn
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; | 2017 |
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; | 2016 |
Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Area Under Curve; Aspirin; Biological Availabi | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolim | 2016 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Th | 2016 |
Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Bi | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atorvastatin; C-Reactive Protein; Clopidogrel; Female; Hepta | 2008 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Corona | 2008 |
Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Biomarkers; Coronary Angiograph | 2009 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Fema | 2009 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incid | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Ci | 2009 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2009 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
A randomized clinical trial to reduce patient prehospital delay to treatment in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Australia; Counseling; Emergency Medical | 2009 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An | 2010 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Thera | 2010 |
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Double-Blind M | 2010 |
Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Double-Blind Method; Drug Th | 2010 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogre | 2010 |
Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
Topics: Acute Coronary Syndrome; Aspirin; Cohort Studies; Cross-Over Studies; Dose-Response Relationship, Dr | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
[Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Circadian Rhythm; Clopidogrel; Humans; Male; Middle A | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 2011 |
Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Cell Adhesio | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Dou | 2012 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2011 |
[Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therap | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combinatio | 2013 |
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Case Management; Checklist; Clopidog | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pum | 2012 |
Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle | 2013 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: findings from the COPES trial.
Topics: Acute Coronary Syndrome; Antidepressive Agents; Aspirin; Depression; Diet; Exercise; Female; Humans; | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aspirin; Collagen; Dose-Response Relationship, Drug; | 2012 |
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Biotransformation; Blood Platelets; Dose-Response Relations | 2013 |
Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Cardiovascular Agents; Chi-Square Distribution; | 2013 |
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Coated Materials, Biocompatible; Corona | 2013 |
To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation In | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Canada; Cl | 2007 |
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Gastrointestinal H | 2007 |
Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Clopidogrel; | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
497 other studies available for aspirin and Acute Coronary Syndrome
| Article | Year |
|---|---|
Prognostic value of haemoglobin drop in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Dual Anti-Platelet Therapy; Female; Hemoglobins; Humans; Mal | 2021 |
FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y | 2021 |
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial.
Topics: Acute Coronary Syndrome; Aspirin; Carbidopa; Drug Combinations; Humans; Levodopa; Percutaneous Coron | 2022 |
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry.
Topics: Acute Coronary Syndrome; Aspirin; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; P | 2021 |
Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Female; Fibrinol | 2021 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Pe | 2022 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhib | 2022 |
Time trends of coronary procedures, guideline-based drugs and all-cause mortality following acute coronary syndrome in patients with bipolar disorder.
Topics: Acute Coronary Syndrome; Aspirin; Bipolar Disorder; Humans; Lipids; Percutaneous Coronary Interventi | 2023 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Ar | 2022 |
Preoperative treatment with clopidogrel and ticagrelor on bleeding complications in off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation | 2022 |
Impact of admitting department on the management of acute coronary syndrome after an out of hospital cardiac arrest.
Topics: Acute Coronary Syndrome; Admitting Department, Hospital; Aspirin; Coronary Angiography; Humans; Out- | 2023 |
Eptifibatide-induced acute profound thrombocytopenia: A case report.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Eptifibatide; Glycoproteins; Hemorrhage; Humans; Male | 2022 |
Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platelet A | 2023 |
Impact of Close Surveillance on Dual-Antiplatelet Therapy Compliance in Myocardial Infarction Patients Post-Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutan | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Hospital- and Patient-Level Analysis of Quality Indicators in Acute Coronary Syndrome Care: A Nationwide Database Study.
Topics: Acute Coronary Syndrome; Aspirin; Hospitals; Humans; Percutaneous Coronary Intervention; Quality Ind | 2023 |
Hospital- and Patient-Level Analysis of Quality Indicators in Acute Coronary Syndrome Care: A Nationwide Database Study.
Topics: Acute Coronary Syndrome; Aspirin; Hospitals; Humans; Percutaneous Coronary Intervention; Quality Ind | 2023 |
Hospital- and Patient-Level Analysis of Quality Indicators in Acute Coronary Syndrome Care: A Nationwide Database Study.
Topics: Acute Coronary Syndrome; Aspirin; Hospitals; Humans; Percutaneous Coronary Intervention; Quality Ind | 2023 |
Hospital- and Patient-Level Analysis of Quality Indicators in Acute Coronary Syndrome Care: A Nationwide Database Study.
Topics: Acute Coronary Syndrome; Aspirin; Hospitals; Humans; Percutaneous Coronary Intervention; Quality Ind | 2023 |
DNA methylation profile in the whole blood of acute coronary syndrome patients with aspirin resistance.
Topics: Acute Coronary Syndrome; Aspirin; CpG Islands; DNA Methylation; Humans; RNA, Messenger | 2023 |
Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; | 2023 |
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combinatio | 2022 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Human | 2022 |
Acetylsalicylic acid challenge or desensitization in sensitive patients with cardiovascular disease.
Topics: Acute Coronary Syndrome; Anaphylaxis; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2023 |
De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Hu | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percut | 2023 |
Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; | 2023 |
Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Femal | 2023 |
[Debate on antiplatelet monotherapy: Why not leaving out good old aspirin for clopidogrel or ticagrelor in monotherapy in chronic coronary syndromes after a percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet | 2023 |
Rectus Sheath Hematoma in a Patient with Dual-Antiplatelet Therapy Including Ticagrelor: A Case Report.
Topics: Abdominal Pain; Acute Coronary Syndrome; Aged, 80 and over; Aspirin; Hematoma; Humans; Male; Percuta | 2023 |
The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
Topics: Acute Coronary Syndrome; Aspirin; East Asian People; Hemorrhage; Humans; Percutaneous Coronary Inter | 2023 |
Clopidogrel vs Aspirin in the Chronic Maintenance Period for Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Treatment Outcome | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibito | 2023 |
Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Is | 2023 |
[Is the NSTEACS pretreatment recommended by the guidelines what reflects the real world?]
Topics: Acute Coronary Syndrome; Aspirin; Coronary Angiography; Humans; Percutaneous Coronary Intervention; | 2023 |
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Plaque, Atheroscleroti | 2023 |
Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Arachidonic Acid; Aspirin; Clopidogrel; Gelsolin; Humans; Mean Platelet Vol | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneo | 2023 |
Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coron | 2023 |
De-escalation from potent P2Y12 inhibitors to clopidogrel: an alternative to short DAPT duration in HBR patients?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Interventio | 2023 |
Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Cohort Studies; Comorbidity; Fe | 2020 |
High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Female; Humans; M | 2019 |
[Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Humans; Myocardial Infarction; Platelet Aggregati | 2019 |
Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Cl | 2020 |
Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cardiovascular System; Clopidogrel; Female; Humans; L | 2020 |
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; | 2019 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Depr | 2020 |
High Residual Platelet Activity in Response to Acetylsalicylic Acid in Acute Coronary Syndrome: A New Challenge for Antiplatelet Treatment?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Humans; Platelet Aggregation Inhibitors | 2019 |
Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Case-Control Studies; China; Clopido | 2019 |
Dual antiplatelet therapy up to the time of non-elective coronary artery bypass grafting with prophylactic platelet transfusion: is it safe?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Combined Modality The | 2019 |
Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Dual Anti-Platelet Therapy; F | 2020 |
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2020 |
Aspirin rechallenge in an adult patient previously diagnosed with Reye syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Reye S | 2020 |
Assessment of platelet function after discontinuation of ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Longitudinal Stud | 2020 |
Concealed Wolff-Parkinson-White Syndrome revealed by acute coronary syndrome.
Topics: Acute Coronary Syndrome; Analgesics, Opioid; Aspirin; Clopidogrel; Drug-Eluting Stents; Electrocardi | 2020 |
GLOBAL LEADERS: looking now at the bigger picture.
Topics: Acute Coronary Syndrome; Aspirin; Cardiology; Dual Anti-Platelet Therapy; Fibrinolytic Agents; Globa | 2019 |
Impact of risk factors of ischemic heart disease on the development of acute coronary syndrome, platelet ultrastructure, and aspirin resistance.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Humans; Middle Aged; R | 2019 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Study of Platelet Indices in Patients with Acute Coronary Syndrome in a Tertiary Care Hospital.
Topics: Acute Coronary Syndrome; Aspirin; Hematologic Tests; Humans; Platelet Aggregation Inhibitors; Tertia | 2020 |
Clinical presentation and treatment of acute coronary syndrome as well as 1-year survival of patients hospitalized due to cancer: A 7-year experience of a nonacademic center.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Coronary Angiography; Female; Humans; Male; | 2020 |
Urgent to correctly understand the role of aspirin in cardiovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reducta | 2020 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Deci | 2020 |
Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials, Phase II | 2020 |
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Antithrombotic therapy: less is more or the more the better?
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor | 2020 |
Antithrombotic therapy: less is more or the more the better? Authors' reply.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor | 2020 |
Temporal trends in management and outcome of patients with acute coronary syndrome according to admission low-density lipoprotein cholesterol levels.
Topics: Acute Coronary Syndrome; Aspirin; Cholesterol, LDL; Coronary Angiography; Diagnostic Tests, Routine; | 2020 |
Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2020 |
Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
Topics: Acute Coronary Syndrome; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; | 2020 |
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Dise | 2020 |
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Fe | 2020 |
Aspirin adherence in subjects with glucose-6-phosphate-dehydrogenase deficiency having an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Glucose-6-Phosphate; Glucosephosphate Dehydrogenase Deficiency; Hu | 2021 |
Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Case-Control Studie | 2020 |
Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Data | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality | 2020 |
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Dual Anti-Platelet Therapy; Female; Human | 2020 |
Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillatio | 2020 |
Effect of a Triage-Based Screening Protocol on Diagnosis and Treatment of Acute Coronary Syndrome in a Tanzanian Emergency Department: A Prospective Pre-Post Study.
Topics: Acute Coronary Syndrome; Aspirin; Body Mass Index; Chest Pain; Dyspnea; Electrocardiography; Emergen | 2020 |
Platelet Reactivity in Hepatitis C Virus-Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hepacivirus; | 2020 |
In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Patients; Percut | 2020 |
High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Beijing; Biomarkers; Blood Platelets; Clopidogrel; Cross-Sec | 2020 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopido | 2021 |
In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy reduced clinical events at 1 y vs. DAPT.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2020 |
The long journey of individualizing antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2020 |
Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Frequency and Reasons for Non-Administration and Suspension of Drugs During an Acute Coronary Syndrome Event. The ERICO Study.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Female; Hum | 2020 |
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Topics: Acute Coronary Syndrome; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2021 |
Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Asia; Aspirin; Biomarkers; Blood Platelets; Drug Resistance; Female; Gene E | 2021 |
Acute coronary syndromes: summary of updated NICE guidance.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Mo | 2021 |
Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2021 |
Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2021 |
Sex and gender differences in presentation, treatment and outcomes in acute coronary syndrome, a 10 year study from a multi-ethnic Asian population: The Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome (NCVD-ACS) registry.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Asian People; Aspirin; Cardiovasc | 2021 |
Creatine kinase and bleeding in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Creatine Kinase; Dual Anti-Platelet Therapy; | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Triflusal in Patients with Acute Coronary Syndrome and Acetylsalicylic Acid Hypersensitivity.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2021 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Cor | 2021 |
Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Dual Anti-Plat | 2021 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Myo | 2021 |
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
Topics: Acute Coronary Syndrome; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet A | 2021 |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Body Mass Index; Case-Control Studies; China; Clopido | 2021 |
Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Beijing; Clopidogrel; Databases, Factual; Diabet | 2021 |
Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Dual Anti-Platelet T | 2021 |
GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Riva | 2017 |
Adult Chest Pain in the Pediatric Emergency Department: Treatment and Timeliness From Door In To Door Out.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Chest Pain; Electrocardiography; Emergency Service, Hospita | 2017 |
Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Blood Urea Nitrogen; Clopidogrel; Creatinine; Drug The | 2016 |
A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Drug Therapy | 2017 |
Acute coronary syndromes: Similar bleeding risks with low-dose rivaroxaban versus aspirin.
Topics: Acute Coronary Syndrome; Aspirin; Double-Blind Method; Hemorrhage; Humans; Platelet Aggregation Inhi | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Ar | 2017 |
Predicting long-term bleeding risk after acute coronary syndrome: a step closer to optimising dual antiplatelet therapy duration?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospita | 2017 |
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitaliz
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cross-Sectional Studies; | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
[Dual Antiplatelet Therapy in the Perioperative Period - To Continue or Discontinue Treatment?]
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Perioperative Peri | 2017 |
Expression of a Nitric Oxide Synthesizing Protein in Arterial Endothelial Cells in Response to Different Anti-Anginal Agents Used in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Animals; Arginine; Arteries; Aspirin; Endothelial Cells; Glucose; Goats; In | 2017 |
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
[Focused update on dual antiplatelet treatment : ESC guidelines 2017].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2017 |
Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2017 |
Impact of Long-Term Dual Antiplatelet Therapy on Immature Platelet Count and Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2018 |
Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Male; Mi | 2018 |
[Platelet inhibition in elderly patients].
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Humans; Percutaneous Coronary Intervention | 2018 |
Preventing recurrent events in survivors of acute coronary syndromes in Australia: consensus recommendations using the Delphi process.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aspirin; Australia; Consensus; Delphi Techniqu | 2018 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; C | 2017 |
Prior exposure to aspirin in acute coronary syndrome patients: a cardiovascular risk marker or a predictor of adverse outcome? A contemporary data of a national registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atr | 2018 |
Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Humans; Male; Middle Aged; Percutaneous Coronary Int | 2018 |
Prognostic Implications of Dual Platelet Reactivity Testing in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Angiograp | 2018 |
Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.
Topics: Acute Coronary Syndrome; Age Factors; Aged; American Heart Association; Aspirin; Chi-Square Distribu | 2018 |
12 months of DAPT after acute coronary syndrome still beats 6 months.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2018 |
Optimal antiplatelet therapy after an acute coronary syndrome in the elderly: An old issue.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2018 |
Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Anticoagulants; Arrhythmias, Cardiac; Aspirin; At | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Database | 2018 |
Long-term follow-up of antithrombotic management patterns in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticoagulants; Aspirin; Female; Follow-Up Studies; Human | 2018 |
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fem | 2018 |
Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.
Topics: Acetaminophen; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammator | 2018 |
[ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Ho | 2018 |
Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Prescriptions; Drug Therapy, Combination; Female; Guide | 2018 |
Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Coronary Vasospasm; Coronary Vessels; | 2018 |
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aspirin; ATP Binding Cassette Transporter | 2018 |
Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrino | 2017 |
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2019 |
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Biotransformation; Clopidogrel; Cyto | 2019 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; | 2020 |
Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Chronic D | 2018 |
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combina | 2018 |
The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects.
Topics: Acute Coronary Syndrome; Aftercare; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Databases, Factua | 2019 |
How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Percutaneous C | 2018 |
Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Pharmacogenomi | 2018 |
Laboratory monitoring of P2Y
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Coagulation; Cardiology; Clopidogrel; Geneti | 2018 |
Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; C-Reactive Protein; Coronary Angiography; Electr | 2019 |
Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2018 |
[ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet Therapy in Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Humans; Male; Platelet A | 2018 |
Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination | 2018 |
Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Cost-Benefit Analysis | 2018 |
Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Dual Anti-Platelet Therapy; Female; Humans; | 2019 |
Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clinical Decision-Making; Coronary Artery Bypass; Drug Thera | 2018 |
Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug-Eluting Stents; Fema | 2019 |
Possible association of influenza A infection and reverse takotsubo syndrome.
Topics: Acute Coronary Syndrome; Aged; Antiviral Agents; Aspirin; Atorvastatin; Chest Pain; Coronary Angiogr | 2018 |
Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Desensitization, Immunologic; Drug Hypers | 2019 |
When can I stop dual antiplatelet therapy in patients with drug-eluting stents?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2019 |
Evaluation of platelet activity by multiple electrode impedance aggregometry in acute coronary syndromes: pilot study in a Brazilian tertiary-care public hospital.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Electric Impedance; Female; Hospitals, Public; Humans; | 2019 |
Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL-ACS).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitor | 2019 |
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu | 2020 |
Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Dru | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocar | 2019 |
Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Coronary Artery Disease; Drug Resistance | 2019 |
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Europe; Female; Humans; Male; Myocardial Infarction; Platele | 2019 |
PURL: Should you switch the DAPT agent one month after ACS?
Topics: Acute Coronary Syndrome; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2019 |
Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Diabetes | 2019 |
[The GLOBAL LEADERS trial: do we still need aspirin in acute coronary syndrome patients undergoing percutaneous coronary intervention?]
Topics: Acute Coronary Syndrome; Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2019 |
Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous | 2019 |
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitu | 2019 |
Critical appraisal of the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fact | 2019 |
In AF with recent ACS or PCI, apixaban reduced bleeding vs VKAs; aspirin increased bleeding vs placebo.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Cor | 2019 |
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas | 2019 |
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Aspirin; Case-Control Studies; Dual Anti-P | 2019 |
Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
Topics: Acute Coronary Syndrome; Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Gastrointestinal | 2013 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Ana | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endo | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; F | 2014 |
Spontaneous platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alprostadil; Antibodies; Aspirin; Blood Platelets; Clopidogrel; Humans; Pla | 2013 |
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control | 2013 |
Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2013 |
Pre-hospital cardiac arrest in acute coronary syndromes: insights from the global registry of acute coronary events and the canadian registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials | 2013 |
Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Corona | 2013 |
Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Asian Peop | 2013 |
[The ARCTIC study].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardi | 2013 |
Mortality trends in women and men presenting with acute coronary syndrome: insights from a 20-year registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Angiotensin Receptor Antagonists; Arachidonic Acid; Aspirin; C | 2014 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
The psychosocial context impacts medication adherence after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adaptation, Psychological; Aged; Aspirin; Depression; Female; Humans; Inter | 2014 |
Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Fibrinogen; Genetic Predisposition to Disease | 2014 |
Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Antiplatelet therapy: DAPT for 3 months is sufficient.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
The enigmatic search for optimal DAPT duration.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors | 2014 |
Sex differences in the treatment and outcome of patients with acute coronary syndrome after percutaneous coronary intervention: a population-based study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Insurance, Health; Male; Odds Ratio; | 2014 |
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; P-Selectin; Platelet Aggregatio | 2014 |
Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combinat | 2015 |
Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Re | 2014 |
Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Anesthesia; Aspirin; Blood Transfusion; Chest | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platele | 2013 |
Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Sc | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Asian People; Aspirin; Blood Platelets; Clo | 2014 |
A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biopsy; Coronary Artery Bypass; Diagnosis, Differential | 2014 |
Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angiotensin-Conver | 2014 |
Dual antiplatelet therapy after stent implantation.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Dual antiplatelet therapy after stent implantation--reply.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thromb | 2014 |
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Card | 2014 |
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Calgranulin A; Calgranulin B; Chronic Disease; Dinoprost; Fe | 2014 |
Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzofurans; Blood Platelets; Clopidogrel; Drugs, Chinese He | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Mal | 2014 |
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytoc | 2015 |
Long-term prognostic impact of the attenuated plaque in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Corona | 2016 |
Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2014 |
Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Convertin | 2015 |
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female | 2016 |
[Clinical pharmacology of current antiplatelet drugs].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Surgical Procedures; Coronary Artery Bypass; Drug T | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
[Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Emergency Medic | 2014 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Combined | 2015 |
[The prevalence of risk factors and status of clinical practice patterns among hospitalized patients with acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; China; Cross-Sectional Studies; | 2014 |
Kounis syndrome secondary to food allergy.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Anti-Allergic Agents; Aspirin; Clopidogrel; Electr | 2014 |
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2014 |
30-year-old man with chest pain and nausea.
Topics: Acute Coronary Syndrome; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ba | 2014 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cause of Death; Drug The | 2014 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
[Factors influencing platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Dr | 2014 |
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Drug Combinations; Heparin; Humans; Male; Middle A | 2015 |
Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiot | 2015 |
[Changes in the diagnosis and treatment of hospitalized patients with acute coronary syndrome from 2006 to 2012 in China].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Female; Hospita | 2014 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cross-Sectional Studies; Delivery of Health Care; Eme | 2015 |
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregatio | 2015 |
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; G | 2015 |
Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; | 2015 |
Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Co | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Dis | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2015 |
Interhospital Variability in Drug Prescription After Acute Coronary Syndrome: Insights From the ACDC Study.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Prescriptions; Drug | 2016 |
Management of Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; T | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Fibrinolytic Agents; Hospital Mortality; Hosp | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor | 2015 |
Bare-metal stent thrombosis two decades after stenting.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Electr | 2015 |
Management of acute coronary syndromes in a developing country; time for a paradigm shift? an observational study.
Topics: Acute Coronary Syndrome; Aged; Alcoholism; Angina, Unstable; Aspirin; Delayed Diagnosis; Developing | 2015 |
A pilot study on the application of the current European guidelines for the management of acute coronary syndrome without elevation of ST segment (NSTEMI) in the Emergency Department setting in the Italian region Lazio.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clinical Protocols; Disease Management; Electrocardiography; | 2014 |
Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Desensitization, | 2016 |
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2015 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Byp | 2016 |
High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Death; Drug | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
Pre-hospital management of acute coronary syndrome patients in Belgium and Luxembourg and other Western European countries.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Belgium | 2016 |
Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiot | 2016 |
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiography, Impedance; Clopidogrel; Cytochrome | 2017 |
The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA).
Topics: Acute Coronary Syndrome; Aspirin; Chest Pain; Evidence-Based Emergency Medicine; Humans; Morphine; N | 2016 |
Aspirin desensitization in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Plate | 2016 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Mal | 2016 |
A Case of Kounis Type I in a Young Woman With Samter's Triad.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combinati | 2016 |
[How long should therapy last?].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination | 2015 |
Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Angiography; Corona | 2017 |
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient.
Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocard | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; C | 2016 |
Editorial on PEGASUS - TIMI 54.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; | 2016 |
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complica | 2016 |
[THE FIRST RESULTS OF THE PREVALENCE OF CYP2C19 GENEPOLYMORPHISM IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE AKTYUBINSK POPULATION].
Topics: Acute Coronary Syndrome; Adult; Aged; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
[ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies | 2016 |
Epidemiological Profile and Quality Indicators in Patients with Acute Coronary Syndrome in Northern Minas Gerais - Minas Telecardio 2 Project.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Brazil; Demography; Emergency Service, Hospital; Female; Gui | 2016 |
Optimizing prevention and guideline-concordant care in Montenegro.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiot | 2016 |
Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Basophils; Blood Platelets; Desensitization, Immunologic; Dr | 2017 |
Antiplatelet therapy: What have we learned from the ANTARCTIC trial?
Topics: Acute Coronary Syndrome; Aged; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
SNAAP to Replace MONA.
Topics: Acute Coronary Syndrome; Advanced Cardiac Life Support; American Heart Association; Anticoagulants; | 2017 |
[Prevalence and prognosis of aspirin resistance in critical limb ischemia patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Drug Resistance; Ex | 2016 |
Letter by Petrie Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention".
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2016 |
Response by Bagai et al to Letter Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention".
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
Perioperative management of dual anti-platelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Elut | 2016 |
Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Clopidogrel; Educational Status; Fem | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Carboxylic Acids; Chromatography, Liquid; Clopidogrel; Cytoc | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Successful drug-coated balloon angioplasty and single anti-platelet therapy to treat an ischaemic stroke patient with haemorrhage and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Brain; Brain Ischemia; Coronary Angiography; | 2016 |
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Arteries; Aspirin; Atheroscl | 2016 |
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet | 2016 |
Spontaneous coronary artery dissection in a young woman with polycystic ovarian syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Chest Pain; Coronary Angiography; Coronary Vesse | 2017 |
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Case-Control Studies; China; Consensus; Coronary | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Association Between Prior Aspirin Use and Morphological Features of Culprit Lesions at First Presentation of Acute Coronary Syndrome Assessed by Optical Coherence Tomography.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aspirin; Case-Control Studies; Dyslipidemias; Female; Hu | 2017 |
Acute Coronary Syndrome
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Earl | 2017 |
Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Desensitizati | 2017 |
Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
Reduction in sex-based mortality difference with implementation of new cardiology guidelines.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2008 |
Benefits and limitations of current antiplatelet therapies.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Protocols; Drug Therapy; Fibrinolytic Agents; Humans; Pla | 2008 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinu | 2008 |
Benefit of clopidogrel for acute coronary syndrome and percutaneous coronary interventions in doubt due to rebound adverse events.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Com | 2008 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As | 2008 |
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Bioc | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggr | 2008 |
Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Fatal Outcome; Female; Humans; Intra | 2010 |
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro | 2008 |
Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cerebral Angiography; Fatal Outcome; Female; Hepar | 2009 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Co | 2008 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Rapid desensitization to acetylsalicylic acid in acute coronary syndrome patients with NSAID intolerance.
Topics: Acute Coronary Syndrome; Angioedema; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-S | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
The impact of aspirin resistance on the long-term cardiovascular mortality in patients with non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Chi-Square Distribution; Drug Resistance; Endpoint Determina | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopi | 2009 |
Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Resistance; Female; Follow-Up Studies; France; Graft Oc | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel | 2009 |
Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Blood | 2010 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Aprotinin reduces the antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aprotinin; Aspirin; Clopidogrel; Coronary Arte | 2009 |
The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Comorbidity; Drug Resistance; Electrocardi | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Size; Drug Resistance; Fem | 2009 |
Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon | 2009 |
Significance of platelet volume indices and platelet count in ischaemic heart disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cell Size; Female; | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad | 2009 |
Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Drug Administratio | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri | 2009 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Platelet monitoring for PCI: which test is the one to choose?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Electric Impedance; Humans; Platelet | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Corona | 2009 |
Spontaneous asymptomatic coronary artery dissection in a young man.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aortic Dissection; Aspirin; Asymptomatic Diseases; Coro | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combina | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He | 2009 |
Acute coronary syndromes: clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon; Angiotensin Recept | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Critical Pathways; Electrocardiography; Emergency Tre | 2009 |
Receipt of cardiac medications upon discharge among men and women with acute coronary syndrome and nonobstructive coronary artery disease.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Angiotensin-Converting Enzyme Inh | 2010 |
Influence of sex on the out-of-hospital management of chest pain.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Aspirin; Chest Pain; Emergency Medical Services; Fem | 2010 |
Clinical outcome after acute coronary syndrome in Japanese patients: an observational cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coron | 2010 |
Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Chi-Square D | 2010 |
The clinical significance of aspirin resistance in patients with chest pain.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Aspirin; Biomarkers, Pharmacological; Blood Pla | 2010 |
[The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.].
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Humans; Platelet Aggregation Inhibitors; Prognosis; Ri | 2009 |
Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program.
Topics: Acute Coronary Syndrome; American Medical Association; Anticoagulants; Aspirin; Biomarkers; Cardiolo | 2010 |
Aspirin administration in ED patients who presented with undifferentiated chest pain: age, race, and sex effects.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aspirin; Biomarkers; Chest Pain; Emergency Service, Hos | 2010 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2010 |
Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Drug Resistance; Epidemiologic Met | 2010 |
Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2010 |
Platelet aspirin resistance in ED patients with suspected acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiac Catheterization; Drug Resistance; Emergen | 2010 |
Improving use of prehospital 12-lead ECG for early identification and treatment of acute coronary syndrome and ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Early Diagnosis; Electrocardiography; Eme | 2010 |
Successful use of endothelial progenitor cell capture stents in a coronary artery disease patient with aspirin hypersensitivity who failed initial aspirin desensitization.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Hy | 2011 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2010 |
The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Dru | 2010 |
[Standard therapy of acute coronary syndrome becomes easier. Dual platelet inhibition with only 1 tablet].
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Germany; | 2010 |
Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiopla | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
Response to antiplatelet treatment: from genes to outcome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP | 2010 |
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Dru | 2011 |
Acute coronary syndromes: finding meaning in OASIS 7.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggr | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr | 2010 |
Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C-Reactive P | 2010 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi | 2010 |
Prior aspirin use and outcomes in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Angiography; Coronary Disease; Female; Humans; Kaplan-Mei | 2010 |
Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Aspirin; Cardiopulm | 2010 |
Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Aspirin; Cardiopulm | 2010 |
Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Aspirin; Cardiopulm | 2010 |
Part 9: Acute coronary syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Aspirin; Cardiopulm | 2010 |
Intravenous high-dose aspirin in acute coronary syndromes?
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Humans; Infusions, Intravenous; Platelet Agg | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug The | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Antagonism; Humans; Platelet Aggregation Inhibit | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality The | 2010 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
[Bleeding risk related to combined aspirin and other antithrombotic drug use in patients with acute coronary syndrome: prevention and therapy strategies].
Topics: Acute Coronary Syndrome; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans | 2010 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; F | 2010 |
[Warfarin combined with blood platelet inhibition].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Hemorrhage; Humans | 2011 |
Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thromb | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A | 2011 |
Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Dipyridamole; Drug | 2012 |
Previous aspirin use in acute coronary syndromes: more than a marker?
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Clinical Trials as Topic; Humans | 2011 |
Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzt
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspir | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioten | 2011 |
Aspirin adherence, depression and one-year prognosis after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Depression; Female; Humans; Male; Medication Adherence; Prognosis; | 2011 |
Malaysia-ACute CORonary syndromes Descriptive study (ACCORD): evaluation of compliance with existing guidelines in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Guideline A | 2011 |
Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clopidogrel; Electrocardiography; Female; Fo | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Differences in the mode of presentation for acute coronary syndrome by pre-hospitalization medication, in relation to coronary risk factors, East-Osaka acute coronary syndrome (EACS) registry.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Arte | 2011 |
Ticagrelor approved for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination | 2011 |
An assessment of the concentration-related prognostic value of cardiac troponin I following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; A | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
[Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug D | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Dia | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after discharge.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2011 |
Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Are we meeting cardiovascular risk targets 3 years after acute coronary syndrome? An evaluation in West Auckland, New Zealand.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitor | 2011 |
Initial treatment of acute coronary syndromes. Is there a future for MONA acronym after the 2010 guidelines?
Topics: Abbreviations as Topic; Acute Coronary Syndrome; Analgesics, Opioid; Aspirin; Humans; Morphine; Nitr | 2012 |
Cost-effectiveness of prasugrel in a US managed care population.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Thera | 2012 |
Apixaban after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Factor Xa Inhibitors; Female; Humans; Male; Platelet Aggregation I | 2011 |
Management of acute coronary syndromes in developing countries: acute coronary events-a multinational survey of current management strategies.
Topics: Acute Coronary Syndrome; Adrenergic Antagonists; Africa; Aged; Angiotensin-Converting Enzyme Inhibit | 2011 |
Managing antiplatelet therapy during ophthalmic procedures: communication is the key.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiology; Clopidogrel; Humans; I | 2011 |
Rivaroxaban (Xarelto) for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; D | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
Low mean corpuscular hemoglobin level is a predictor of discontinuation of antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2011 |
Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug The | 2012 |
[Aspirin response and related factors in aged patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease | 2011 |
Persistent high on-treatment platelet reactivity in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Arachidonic Acid; Aspirin; Dose-Response Relationship, Drug; Female; | 2012 |
Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Ambulatory Care; Angioplasty, Balloon, Coronary; A | 2013 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang | 2012 |
Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Chronic Disease; Coronary Angiography; Electroca | 2012 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogr | 2012 |
Treatment and outcomes of acute coronary syndrome in the cancer population.
Topics: Academic Medical Centers; Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Cardi | 2012 |
[Assessment of the quality of medical assistance for patients with acute ST elevation coronary syndrome for 2009-2010 in regions of the Russian Federation participating in the "vascular program" (by the data of the Russian ACS Register)].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiology Service, Hospital | 2012 |
Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Adhesion Molecul | 2012 |
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Clopidogrel; Computer Simulation; Cost-Ben | 2012 |
Measurements of thromboxane production and their clinical significance in coronary heart disease.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Female; Humans; Male; Thromboxane A2 | 2012 |
On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Humans; Thromboxane B2 | 2012 |
Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Humans; Platelet Aggregati | 2012 |
Aspirin administration by emergency medical dispatchers using a protocol-driven aspirin diagnostic and instruction tool.
Topics: Acute Coronary Syndrome; Aspirin; Chest Pain; Emergency Medical Service Communication Systems; Emerg | 2013 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive Syste | 2012 |
[Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Avena; Chest Pain; Clopidogrel; Co | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Chronic aspirin and statin therapy in patients with impaired renal function and acute coronary syndromes: results from the IN-ACS Outcome Registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therap | 2014 |
Bimodal response to aspirin loading in acute ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Electrocardiography; Female; Humans; Male; Middle Aged; Myoc | 2013 |
[Surgery shortly after stent implantation?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Contr | 2012 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Femal | 2012 |
Clopidogrel and cardiac surgery: enemy or friend?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Occlusion; | 2012 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorb | 2012 |
[The value of compliance during chronic administration of acetylsalicylic acid in patients with acute coronary syndrome: results of the study FORPOST].
Topics: Abdominal Pain; Acute Coronary Syndrome; Aged; Aspirin; Drug-Related Side Effects and Adverse Reacti | 2012 |
Monitoring residual platelet activity among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Fema | 2014 |
Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cell Size; Clopidogrel; Female; Humans; Mal | 2012 |
Local administration of abciximab using a ClearWay RX infusion catheter in a patient with acute coronary syndrome caused by late in-stent thrombosis.
Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Antibodies, Monoclonal; Anticoagula | 2012 |
Therapeutic momentum: a concept opposite to therapeutic inertia.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cross-Sectional Studies; Humans; Platelet Aggregation | 2013 |
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Fema | 2013 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2013 |
Incidence and risk factors of gastrointestinal bleeding in patients on low-dose aspirin therapy after percutaneous coronary intervention in Japan.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; | 2013 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Elec | 2007 |
Utilisation review of clopidogrel: are they used under the FDA-approved indications?
Topics: Acute Coronary Syndrome; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aspirin; | 2007 |
Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Ac | 2007 |
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Hemorrhag | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona | 2008 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
Gender-related differences in the management of non-ST-elevation acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Fema | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2007 |
Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atherectomy, Coronary; Clopidogrel; Coronary | 2007 |
Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Di | 2008 |
Impact of duty hours restrictions on quality of care and clinical outcomes.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Aspirin; Fem | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Asp | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Antiplatelet therapy in acute coronary syndrome: not as confusing as you think.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
[Efficacy of intravenous aspirin use in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Aged, 80 and over; Angina, Unstable; Asp | 2007 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarctio | 2008 |
Current challenges and directions in antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Human | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.
Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Aged, 80 and over; Angina, Unstable; Aspirin | 2008 |
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Arachidonic Acid; Aspirin; Body Mass Index; Cell Adhesio | 2009 |
Adverse events associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk; Ticlop | 2008 |